<SEC-DOCUMENT>0001104659-21-122546.txt : 20211004
<SEC-HEADER>0001104659-21-122546.hdr.sgml : 20211004
<ACCEPTANCE-DATETIME>20211004164616
ACCESSION NUMBER:		0001104659-21-122546
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		18
CONFORMED PERIOD OF REPORT:	20211001
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20211004
DATE AS OF CHANGE:		20211004

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NeuroBo Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001638287
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				472389984
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37809
		FILM NUMBER:		211303521

	BUSINESS ADDRESS:	
		STREET 1:		200 BERKELEY ST.
		STREET 2:		FL 19
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116
		BUSINESS PHONE:		(857) 702-9600

	MAIL ADDRESS:	
		STREET 1:		200 BERKELEY ST.
		STREET 2:		FL 19
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Gemphire Therapeutics Inc.
		DATE OF NAME CHANGE:	20150331
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2129080d2_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:nrbo="http://neurobopharma.com/20211001">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_029_US%2DGAAP%2D2020 -->
<!-- Field: Set; Name: xdx; ID: xdx_038_nrbo_neurobopharma.com_20211001 -->
<!-- Field: Set; Name: xdx; ID: xdx_041_20211001_20211001 -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DEntityCentralIndexKey_0001638287 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2021-10-01to2021-10-01" name="dei:EntityCentralIndexKey">0001638287</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-10-01to2021-10-01" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="nrbo-20211001.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2021-10-01to2021-10-01">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2021-10-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0pt"></p>

<p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: center"><b>WASHINGTON, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman; margin: 0pt 0">&#160;</p>

<p style="border-bottom: black 1pt solid; font: 1pt Times New Roman; margin: 0pt 0; text-align: center">&#8203;</p>

<p style="font: 10pt Times New Roman; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: center"><b>FORM&#160;<span id="xdx_901_edei--DocumentType_c20211001__20211001_zvBmXipqIA36"><ix:nonNumeric contextRef="From2021-10-01to2021-10-01" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; margin: 0pt 0; text-align: center"><b>&#8203;</b></p>

<p style="font: 10pt Times New Roman; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: center"><b>CURRENT REPORT&#160;</b></p>

<p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: center"><b>Pursuant to Section&#160;13 or 15(d)&#160;</b></p>

<p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: center"><b>of the Securities Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: center"><b>Date of Report (Date of earliest event reported): <span id="xdx_908_edei--DocumentPeriodEndDate_c20211001__20211001_zvYgJOkDlBod"><ix:nonNumeric contextRef="From2021-10-01to2021-10-01" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">October 1, 2021</ix:nonNumeric></span></b></p>

<p style="border-bottom: Black 1pt solid; font: 10pt Times New Roman; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: center"><span style="font-size: 14pt"><b><span id="xdx_909_edei--EntityRegistrantName_c20211001__20211001_zqA4kY0Y4Ehl"><ix:nonNumeric contextRef="From2021-10-01to2021-10-01" name="dei:EntityRegistrantName">NeuroBo Pharmaceuticals,&#160;Inc.</ix:nonNumeric></span></b></span><b></b></p>

<p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: center"><b>(Exact name of registrant as specified in its charter)</b></p>

<p style="font: 10pt Times New Roman; margin: 0pt 0">&#160;</p>

<p style="border-bottom: black 1pt solid; font: 10pt Times New Roman; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr>
    <td style="vertical-align: top; font-family: Times New Roman,serif; text-align: center; width: 41%"><span style="font: 10pt Times New Roman"><b><span id="xdx_905_edei--EntityIncorporationStateCountryCode_c20211001__20211001_zlQryqppiuU8"><ix:nonNumeric contextRef="From2021-10-01to2021-10-01" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman,serif; width: 2%">&#160;</td>
    <td style="vertical-align: top; font-family: Times New Roman,serif; text-align: center; width: 15%"><span style="font: 10pt Times New Roman"><b><span id="xdx_900_edei--EntityFileNumber_c20211001__20211001_zCI7243vHsTe"><ix:nonNumeric contextRef="From2021-10-01to2021-10-01" name="dei:EntityFileNumber">001-37809</ix:nonNumeric></span></b></span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman,serif; width: 2%">&#160;</td>
    <td style="vertical-align: top; font-family: Times New Roman,serif; text-align: center; width: 40%"><span style="font: 10pt Times New Roman"><b><span id="xdx_909_edei--EntityTaxIdentificationNumber_c20211001__20211001_zOs1KkpNzDu4"><ix:nonNumeric contextRef="From2021-10-01to2021-10-01" name="dei:EntityTaxIdentificationNumber">47-2389984</ix:nonNumeric></span></b></span></td></tr>
  <tr>
    <td style="vertical-align: top">
    <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: center"><b>(State or other jurisdiction</b></p>
    <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: center"><b>of incorporation)</b></p></td>
    <td style="vertical-align: bottom; font-family: Times New Roman,serif"><span style="font: 10pt Times New Roman">&#8203;</span></td>
    <td style="vertical-align: top">
    <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: center"><b>(Commission</b></p>
    <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: center"><b>File Number)</b></p></td>
    <td style="vertical-align: bottom; font-family: Times New Roman,serif"><span style="font: 10pt Times New Roman">&#8203;</span></td>
    <td style="vertical-align: top">
    <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: center"><b>(IRS Employer</b></p>
    <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: center"><b>Identification No.)</b></p></td></tr>
  <tr>
    <td style="vertical-align: top; font-family: Times New Roman,serif; text-align: center"><span style="font: 10pt Times New Roman"><b>&#8203;</b></span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman,serif"><span style="font: 10pt Times New Roman">&#8203;</span></td>
    <td style="vertical-align: top; font-family: Times New Roman,serif; text-align: center"><span style="font: 10pt Times New Roman"><b>&#8203;</b></span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman,serif"><span style="font: 10pt Times New Roman">&#8203;</span></td>
    <td style="vertical-align: top; font-family: Times New Roman,serif; text-align: center"><span style="font: 10pt Times New Roman"><b>&#8203;</b></span></td></tr>
  <tr style="vertical-align: top">
    <td colspan="5">
    <p style="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman"><b><span id="xdx_904_edei--EntityAddressAddressLine1_c20211001__20211001_zJW8oYvbT6Qg"><ix:nonNumeric contextRef="From2021-10-01to2021-10-01" name="dei:EntityAddressAddressLine1">200 Berkeley Street</ix:nonNumeric></span>, <span id="xdx_90C_edei--EntityAddressAddressLine2_c20211001__20211001_zqGurSI3XNx"><ix:nonNumeric contextRef="From2021-10-01to2021-10-01" name="dei:EntityAddressAddressLine2">19th Floor</ix:nonNumeric></span></b></span></p>
    <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: center"><b><span id="xdx_906_edei--EntityAddressCityOrTown_c20211001__20211001_ze5JqyJYzvN2"><ix:nonNumeric contextRef="From2021-10-01to2021-10-01" name="dei:EntityAddressCityOrTown">Boston</ix:nonNumeric></span>, <span id="xdx_907_edei--EntityAddressStateOrProvince_c20211001__20211001_zYKbl0KWzgQ9"><ix:nonNumeric contextRef="From2021-10-01to2021-10-01" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">Massachusetts</ix:nonNumeric></span>, <span id="xdx_90D_edei--EntityAddressPostalZipCode_c20211001__20211001_z4lZ8Xg18bb1"><ix:nonNumeric contextRef="From2021-10-01to2021-10-01" name="dei:EntityAddressPostalZipCode">02116</ix:nonNumeric></span></b></p>
    <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: center"><b>(Address of principal executive offices, including Zip
Code)</b></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman"><b>Registrant&#8217;s
Telephone Number,&#160;Including Area Code: </b></span><b><span style="font-size: 9pt">(<span id="xdx_901_edei--CityAreaCode_c20211001__20211001_zcBhaxypbxG"><ix:nonNumeric contextRef="From2021-10-01to2021-10-01" name="dei:CityAreaCode">857</ix:nonNumeric></span>) <span id="xdx_90F_edei--LocalPhoneNumber_c20211001__20211001_zCVWvRCyFAI"><ix:nonNumeric contextRef="From2021-10-01to2021-10-01" name="dei:LocalPhoneNumber">702-9600</ix:nonNumeric></span></span></b></p>

<p style="font: 10pt Times New Roman; margin: 0pt 0">&#160;</p>

<p style="border-bottom: black 1pt solid; font: 10pt Times New Roman; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font: 10pt Times New Roman; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr>
    <td style="white-space: nowrap; width: 48px; font-family: Times New Roman,serif"><span style="font: 10pt MS Gothic"><span style="font-family: Wingdings"><span id="xdx_909_edei--WrittenCommunications_c20211001__20211001_zxxN9txx0ubb"><ix:nonNumeric contextRef="From2021-10-01to2021-10-01" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span></span></span></td>
    <td style="font-family: Times New Roman,serif"><span style="font: 10pt Times New Roman">Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr>
    <td style="white-space: nowrap; width: 48px; font-family: Times New Roman,serif"><span style="font: 10pt MS Gothic"><span style="font-family: Wingdings"><span id="xdx_907_edei--SolicitingMaterial_c20211001__20211001_zJJFZ2WL1tWc"><ix:nonNumeric contextRef="From2021-10-01to2021-10-01" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></span></span></td>
    <td style="font-family: Times New Roman,serif"><span style="font: 10pt Times New Roman">Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr>
    <td style="white-space: nowrap; width: 48px; font-family: Times New Roman,serif"><span style="font: 10pt MS Gothic"><span style="font-family: Wingdings"><span id="xdx_90B_edei--PreCommencementTenderOffer_c20211001__20211001_zRFOvAGEOOl8"><ix:nonNumeric contextRef="From2021-10-01to2021-10-01" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></span></span></td>
    <td style="font-family: Times New Roman,serif"><span style="font: 10pt Times New Roman">Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr>
    <td style="white-space: nowrap; width: 48px; font-family: Times New Roman,serif"><span style="font: 10pt MS Gothic"><span style="font-family: Wingdings"><span id="xdx_901_edei--PreCommencementIssuerTenderOffer_c20211001__20211001_zuZdZACS2FL8"><ix:nonNumeric contextRef="From2021-10-01to2021-10-01" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></span></span></td>
    <td style="font-family: Times New Roman,serif"><span style="font: 10pt Times New Roman">Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in; border-left-width: 0in; border-left-color: Black">Securities
registered pursuant to Section&#160;12(b)&#160;of the Act:</p>




<p style="font: 10pt Times New Roman,serif; margin: 0pt 0">&#160;&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; white-space: nowrap; font-family: Times New Roman,serif; text-align: center; width: 41%"><span style="font: 10pt Times New Roman"><b>Title&#160;of&#160;each&#160;class</b></span></td>
    <td style="font-family: Times New Roman,serif; width: 2%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 15%">
    <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: center"><b>Trading<br />
Symbol(s)</b></p></td>
    <td style="font-family: Times New Roman,serif; width: 2%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 40%">
    <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: center"><b>Name&#160;of&#160;each&#160;exchange<br />
on&#160;which&#160;registered</b></p></td></tr>
  <tr>
    <td style="vertical-align: top; font-family: Times New Roman,serif; text-align: center"><span style="font: 10pt Times New Roman"><b><span id="xdx_906_edei--Security12bTitle_c20211001__20211001_ze6wZNJ0ucef"><ix:nonNumeric contextRef="From2021-10-01to2021-10-01" name="dei:Security12bTitle">Common Stock, par value $0.001 per share</ix:nonNumeric></span></b></span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman,serif">&#160;</td>
    <td style="vertical-align: top; font-family: Times New Roman,serif; text-align: center"><span style="font: 10pt Times New Roman"><b><span id="xdx_901_edei--TradingSymbol_c20211001__20211001_z6O2jVRIVEUk"><ix:nonNumeric contextRef="From2021-10-01to2021-10-01" name="dei:TradingSymbol">NRBO</ix:nonNumeric></span></b></span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman,serif">&#160;</td>
    <td style="vertical-align: top; font-family: Times New Roman,serif; text-align: center"><span style="font: 10pt Times New Roman"><b><span id="xdx_902_edei--SecurityExchangeName_c20211001__20211001_zmi6CPIdn431"><ix:nonNumeric contextRef="From2021-10-01to2021-10-01" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">The Nasdaq Stock Market, LLC</ix:nonNumeric></span></b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman,serif; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant is an emerging growth company as defined
in Rule&#160;405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2 of the Securities Exchange Act of 1934
(&#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: right"><span style="font: 10pt Times New Roman">Emerging
growth company&#160;&#160;<span style="font-family: Wingdings"><span id="xdx_906_edei--EntityEmergingGrowthCompany_c20211001__20211001_zDT004zzVX65"><ix:nonNumeric contextRef="From2021-10-01to2021-10-01" format="ixt:booleantrue" name="dei:EntityEmergingGrowthCompany">&#120;</ix:nonNumeric></span></span></span></p>

<p style="font: 10pt Times New Roman; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman">If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act.&#160;&#160;</span><span style="font-family: MS Gothic"><span style="font-family: Wingdings"><span id="xdx_906_edei--EntityExTransitionPeriod_c20211001__20211001_za9m8LYcZkp7"><ix:nonNumeric contextRef="From2021-10-01to2021-10-01" format="ixt:booleantrue" name="dei:EntityExTransitionPeriod">&#120;</ix:nonNumeric></span></span></span></p>

<p style="font: 10pt Times New Roman; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman; margin: 0pt 0">&#160;</p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman; margin: 0pt 0">&#160;&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="width: 9%; font-family: Times New Roman,serif; text-align: justify"><span style="font: 10pt Times New Roman"><b>Item 1.01</b></span></td>
    <td style="width: 91%; font-family: Times New Roman,serif; text-align: justify"><span style="font: 10pt Times New Roman"><b>Entry into a Material Definitive Agreement</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman,serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman; margin: 0pt 0; background-color: white"><i>Registered Direct Offering</i></p>

<p style="font: 10pt Times New Roman; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; background-color: white">On October&#160;1, 2021, the NeuroBo Pharmaceuticals,&#160;Inc.
(the &#8220;Company&#8221;) entered into a securities purchase agreement (the &#8220;Securities Purchase Agreement&#8221;) with several
institutional investors for the purchase and sale in a registered direct offering of 4,307,693 shares of the Company&#8217;s common stock,
at a purchase price of $3.25 per share for gross proceeds of approximately $14,000,000, before deducting the placement agent&#8217;s fees
and related offering expenses. The Securities Purchase Agreement contains customary representations, warranties and agreements by the
Company, customary conditions to closing, indemnification obligations of the Company, other obligations of the parties and termination
provisions.</p>

<p style="font: 10pt Times New Roman; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; background-color: white">The offering of the shares (the &#8220;Registered Offering&#8221;)
is being made pursuant to the Company&#8217;s effective shelf registration statement (the &#8220;Registration Statement&#8221;) on Form&#160;S-3
(Registration No.&#160;333-256135), initially filed with the Securities and Exchange Commission (the &#8220;Commission&#8221;) on May&#160;14,
2021and declared effective by the Commission on May&#160;26, 2021, and a prospectus supplement dated as of October&#160;1, 2021.</p>

<p style="font: 10pt Times New Roman; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman; margin: 0pt 0; background-color: white"><i>Private Placement</i></p>

<p style="font: 10pt Times New Roman; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; background-color: white">The Purchase Agreement also provides for a concurrent private
placement (the &#8220;Private Placement&#8221;) of warrants to purchase the Company&#8217;s common stock (the &#8220;Warrants&#8221;)
with the purchasers in the Registered Offering. The Warrants will be exercisable for up to an aggregate of 4,307,693 shares of common
stock. The Warrants will have an exercise price of $3.75 per share, will be exercisable commencing six months from the issuance date (the
&#8220;Initial Exercise Date&#8221;), and will expire three and one-half years following the Initial Exercise Date. Subject to limited
exceptions, a holder of a Warrant will not have the right to exercise any portion of its Warrants if the holder, together with its affiliates,
would beneficially own in excess of 4.99% (or, at the election of a holder prior to the date of issuance, 9.99%) of the number of shares
of Common Stock outstanding immediately after giving effect to such exercise (the &#8220;Beneficial Ownership Limitation&#8221;); provided,
however, that upon prior notice to the Company, the holder may increase or decrease the Beneficial Ownership Limitation, provided further
that in no event shall the Beneficial Ownership Limitation exceed 9.99% and any increase in the beneficial ownership limitation will not
be effective until 61 days following notice to us.</p>

<p style="font: 10pt Times New Roman; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; background-color: white">H.C. Wainwright&#160;&amp; Co., LLC (the&#160;&#8220;Placement
Agent&#8221;) acted as the exclusive placement agent for the Company in connection with the Registered Offering and the Private Placement
pursuant to an engagement letter, dated as of September&#160;29, 2021, entered into by and between the Company and the Placement Agent.
As compensation in connection with the Registered Offering and Private Placement, the Company agreed to pay the Placement Agent a cash
fee equal to 7.0% of the gross proceeds of the Registered Offering Private Placement, non-accountable expenses in the amount of $75,000
and clearing fees of $15,950. The Company expects to pay fees and expenses of approximately $1,070,950 in the aggregate to the Placement
Agent.</p>

<p style="font: 10pt Times New Roman; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; background-color: white">The Securities Purchase Agreement and form of Warrant are
filed as Exhibits 10.1 and 4.1, respectively, to this Current Report on Form&#160;8-K and are incorporated herein by reference. The above
descriptions of the terms of the Securities Purchase Agreement and Warrants are qualified in their entirety by reference to such exhibits.</p>

<p style="font: 10pt Times New Roman; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="width: 9%; font-family: Times New Roman,serif"><span style="font: 10pt Times New Roman"><b>Item 3.02</b></span></td>
    <td style="width: 91%; font-family: Times New Roman,serif"><span style="font: 10pt Times New Roman"><b>Unregistered Sales of Equity Securities</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify"><span style="background-color: white">The disclosures under Item 1.01 above regarding
the unregistered sale of the Warrants and the shares issuable thereunder are incorporated herein by reference. The warrants and the shares
of common stock issuable thereunder will be issued in reliance upon the exemption from the registration requirements in Section&#160;4(a)(2)&#160;of
the Securities Act of 1933, as amended, and Regulation D promulgated thereunder.</span></p>

<p style="font: 10pt Times New Roman; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="width: 9%; font-family: Times New Roman,serif; text-align: justify"><span style="font: 10pt Times New Roman"><b>Item 8.01</b></span></td>
    <td style="width: 91%; font-family: Times New Roman,serif; text-align: justify"><span style="font: 10pt Times New Roman"><b>Other Events</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify"><span style="background-color: white">On October&#160;1, 2021, the Company issued
a press release announcing the Registered Offering and Private Placement. A copy of the press release is attached as Exhibit&#160;99.1
to this Current Report on Form&#160;8-K. The Company is filing the opinion of its counsel, Honigman LLP, as Exhibit&#160;5.1 hereto, regarding
the legality of the shares covered by the Securities Purchase Agreement.</span></p>

<p style="font: 10pt Times New Roman; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="width: 9%; font-family: Times New Roman,serif; text-align: justify"><span style="font: 10pt Times New Roman"><b>Item 9.01</b></span></td>
    <td style="width: 91%; font-family: Times New Roman,serif; text-align: justify"><span style="font: 10pt Times New Roman"><b>Financial Statements and Exhibits</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="width: 3%; font-family: Times New Roman,serif"><span style="font: 10pt Times New Roman">&#160;(d)</span></td>
    <td style="width: 97%; font-family: Times New Roman,serif"><span style="font: 10pt Times New Roman"><span style="text-decoration: underline">Exhibits</span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman; margin: 0pt 0">&#160;&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 11pt">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: white 1pt solid; width: 5%">
    <p style="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: center"><b>Exhibit<br />
 No.</b></p></td>
    <td style="border-bottom: white 1pt solid; font: 11pt Calibri,sans-serif; width: 95%; text-align: center"><span style="font: 10pt Times New Roman,serif"><b>Description</b></span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 11pt">
  <tr style="vertical-align: top">
    <td style="font-family: Calibri,sans-serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Calibri,sans-serif"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Calibri,sans-serif; width: 5%"><span style="font: 10pt Times New Roman, Times, Serif"><a href="tm2129080d2_ex4-1.htm" style="-sec-extract: exhibit">4.1</a></span></td>
    <td style="font-family: Calibri,sans-serif; width: 95%"><a href="tm2129080d2_ex4-1.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman,serif">Form&#160;of Warrant to purchase shares of common stock.</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Calibri,sans-serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Calibri,sans-serif">&#160;</td></tr>
  <tr>
    <td style="font-family: Calibri,sans-serif"><span style="font: 10pt Times New Roman, Times, Serif"><a href="tm2129080d2_ex5-1.htm">5.1</a></span></td>
    <td style="font-family: Calibri,sans-serif"><a href="tm2129080d2_ex5-1.htm"><span style="font: 10pt Times New Roman,serif">Opinion of Honigman LLP.</span></a></td></tr>
  <tr>
    <td style="font-family: Calibri,sans-serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Calibri,sans-serif">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top; font-family: Calibri,sans-serif"><span style="font: 10pt Times New Roman, Times, Serif"><a href="tm2129080d2_ex10-1.htm" style="-sec-extract: exhibit">10.1</a></span></td>
    <td style="text-align: justify; vertical-align: bottom; font-family: Calibri,sans-serif"><a href="tm2129080d2_ex10-1.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman,serif">Form&#160;of Securities Purchase Agreement, dated as of October&#160;1, 2021, by and among NeuroBo Pharmaceuticals,&#160;Inc. and the purchasers identified on the signature pagers thereto.</span></a></td></tr>
  <tr>
    <td style="vertical-align: top; font-family: Calibri,sans-serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify; vertical-align: bottom; font-family: Calibri,sans-serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Calibri,sans-serif"><span style="font: 10pt Times New Roman, Times, Serif"><a href="tm2129080d2_ex5-1.htm">23.1</a></span></td>
    <td style="font-family: Calibri,sans-serif"><a href="tm2129080d2_ex5-1.htm"><span style="font: 10pt Times New Roman,serif">Consent of Honigman LLP (included in Exhibit&#160;5.1).</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Calibri,sans-serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Calibri,sans-serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Calibri,sans-serif"><span style="font: 10pt Times New Roman, Times, Serif"><a href="tm2129080d2_ex99-1.htm">99.1</a></span></td>
    <td style="font-family: Calibri,sans-serif"><a href="tm2129080d2_ex99-1.htm"><span style="font: 10pt Times New Roman,serif">Press Release of NeuroBo Pharmaceuticals,&#160;Inc. dated October&#160;1, 2021.</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Calibri,sans-serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Calibri,sans-serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Calibri,sans-serif"><span style="font: 10pt Times New Roman, Times, Serif">104</span></td>
    <td style="font-family: Calibri,sans-serif"><span style="font: 10pt Times New Roman, Times, Serif">Cover Page Interactive Data File (cover page XBRL tags are embedded within the Inline XBRL document).</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman; margin: 0pt 0">&#160;&#160;</p>


<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman,serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
  <td style="width: 50%">Date: October&#160;4, 2021</td>
  <td style="width: 50%"><span style="text-transform: uppercase"><b>CHF SOLUTIONS,&#160;Inc.</b></span></td></tr>
</table>


<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman,serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
  <td style="width: 50%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
  <td style="width: 6%"><span style="font-family: Times New Roman, Times, Serif">By:</span></td>
  <td style="border-bottom: Black 1pt solid; width: 44%"><span style="font-family: Times New Roman, Times, Serif; font-variant: small-caps">/s/
  Richard Kang</span></td></tr>

<tr style="vertical-align: top">
  <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
  <td><span style="font-family: Times New Roman, Times, Serif">Name:</span></td>
  <td style="border-bottom: Black 1pt solid"><span style="font-family: Times New Roman, Times, Serif">Richard Kang</span></td></tr>

<tr style="vertical-align: top">
  <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
  <td><span style="font-family: Times New Roman, Times, Serif">Title:</span></td>
  <td style="border-bottom: Black 1pt solid"><span style="font-family: Times New Roman, Times, Serif">President and Chief Executive Officer</span></td></tr>
</table>


<p style="font: 10pt Times New Roman; margin: 0pt 0">&#160;</p>

<p style="font: 8pt Times New Roman; margin: 0pt 0"><span style="background-color: lightgrey"></span></p>

<p style="font: 8pt Times New Roman; margin: 0pt 0"><span style="background-color: lightgrey"></span></p>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 8pt Times New Roman; margin: 0pt 0"><span style="background-color: lightgrey"></span></p>

<p style="font: 10pt Times New Roman; margin: 0pt 0">&#160;</p>



<p style="margin: 0pt"></p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjU0KwjAQhU/QOwxZiyZFXXRpURGrlFLEbbCjBNtMmcSfHslbmraIw8AwvPe9J8REbGljamQ4r4oMSmzaWnuEAq/IaC8YHOlun0C4Bd6M86ytH94fmFJgMDCLqZI6CIP1aRxWCSg5k2oWK5DzRC4hP4io11OyV1Oh9UbXoG0FOVPLBr3mbkwo9ZssNd1QdUJ2hmyIm8pR/kAsVQxHeuoX8d1BlqUimgwTiS3To+1rHs5TA+sam9DlRvS/0RcPq0k8 -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>tm2129080d2_ex4-1.htm
<DESCRIPTION>EXHIBIT 4.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

                           <P STYLE="margin: 0pt"></P>

<P STYLE="font: 12pt Times New Roman; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman; margin: 0pt 0; text-align: right"><FONT STYLE="font-size: 10pt"><B>&nbsp;Exhibit 4.1</B></FONT></P>

<P STYLE="font: 12pt Times New Roman; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">NEITHER THIS SECURITY NOR THE
SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES
COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &#8220;SECURITIES
ACT&#8221;), AND, ACCORDINGLY, MAY&nbsp;NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES
ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT
AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY&nbsp;BE
PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.</FONT></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>COMMON STOCK PURCHASE WARRANT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>NEUROBO
PHARMACEUTICALS,&nbsp;INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman; width: 40%; text-align: left"><FONT STYLE="font-size: 10pt">Warrant Shares: _______</FONT></TD>
    <TD STYLE="width: 20%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman; padding-left: 1in; width: 40%; text-align: left"><FONT STYLE="font-size: 10pt">Issue Date:______, 2021</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman; padding-left: 1in; text-align: left"><FONT STYLE="font-size: 10pt">Initial Exercise Date: ___, 2021</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman,serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman; font-size: 10pt">THIS
COMMON STOCK PURCHASE WARRANT (the &#8220;<U>Warrant</U>&#8221;) certifies that, for value received, _____________ or its assigns
(the &#8220;<U>Holder</U>&#8221;) is entitled, upon the terms and subject to the limitations on exercise and the conditions
hereinafter set forth, at any time on or after ___________ </FONT><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt"><SUP>1 </SUP></FONT><FONT STYLE="font-family: Times New Roman; font-size: 10pt">(the
 &#8220;<U>Initial Exercise Date</U>&#8221;) and on or prior to 5:00 p.m.&nbsp;(New York City time) on ______________</FONT><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt"><SUP>2 </SUP></FONT><FONT STYLE="font-family: Times New Roman; font-size: 10pt">(the
 &#8220;<U>Termination Date</U>&#8221;) but not thereafter, to subscribe for and purchase from NeuroBo Pharmaceuticals,&nbsp;Inc., a
Delaware corporation (the &#8220;<U>Company</U>&#8221;), up to ______ shares (as subject to adjustment hereunder, the
 &#8220;<U>Warrant Shares</U>&#8221;) of the Company&#8217;s Common Stock. The purchase price of one share of Common Stock under this
Warrant shall be equal to the Exercise Price, as defined in Section&nbsp;2(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman; font-size: 10pt"><U>Section&nbsp;1</U></FONT><FONT STYLE="font-size: 10pt">.&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Definitions</U>.
Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain Securities Purchase Agreement
(the &#8220;<U>Purchase Agreement</U>&#8221;), dated October&nbsp;1, 2021, among the Company and the purchasers signatory thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><SUP>1</SUP> Insert the date that is six-months following
the issuance date.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><SUP>2</SUP> Insert the date that is the three and
one-half (3.5) year anniversary of the Issue Date, provided that, if such date is not a Trading Day, insert the immediately following
Trading Day.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman; font-size: 10pt"><U>Section&nbsp;2</U></FONT><FONT STYLE="font-size: 10pt">.&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Exercise</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman; font-size: 10pt">a)</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Exercise
of Warrant</U>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times
on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed facsimile
copy or PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the
 &#8220;<U>Notice of Exercise</U>&#8221;). Within the earlier of (i)&nbsp;two (2)&nbsp;Trading Days and (ii)&nbsp;the number of
Trading Days comprising the Standard Settlement Period (as defined in Section&nbsp;2(d)(i)&nbsp;herein) following the date of
exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the Warrant Shares specified in the applicable
Notice of Exercise by wire transfer or cashier&#8217;s check drawn on a United States bank unless the cashless exercise procedure
specified in Section&nbsp;2(c)&nbsp;below is specified in the applicable Notice of Exercise. No ink-original Notice of Exercise
shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be
required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to
the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full,
in which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3)&nbsp;Trading Days of the
date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of
a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of
Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the
Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall
deliver any objection to any Notice of Exercise within one (1)&nbsp;Trading Day of receipt of such notice. <B>The Holder and any
assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the
purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given
time may be less than the amount stated on the face hereof.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman; font-size: 10pt">b)</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Exercise
Price</U>. The exercise price per share of Common Stock under this Warrant shall be <B>$3.75</B>, subject to adjustment hereunder (the
 &#8220;<U>Exercise Price</U>&#8221;).</FONT></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman; font-size: 10pt">c)</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Cashless
Exercise</U>. If at the time of exercise hereof there is no effective registration statement registering, or the prospectus contained
therein is not available for the issuance of the Warrant Shares to the Holder, then this Warrant may also be exercised, in whole or in
part, at such time by means of a &#8220;cashless exercise&#8221; in which the Holder shall be entitled to receive a number of Warrant
Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</FONT></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 12pt Times New Roman; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 10%"></TD><TD STYLE="vertical-align: top; white-space: nowrap; width: 3%; text-align: left"><FONT STYLE="font-size: 10pt">(A) =</FONT>&nbsp;</TD><TD STYLE="vertical-align: top; text-align: justify; width: 87%"><FONT STYLE="font-size: 10pt">as applicable: (i)&nbsp;the
VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1)&nbsp;both
executed and delivered pursuant to Section&nbsp;2(a)&nbsp;hereof on a day that is not a Trading Day or (2)&nbsp;both executed and delivered
pursuant to Section&nbsp;2(a)&nbsp;hereof on a Trading Day prior to the opening of &#8220;regular trading hours&#8221; (as defined in
Rule&nbsp;600(b)&nbsp;of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii)&nbsp;at the option of
the Holder, either (y)&nbsp;the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise or (z)&nbsp;the
Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. as of the time of the Holder&#8217;s execution
of the applicable Notice of Exercise if such Notice of Exercise is executed during &#8220;regular trading hours&#8221; on a Trading Day
and is delivered within two (2)&nbsp;hours thereafter (including until two (2)&nbsp;hours after the close of &#8220;regular trading hours&#8221;
on a Trading Day) pursuant to Section&nbsp;2(a)&nbsp;hereof or (iii)&nbsp;the VWAP on the date of the applicable Notice of Exercise if
the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section&nbsp;2(a)&nbsp;hereof
after the close of &#8220;regular trading hours&#8221; on such Trading Day;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 12pt Times New Roman; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 10%"></TD><TD STYLE="vertical-align: top; white-space: nowrap; text-align: left; width: 3%"><FONT STYLE="font-size: 10pt">(B) =</FONT>&nbsp;</TD><TD STYLE="vertical-align: top; text-align: justify; width: 87%"><FONT STYLE="font-size: 10pt">the Exercise Price of this Warrant,
as adjusted hereunder; and</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 12pt Times New Roman; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 10%"></TD><TD STYLE="vertical-align: top; white-space: nowrap; width: 3%; text-align: left"><FONT STYLE="font-size: 10pt">(X) =</FONT>&nbsp;</TD><TD STYLE="vertical-align: top; text-align: justify; width: 87%"><FONT STYLE="font-size: 10pt">the
                                            number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance
                                            with the terms of this Warrant if such exercise were by means of a cash exercise rather than
                                            a cashless exercise.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman,serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman; font-size: 10pt; background-color: white"><U>&#8220;Bid
Price</U></FONT><FONT STYLE="font-size: 10pt; background-color: white">&#8221; means, for any date, the price determined by the first
of the following clauses that applies: (a)&nbsp;if the Common Stock is then listed or quoted on a Trading Market, the bid price of the
Common Stock for the time in question (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed
or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m.&nbsp;(New York City time) to 4:02 p.m.&nbsp;(New York
City time)), (b)&nbsp; if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common Stock for such date
(or the nearest preceding date) on OTCQB or OTCQX as applicable, (c)&nbsp;if the Common Stock is not then listed or quoted for trading
on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market (or a similar organization or agency succeeding
to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d)&nbsp;in all other
cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Holders
of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which
shall be paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman,serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman; font-size: 10pt; background-color: white">&#8220;<U>VWAP</U>&#8221; </FONT><FONT STYLE="font-size: 10pt">means,
for any date, the price determined by the first of the following clauses that applies: (a)&nbsp;if the Common Stock is then listed
or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding
date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day
from 9:30 a.m.&nbsp;(New York City time) to 4:02 p.m.&nbsp;(New York City time)), (b)&nbsp; if OTCQB or OTCQX is not a Trading
Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as
applicable, (c)&nbsp;if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common
Stock are then reported on The Pink Open Market (or a similar organization or agency succeeding to its functions of reporting
prices), the most recent bid price per share of the Common Stock so reported, or (d)&nbsp;in all other cases, the fair market value
of a share of Common Stock as determined by an independent appraiser selected in good faith by the Holders of a majority in interest
of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the
Company<FONT STYLE="background-color: white">.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt; background-color: white">If
Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section&nbsp;3(a)(9)&nbsp;of
the Securities Act, the Warrant Shares shall take on the characteristics of the Warrants being exercised, and the holding period of the
Warrant Shares being issued may be tacked on to the holding period of this Warrant.&nbsp;&nbsp;The Company agrees not to take any position
contrary to this Section&nbsp;2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman; font-size: 10pt">d)</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Mechanics
of Exercise</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman; font-size: 10pt">i.</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Delivery
of Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the
Transfer Agent to the Holder by crediting the account of the Holder&#8217;s or its designee&#8217;s balance account with The
Depository Trust Company through its Deposit or Withdrawal at Custodian system (&#8220;<U>DWAC</U>&#8221;) if the Company is then a
participant in such system and either (A)&nbsp;there is an effective registration statement permitting the issuance of the Warrant
Shares to or resale of the Warrant Shares by the Holder or (B)&nbsp;the Warrant Shares are eligible for resale by the Holder without
volume or manner-of-sale limitations pursuant to Rule&nbsp;144 (assuming cashless exercise of the Warrants), and otherwise by
physical delivery of a certificate, registered in the Company&#8217;s share register in the name of the Holder or its designee, for
the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the
Notice of Exercise by the date that is the earliest of (i)&nbsp;two (2)&nbsp;Trading Days after the delivery to the Company of the
Notice of Exercise, (ii)&nbsp;one (1)&nbsp;Trading Day after delivery of the aggregate Exercise Price to the Company and
(iii)&nbsp;the number of Trading Days comprising the Standard Settlement Period after the delivery to the Company of the Notice of
Exercise (such date, the &#8220;<U>Warrant Share Delivery Date</U>&#8221;). Upon delivery of the Notice of Exercise, the Holder
shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this
Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment of the aggregate
Exercise Price (other than in the case of a cashless exercise) is received by the Warrant Share Delivery Date. If the Company fails
for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, the
Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to
such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day
(increasing to $20 per Trading Day on the third Trading Day after the Warrant Share Delivery Date) for each Trading Day after such
Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain
a transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As used
herein, &#8220;<U>Standard Settlement Period</U>&#8221; means the standard settlement period, expressed in a number of Trading Days,
on the Company&#8217;s primary Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice of
Exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman; font-size: 10pt">ii.</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Delivery
of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and
upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing
the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other
respects be identical with this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman; font-size: 10pt">iii.</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Rescission
Rights</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section&nbsp;2(d)(i)&nbsp;by
the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman; font-size: 10pt">iv.</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Compensation
for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</U>. In addition to any other rights available to the Holder,
if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of
Section&nbsp;2(d)(i)&nbsp;above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the
Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder&#8217;s brokerage firm
otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the
Holder anticipated receiving upon such exercise (a &#8220;<U>Buy-In</U>&#8221;), then the Company shall (A)&nbsp;pay in cash to the
Holder the amount, if any, by which (x)&nbsp;the Holder&#8217;s total purchase price (including brokerage commissions, if any) for
the shares of Common Stock so purchased exceeds (y)&nbsp;the amount obtained by multiplying (1)&nbsp;the number of Warrant Shares
that the Company was required to deliver to the Holder in connection with the exercise at issue times (2)&nbsp;the price at which
the sell order giving rise to such purchase obligation was executed, and (B)&nbsp;at the option of the Holder, either reinstate the
portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in which case such exercise
shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been issued had the Company
timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common Stock having a
total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with an aggregate
sale price giving rise to such purchase obligation of $10,000, under clause (A)&nbsp;of the immediately preceding sentence the
Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts
payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein
shall limit a Holder&#8217;s right to pursue any other remedies available to it hereunder, at law or in equity including, without
limitation, a decree of specific performance and/or injunctive relief with respect to the Company&#8217;s failure to timely deliver
shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman; font-size: 10pt">v.</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this
Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall,
at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the
Exercise Price or round up to the next whole share.</FONT></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman; font-size: 10pt">vi.</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Charges,
Taxes and Expenses</U>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other
incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and
such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; <U>provided</U>,
<U>however</U>, that in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when
surrendered for exercise shall be accompanied by the Assignment Form&nbsp;attached hereto duly executed by the Holder and the Company
may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company
shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company
(or another established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman; font-size: 10pt">vii.</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Closing
of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant,
pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman; font-size: 10pt">e)</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Holder&#8217;s
Exercise Limitations</U>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to
exercise any portion of this Warrant, pursuant to Section&nbsp;2 or otherwise, to the extent that after giving effect to such
issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&#8217;s Affiliates,
and any other Persons acting as a group together with the Holder or any of the Holder&#8217;s Affiliates (such Persons,
 &#8220;<U>Attribution Parties</U>&#8221;)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined
below).&nbsp; For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its
Affiliates and Attribution Parties shall include the number of shares of Common Stock issuable upon exercise of this Warrant with
respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would be issuable
upon (i)&nbsp;exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of its
Affiliates or Attribution Parties and (ii)&nbsp;exercise or conversion of the unexercised or nonconverted portion of any other
securities of the Company (including, without limitation, any other Common Stock Equivalents) subject to a limitation on conversion
or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates or Attribution
Parties.&nbsp; Except as set forth in the preceding sentence, for purposes of this Section&nbsp;2(e), beneficial ownership shall be
calculated in accordance with Section&nbsp;13(d)&nbsp;of the Exchange Act and the rules&nbsp;and regulations promulgated thereunder,
it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with
Section&nbsp;13(d)&nbsp;of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in
accordance therewith. To the extent that the limitation contained in this Section&nbsp;2(e)&nbsp;applies, the determination of
whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and
Attribution Parties) and of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the
submission of a Notice of Exercise shall be deemed to be the Holder&#8217;s determination of whether this Warrant is exercisable (in
relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this
Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to
verify or confirm the accuracy of such determination and shall have no liability for exercises of the Warrant that are not in
compliance with the Beneficial Ownership Limitation, except to the extent the Holder relies on the number of outstanding shares of
Common Stock that was provided by the Company. In addition, a determination as to any group status as contemplated above shall be
determined in accordance with Section&nbsp;13(d)&nbsp;of the Exchange Act and the rules&nbsp;and regulations promulgated thereunder,
and the Company shall have no obligation to verify or confirm the accuracy of such determination and shall have no liability for
exercises of the Warrant that are not in compliance with the Beneficial Ownership Limitation, except to the extent the Holder relies
on the number of outstanding shares of Common Stock that was provided by the Company. For purposes of this Section&nbsp;2(e), in
determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock
as reflected in (A)&nbsp;the Company&#8217;s most recent periodic or annual report filed with the Commission, as the case may be,
(B)&nbsp;a more recent public announcement by the Company or (C)&nbsp;a more recent written notice by the Company or the Transfer
Agent setting forth the number of shares of Common Stock outstanding.&nbsp; Upon the written or oral request of a Holder, the
Company shall within two (2)&nbsp;Trading Days confirm orally and in writing to the Holder the number of shares of Common Stock then
outstanding.&nbsp; In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the
conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties
since the date as of which such number of outstanding shares of Common Stock was reported. The &#8220;<U>Beneficial Ownership
Limitation</U>&#8221; shall be [4.99%/9.99%] of the number of shares of the Common Stock outstanding immediately after giving effect
to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may
increase or decrease the Beneficial Ownership Limitation provisions of this Section&nbsp;2(e), provided that the Beneficial
Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately after giving
effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions of this
Section&nbsp;2(e)&nbsp;shall continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective until the
61<SUP>st</SUP> day after such notice is delivered to the Company. The provisions of this paragraph shall be construed and
implemented in a manner otherwise than in strict conformity with the terms of this Section&nbsp;2(e)&nbsp;to correct this paragraph
(or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or
to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this
paragraph shall apply to a successor holder of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman; font-size: 10pt"><U>Section&nbsp;3</U></FONT><FONT STYLE="font-size: 10pt">.&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Certain
Adjustments</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman; font-size: 10pt">a)</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Stock
Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i)&nbsp;pays a stock dividend or otherwise
makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in
shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon
exercise of this Warrant), (ii)&nbsp;subdivides outstanding shares of Common Stock into a larger number of shares,
(iii)&nbsp;combines (including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or
(iv)&nbsp;issues by reclassification of shares of the Common Stock any shares of capital stock of the Company, then in each case the
Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding
treasury shares, if any) outstanding immediately before such event and of which the denominator shall be the number of shares of
Common Stock outstanding immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be
proportionately adjusted such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant
to this Section&nbsp;3(a)&nbsp;shall become effective immediately after the record date for the determination of stockholders
entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a
subdivision, combination or re&#45;classification.</FONT></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman; font-size: 10pt">b)</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Subsequent
Rights Offerings</U>. In addition to any adjustments pursuant to Section&nbsp;3(a)&nbsp;above, if at any time the Company grants, issues
or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders
of any class of shares of Common Stock (the &#8220;<U>Purchase Rights</U>&#8221;), then the Holder will be entitled to acquire, upon
the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held
the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise
hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for
the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares
of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (<U>provided</U>, <U>however</U>, that to the
extent that the Holder&#8217;s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership
Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such
shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance
for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</FONT></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman; font-size: 10pt; background-color: White">c)</FONT><FONT STYLE="font-size: 10pt; background-color: White">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Pro
Rata Distributions</U>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other
distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or
otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of a
dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a
 &#8220;<U>Distribution</U>&#8221;), at any time after the issuance of this Warrant, then, in each such case, the Holder shall be
entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had
held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on
exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date of which a record is
taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are
to be determined for the participation in such Distribution (<U>provided</U>, <U>however</U>, that to the extent that the Holder's
right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation, then the
Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any shares of
Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the
benefit of the Holder until such time, </FONT><FONT STYLE="font-size: 10pt">if ever, as its right thereto would not result in the
Holder exceeding the Beneficial Ownership Limitation).</FONT></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman; font-size: 10pt">d)</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Fundamental
Transaction</U>. If, at any time while this Warrant is outstanding, (i)&nbsp;the Company, directly or indirectly, in one or more
related transactions effects any merger or consolidation of the Company with or into another Person, (ii)&nbsp;the Company (and all
of its Subsidiaries, taken as a whole), directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance
or other disposition of all or substantially all of its assets in one or a series of related transactions, (iii)&nbsp;any, direct or
indirect, purchase offer, tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which
holders of Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has been
accepted by the holders of 50% or more of the outstanding Common Stock, (iv)&nbsp;the Company, directly or indirectly, in one or
more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory
share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property,
or (v)&nbsp;the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement
or other business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of
arrangement) with another Person or group of Persons whereby such other Person or group acquires more than 50% of the outstanding
shares of Common Stock (not including any shares of Common Stock held by the other Person or other Persons making or party to, or
associated or affiliated with the other Persons making or party to, such stock or share purchase agreement or other business
combination) (each a &#8220;<U>Fundamental Transaction</U>&#8221;), then, upon any subsequent exercise of this Warrant, the Holder
shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the
occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in
Section&nbsp;2(e)&nbsp;on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring
corporation or of the Company, if it is the surviving corporation, and any additional consideration (the &#8220;<U>Alternate
Consideration</U>&#8221;) receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock
for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in
Section&nbsp;2(e)&nbsp;on the exercise of this Warrant). For purposes of any such exercise, the determination of the Exercise Price
shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in
respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the
Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate
Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be received in a
Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any
exercise of this Warrant following such Fundamental Transaction. The Company shall cause any successor entity in a Fundamental
Transaction in which the Company is not the survivor (the &#8220;<U>Successor Entity</U>&#8221;) to assume in writing all of the
obligations of the Company under this Warrant and the other Transaction Documents in accordance with the provisions of this
Section&nbsp;3(d)&nbsp;pursuant to written agreements in form and substance reasonably satisfactory to the Holder and approved by
the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the
Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially similar in
form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor
Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant
(without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise
price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative value of the
shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares
of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to
the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon
the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so that from and
after the date of such Fundamental Transaction, the provisions of this Warrant and the other Transaction Documents referring to the
 &#8220;Company&#8221; shall refer instead to the Successor Entity), and may exercise every right and power of the Company and shall
assume all of the obligations of the Company under this Warrant and the other Transaction Documents with the same effect as if such
Successor Entity had been named as the Company herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Split-Segment; Name: SP2 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Calculations</U>.
All calculations under this Section&nbsp;3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For
purposes of this Section&nbsp;3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be
the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notice
to Holder</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Adjustment
to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section&nbsp;3, the Company shall promptly
deliver to the Holder by facsimile or email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment
to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notice
to Allow Exercise by Holder</U>. If (A)&nbsp;the Company shall declare a dividend (or any other distribution in whatever form) on the
Common Stock, (B)&nbsp;the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C)&nbsp;the
Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of
capital stock of any class or of any rights, (D)&nbsp;the approval of any stockholders of the Company shall be required in connection
with any reclassification of the Common Stock, any consolidation or merger to which the Company is a party, any sale or transfer of all
or substantially all of the assets of the Company, or any compulsory share exchange whereby the Common Stock is converted into other
securities, cash or property, or (E)&nbsp;the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding
up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by facsimile or email to the Holder at
its last facsimile number or email address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior
to the applicable record or effective date hereinafter specified, a notice stating (x)&nbsp;the date on which a record is to be taken
for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which
the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined
or (y)&nbsp;the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective
or close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares
of the Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer
or share exchange; provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect
the validity of the corporate action required to be specified in such notice. To the extent that any notice provided in this Warrant
constitutes, or contains, material, non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously
file such notice with the Commission pursuant to a Current Report on Form&nbsp;8-K. The Holder shall remain entitled to exercise this
Warrant during the period commencing on the date of such notice to the effective date of the event triggering such notice except as may
otherwise be expressly set forth herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section&nbsp;4</U>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Transfer
of Warrant</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Transferability</U>.
Subject to compliance with any applicable securities laws and the conditions set forth in Section&nbsp;4(d)&nbsp;hereof and to the
provisions of Section&nbsp;4.1 of the Purchase Agreement, this Warrant and all rights hereunder (including, without limitation, any
registration rights) are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company or
its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto duly executed by
the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon
such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the
assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall
issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be
cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to
the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the
Company within three (3)&nbsp;Trading Days of the date on which the Holder delivers an assignment form to the Company assigning this
Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of
Warrant Shares without having a new Warrant issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>New
Warrants</U>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company,
together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or
its agent or attorney. Subject to compliance with Section&nbsp;4(a), as to any transfer which may be involved in such division or combination,
the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in
accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the Issue Date of this Warrant and shall be
identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Warrant
Register</U>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the &#8220;<U>Warrant
Register</U>&#8221;), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder
of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other
purposes, absent actual notice to the contrary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Transfer
Restrictions</U>. If, at the time of the surrender of this Warrant in connection with any transfer of this Warrant, the transfer of this
Warrant shall not be either (i)&nbsp;registered pursuant to an effective registration statement under the Securities Act and under applicable
state securities or blue sky laws or (ii)&nbsp;eligible for resale without volume or manner-of-sale restrictions or current public information
requirements pursuant to Rule&nbsp;144, the Company may require, as a condition of allowing such transfer, that the Holder or transferee
of this Warrant, as the case may be, comply with the provisions of Section&nbsp;5.7 of the Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Representation
by the Holder</U>. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Warrant and, upon any
exercise hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account and not with a view to or for
distributing or reselling such Warrant Shares or any part thereof in violation of the Securities Act or any applicable state
securities law, except pursuant to sales registered or exempted under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section&nbsp;5</U>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Miscellaneous</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Rights as Stockholder Until Exercise; No Settlement in Cash</U>. This Warrant does not entitle the Holder to any voting rights, dividends
or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section&nbsp;2(d)(i), except as expressly
set forth in Section&nbsp;3. Without limiting the rights of a Holder to receive Warrant Shares on a &#8220;cashless exercise,&#8221;
and to receive the cash payments contemplated pursuant to Sections 2(d)(i)&nbsp;and 2(d)(iv), in no event will the Company be required
to net cash settle an exercise of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Loss,
Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory
to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case
of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include
the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make
and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Saturdays,
Sundays, Holidays,&nbsp;etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required or
granted herein shall not be a Trading Day, then, such action may be taken or such right may be exercised on the next succeeding Trading
Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Authorized
Shares</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a
sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant.
The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with
the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all
such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any
applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants
that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise
of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly
issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof
(other than taxes in respect of any transfer occurring contemporaneously with such issue).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending
its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale
of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant,
but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary
or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the
foregoing, the Company will (i)&nbsp;not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise
immediately prior to such increase in par value, (ii)&nbsp;take all such action as may be necessary or appropriate in order that the
Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii)&nbsp;use
commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction
thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the
Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from
any public regulatory body or bodies having jurisdiction thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Jurisdiction</U>.
All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined in accordance
with the provisions of the Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Restrictions</U>.
The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder does not
utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Nonwaiver
and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as
a waiver of such right or otherwise prejudice the Holder&#8217;s rights, powers or remedies, notwithstanding the fact that the right
to exercise this Warrant terminates on the Termination Date. Without limiting any other provision of this Warrant or the Purchase Agreement,
if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages to the
Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including, but not limited
to, reasonable attorneys&#8217; fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts due
pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notices</U>.
Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall be delivered
in accordance with the notice provisions of the Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Limitation
of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant
Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase
price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the
Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Remedies</U>.
The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific
performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss
incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any
action for specific performance that a remedy at law would be adequate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Successors
and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the
benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder.
The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable
by the Holder or holder of Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Amendment</U>.
This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company, on the one hand, and
the Holder of this Warrant, on the other hand.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Severability</U>.
Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law,
but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the
extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">n)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Headings</U>.
The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this
Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">********************</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Signature
Page&nbsp;Follows)<BR STYLE="clear: both"></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I></I></FONT></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above
indicated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase"><B>NEUROBO PHARMACEUTICALS,&nbsp;INC.
    &nbsp; &nbsp;</B></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 48%">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Name:</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Title: &nbsp;</TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTICE
OF EXERCISE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">To:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>NEUROBO
PHARMACEUTICALS,&nbsp;INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised
in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Payment
shall take the form of (check applicable box):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[
] in lawful money of the United States; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[
] if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection
2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure
set forth in subsection 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Please
issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Warrant Shares shall be delivered to the following DWAC Account Number:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Accredited
Investor</U>. The undersigned is an &#8220;accredited investor&#8221; as defined in Regulation D promulgated under the Securities Act
of 1933, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="white-space: nowrap; width: 15%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name</FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif">
of Investing Entity: </FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: justify; width: 85%"></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="white-space: nowrap; width: 20%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Signature
of Authorized Signatory of Investing Entity</I>:</FONT></TD>
<TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap; width: 80%; text-align: left">&nbsp;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="white-space: nowrap; width: 15%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name</FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif">
of Authorized Signatory: </FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: justify; width: 85%"></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="white-space: nowrap; width: 15%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
of Authorized Signatory:</FONT></TD>
<TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap; width: 85%; text-align: left">&nbsp;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: justify"></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASSIGNMENT
FORM</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(To
assign the foregoing Warrant, execute this form and supply required information. Do not use this form to exercise the Warrant to purchase
shares.)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FOR
VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U></U></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please
    Print)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U></U></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P></TD>
    <TD STYLE="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please
Print)</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Phone
Number:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Email
    Address: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    _________________ ____, ________________</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&#8217;s Signature:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 40%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&#8217;s Address:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 17; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>tm2129080d2_ex5-1.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 412.5pt"><B>Exhibit&nbsp;5.1</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 53%; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 47%; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: right">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><IMG SRC="tm2129080d2_ex5-1img001.jpg" ALT=""><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD>
    <TD STYLE="vertical-align: top; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>(269) 337-7700</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Fax: (269) 337-7701</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center">October&nbsp;4, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">NeuroBo Pharmaceuticals,&nbsp;Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">200 Berkeley Street, 19th Floor<BR>
Boston, Massachusetts, 02116</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><B><I>Re:&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prospectus
Supplement to Registration Statement on Form&nbsp;S-3 (File No.&nbsp;333-256135)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
</FONT>have acted as counsel to NeuroBo Pharmaceuticals,&nbsp;Inc., a Delaware corporation (the &ldquo;<B><I>Company</I></B>&rdquo;),
in connection with preparing and filing with the Securities and Exchange Commission (the &ldquo;<B><I>Commission</I></B>&rdquo;) pursuant
to the Securities Act of 1933, as amended (the &ldquo;<B><I>Securities Act</I></B>&rdquo;), (i)&nbsp;a Registration Statement on Form&nbsp;S-3
(File No.&nbsp;333-256135) (such registration statement as amended or supplemented from time to time, the &ldquo;<B><I>Registration Statement</I></B>&rdquo;)
declared effective on May&nbsp;26, 2021, and the prospectus of the Company included in the Registration Statement (the &ldquo;<B><I>Base
Prospectus</I></B>&rdquo;); and (ii)&nbsp;a prospectus supplement to the Base Prospectus dated October&nbsp;1, 2021 (the &ldquo;<B><I>Prospectus
Supplement</I></B>&rdquo;), pertaining to the issuance and sale by the Company of 4,307,693 shares (the &ldquo;<B><I>Offered Shares</I></B>&rdquo;)
of common stock, par value $0.001 per share. We understand that the Offered Shares are to be offered and sold in the manner set forth
in the Securities Purchase Agreement dated October&nbsp;1, 2021, entered into by the Company with the purchasers named in the signature
pages&nbsp;thereto (the &ldquo;<B><I>Purchase Agreement</I></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">For the purpose of rendering
this opinion, we examined originals or copies of such documents as we deemed relevant. In conducting our examination, we assumed, without
investigation, the genuineness of all signatures, the correctness of all certificates, the authenticity of all documents submitted to
us as originals, the conformity to original documents of all documents submitted as certified or photostatic copies, and the authenticity
of the originals of such copies, and the accuracy and completeness of all records made available to us by the Company. As to certain
factual matters, we have relied upon a certificate of officers of the Company and have not independently sought to verify such matters.
In addition, in rendering this opinion, we have assumed that the Offered Shares will be offered in the manner and on the terms identified
or referred to in the Registration Statement, the Base Prospectus and the Prospectus Supplement, including all supplements and amendments
thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">Our opinion is limited solely
to matters set forth herein. The law covered by the opinions expressed herein is limited to the federal law of the United States, New
York law applicable to contracts and Delaware corporate law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">Based upon our examination
of such documents and other matters as we deem relevant, we are of the opinion that the Offered Shares have been duly authorized by the
Company and, when issued and sold in accordance with the Registration Statement and the Prospectus Supplement, with payment received
by the Company in the manner described in the Purchase Agreement, will be validly issued, fully paid and non-assessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-top: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Honigman LLP &bull; 650 Trade Centre Way &bull; Suite&nbsp;200 &bull; Kalamazoo, Michigan 49002-0402</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="border-top: Black 1pt solid; padding: 2pt 5.4pt; vertical-align: top; width: 52%; border-bottom: Black 1pt solid; font-size: 10pt"><IMG SRC="tm2129080d2_ex5-1img002.jpg" ALT=""><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD>
    <TD STYLE="width: 48%; border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: right">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">NeuroBo Pharmaceuticals,&nbsp;Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">October&nbsp;4, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Page&nbsp;2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">We hereby consent to the
filing of this opinion with the Commission as Exhibit&nbsp;5.1 to the Registration Statement and to the reference to our firm under the
caption &ldquo;Legal Matters&rdquo; in the Registration Statement and the Prospectus Supplement. In giving such consent, we do not admit
that we are within the category of persons whose consent is required by Section&nbsp;7 of the Securities Act or the rules&nbsp;and regulations
promulgated thereunder by the Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%; font: 10pt Times New Roman, Times, Serif">Very truly yours,</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">/s/ Honigman LLP</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: small-caps 10pt Times New Roman, Times, Serif">Honigman LLP</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">PDT/JHK/JPK</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-top: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Honigman LLP &bull; 650 Trade Centre Way &bull; Suite&nbsp;200 &bull; Kalamazoo, Michigan 49002-0402</FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>4
<FILENAME>tm2129080d2_ex10-1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

                           <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.1</B>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>SECURITIES
PURCHASE AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Securities Purchase Agreement (this &ldquo;<U>Agreement</U>&rdquo;) is dated as of October&nbsp;1, 2021, between NeuroBo Pharmaceuticals,&nbsp;Inc.,
a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), and each purchaser identified on the signature pages&nbsp;hereto (each, including
its successors and assigns, a &ldquo;<U>Purchaser</U>&rdquo; and collectively the &ldquo;<U>Purchasers</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
subject to the terms and conditions set forth in this Agreement and pursuant to (i)&nbsp;an effective registration statement under the
Securities Act (as defined below) as to the Shares and (ii)&nbsp;an exemption from the registration requirements of Section&nbsp;5 of
the Securities Act contained in Section&nbsp;4(a)(2)&nbsp;thereof and/or Regulation D promulgated thereunder as to the Warrants, the
Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company,
securities of the Company as more fully described in this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOW,
THEREFORE,&nbsp;IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration the
receipt and adequacy of which are hereby acknowledged, the Company and each Purchaser agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE&nbsp;I.</B><BR>
DEFINITIONS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1 <U>Definitions</U>.
In addition to the terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following terms have the
meanings set forth in this Section&nbsp;1.1:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Acquiring
Person</U>&rdquo; shall have the meaning ascribed to such term in Section&nbsp;4.5.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Action</U>&rdquo;
shall have the meaning ascribed to such term in Section&nbsp;3.1(j).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person as such terms are used in and construed under Rule&nbsp;405 under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Board
of Directors</U>&rdquo; means the board of directors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Business
Day</U>&rdquo; means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized
or required by law to remain closed; <U>provided</U>, <U>however</U>, for clarification, commercial banks shall not be deemed to be authorized
or required by law to remain closed due to &ldquo;stay at home&rdquo;, &ldquo;shelter-in-place&rdquo;, &ldquo;non-essential employee&rdquo;&nbsp;
or any other similar orders or restrictions or the closure of any physical branch locations at the direction of any governmental authority
so long as the electronic funds transfer systems (including for wire transfers) of commercial banks in The City of New York are generally
open for use by customers on such day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Closing</U>&rdquo;
means the closing of the purchase and sale of the Securities pursuant to Section&nbsp;2.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Closing
Date</U>&rdquo; means the Trading Day on which all of the Transaction Documents have been executed and delivered by the applicable parties
thereto, and all conditions precedent to (i)&nbsp;the Purchasers&rsquo; obligations to pay the Subscription Amount and (ii)&nbsp;the
Company&rsquo;s obligations to deliver the Securities, in each case, have been satisfied or waived, but in no event later than the second
(2<SUP>nd</SUP>) Trading Day following the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common
Stock</U>&rdquo; means the common stock of the Company, par value $0.001 per share, and any other class of securities into which such
securities may hereafter be reclassified or changed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common
Stock Equivalents</U>&rdquo; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire
at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is
at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Company
Counsel</U>&rdquo; means Honigman LLP, with offices located at 2290 First National Building, 660 Woodward Avenue, Detroit, Michigan 48226-3506.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Disclosure
Schedules</U>&rdquo; means the Disclosure Schedules of the Company delivered concurrently herewith.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Disclosure
Time</U>&rdquo; means, (i)&nbsp;if this Agreement is signed on a day that is not a Trading Day or after 9:00 a.m.&nbsp;(New York City
time) and before midnight (New York City time) on any Trading Day, 9:01 a.m.&nbsp;(New York City time) on the Trading Day immediately
following the date hereof, unless otherwise instructed as to an earlier time by the Placement Agent, and (ii)&nbsp;if this Agreement
is signed between midnight (New York City time) and 9:00 a.m.&nbsp;(New York City time) on any Trading Day, no later than 9:01 a.m.&nbsp;(New
York City time) on the date hereof, unless otherwise instructed as to an earlier time by the Placement Agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Evaluation
Date</U>&rdquo; shall have the meaning ascribed to such term in Section&nbsp;3.1(s).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules&nbsp;and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Exempt
Issuance</U>&rdquo; means the issuance of (a)&nbsp;shares of Common Stock or options, restricted stock unit or other equity awards to
consultants, employees, officers or directors of the Company pursuant to any equity incentive plan duly adopted for such purpose, by
a majority of the non-employee members of the Board of Directors or a majority of the members of a committee of non-employee directors
established for such purpose for services rendered to the Company, provided that such issuances to consultants and such issuances of
restricted stock unit or other equity awards to consultants, employees, officers or directors of the Company are issued as &ldquo;restricted
securities&rdquo; (as defined in Rule&nbsp;144) and carry no registration rights that require or permit the filing of any registration
statement in connection therewith during the prohibition period in Section&nbsp;4.12(a)&nbsp;herein, (b)&nbsp;warrants to the Placement
Agent in connection with the transactions pursuant to this Agreement and any shares of Common Stock upon exercise of the warrants to
the Placement Agent, if applicable, and/or shares of Common Stock upon the exercise or exchange of or conversion of any Securities issued
hereunder and/or other securities exercisable or exchangeable for or convertible into shares of Common Stock issued and outstanding on
the date of this Agreement, provided that such securities have not been amended since the date of this Agreement to increase the number
of such securities or to decrease the exercise price, exchange price or conversion price of such securities (other than in connection
with stock splits or combinations) or to extend the term of such securities, (c)&nbsp;securities issued pursuant to acquisitions or strategic
transactions approved by a majority of the disinterested directors of the Company, provided that such securities are issued as &ldquo;restricted
securities&rdquo; (as defined in Rule&nbsp;144) and carry no registration rights that require or permit the filing of any registration
statement in connection therewith during the prohibition period in Section&nbsp;4.12(a)&nbsp;herein, and provided that any such issuance
shall only be to a Person (or to the equityholders of a Person) which is, itself or through its subsidiaries, an operating company or
an owner of an asset in a business synergistic with the business of the Company and shall provide to the Company additional benefits
in addition to the investment of funds, but shall not include a transaction in which the Company is issuing securities primarily for
the purpose of raising capital or to an entity whose primary business is investing in securities, (d)&nbsp;shares issuable upon a stock
split, stock dividend or any similar recapitalization, and (e)&nbsp;shares of Common Stock issued to consultants, provided that such
securities are issued as &ldquo;restricted securities&rdquo; (as defined in Rule&nbsp;144) and carry no registration rights that require
or permit the filing of any registration statement in connection therewith during the prohibition period in Section&nbsp;4.12(a)&nbsp;herein..</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>FCPA</U>&rdquo;
means the Foreign Corrupt Practices Act of 1977, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>FDA</U>&rdquo;
shall have the meaning ascribed to such term in Section&nbsp;3.1(hh).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>FDCA</U>&rdquo;
shall have the meaning ascribed to such term in Section&nbsp;3.1(hh).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>GAAP</U>&rdquo;
shall have the meaning ascribed to such term in Section&nbsp;3.1(h).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Indebtedness</U>&rdquo;
shall have the meaning ascribed to such term in Section&nbsp;3.1(aa).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Intellectual
Property Rights</U>&rdquo; shall have the meaning ascribed to such term in Section&nbsp;3.1(p).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Legend
Removal Date</U>&rdquo; shall have the meaning ascribed to such term in Section&nbsp;4.1(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Liens</U>&rdquo;
means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Material
Adverse Effect</U>&rdquo; shall have the meaning assigned to such term in Section&nbsp;3.1(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Material
Permits</U>&rdquo; shall have the meaning ascribed to such term in Section&nbsp;3.1(n).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Per
Share Purchase Price</U>&rdquo; equals $3.25, subject to adjustment for reverse and forward stock splits, stock dividends, stock combinations
and other similar transactions of the Common Stock that occur after the date of this Agreement and prior to the Closing Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Pharmaceutical
Product</U>&rdquo; shall have the meaning ascribed to such term in Section&nbsp;3.1(hh).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Placement
Agent</U>&rdquo; means H.C. Wainwright&nbsp;&amp; Co., LLC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Proceeding</U>&rdquo;
means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial proceeding,
such as a deposition), whether commenced or threatened.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Prospectus</U>&rdquo;
means the final base prospectus filed for the Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Prospectus
Supplement</U>&rdquo; means the supplement to the Prospectus complying with Rule&nbsp;424(b)&nbsp;of the Securities Act that is filed
with the Commission and delivered by the Company to each Purchaser at the Closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Purchaser
Party</U>&rdquo; shall have the meaning ascribed to such term in Section&nbsp;4.8.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Registration
Statement</U>&rdquo; means the effective registration statement with Commission (File No.&nbsp;333-256135), including all information,
documents and exhibits filed with or incorporated by reference into such registration statement, which registers the sale of the Shares
to the Purchasers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Required
Approvals</U>&rdquo; shall have the meaning ascribed to such term in Section&nbsp;3.1(e).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Rule&nbsp;144</U>&rdquo;
means Rule&nbsp;144 promulgated by the Commission pursuant to the Securities Act, as such Rule&nbsp;may be amended or interpreted from
time to time, or any similar rule&nbsp;or regulation hereafter adopted by the Commission having substantially the same purpose and effect
as such Rule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Rule&nbsp;424</U>&rdquo;
means Rule&nbsp;424 promulgated by the Commission pursuant to the Securities Act, as such Rule&nbsp;may be amended or interpreted from
time to time, or any similar rule&nbsp;or regulation hereafter adopted by the Commission having substantially the same purpose and effect
as such Rule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>SEC
Reports</U>&rdquo; shall have the meaning ascribed to such term in Section&nbsp;3.1(h).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Securities</U>&rdquo;
means the Shares, the Warrants and the Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended, and the rules&nbsp;and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Shares</U>&rdquo;
means the shares of Common Stock issued or issuable to each Purchaser pursuant to this Agreement, but excluding the Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Short
Sales</U>&rdquo; means all &ldquo;short sales&rdquo; as defined in Rule&nbsp;200 of Regulation SHO under the Exchange Act (but shall
not be deemed to include locating and/or borrowing shares of Common Stock).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Subscription
Amount</U>&rdquo; means, as to each Purchaser, the aggregate amount to be paid for Shares and Warrants purchased hereunder as specified
below such Purchaser&rsquo;s name on the signature page&nbsp;of this Agreement and next to the heading &ldquo;Subscription Amount,&rdquo;
in United States dollars and in immediately available funds.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Subsidiary</U>&rdquo;
means any subsidiary of the Company as set forth in the SEC Reports, and shall, where applicable, also include any direct or indirect
subsidiary of the Company formed or acquired after the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Trading
Day</U>&rdquo; means a day on which the principal Trading Market is open for trading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Trading
Market</U>&rdquo; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date
in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market or the New York
Stock Exchange (or any successors to any of the foregoing).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Transaction
Documents</U>&rdquo; means this Agreement, the Warrants, all exhibits and schedules thereto and hereto and any other documents or agreements
executed in connection with the transactions contemplated hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Transfer
Agent</U>&rdquo; means Computershare,&nbsp;Inc., the current transfer agent of the Company, with a mailing address of 7530 Lucerne Drive,
Suite&nbsp;305, Cleveland, Ohio 44130, and any successor transfer agent of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Variable
Rate Transaction</U>&rdquo; shall have the meaning ascribed to such term in Section&nbsp;4.12(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a)&nbsp;if the Common Stock is then listed
or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30
a.m.&nbsp;(New York City time) to 4:02 p.m.&nbsp;(New York City time)), (b)&nbsp; if OTCQB or OTCQX is not a Trading Market, the volume
weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c)&nbsp;if
the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the
Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per
share of the Common Stock so reported, or (d)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined
by an independent appraiser selected in good faith by the Purchasers of a majority in interest of the Securities then outstanding and
reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Warrants</U>&rdquo;
means, collectively, the Common Stock purchase warrants delivered to the Purchasers at the Closing in accordance with Section&nbsp;2.2(a)&nbsp;hereof,
which Warrants shall be exercisable commencing six (6)&nbsp;month following the issuance date and have a term equal to three and one-half
(3.5) years, in the form of Exhibit&nbsp;A attached hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Warrant
Shares</U>&rdquo; means the shares of Common Stock issuable upon exercise of the Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE&nbsp;II.</B><BR>
PURCHASE AND SALE</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1 <U>Closing</U>.
On the Closing Date, upon the terms and subject to the conditions set forth herein, the Company agrees to sell, and the Purchasers,
severally and not jointly, agree to purchase, up to an aggregate of approximately $14.0 million of Shares and Warrants. Each
Purchaser&rsquo;s Subscription Amount as set forth on the signature page&nbsp;hereto executed by such Purchaser shall be made
available for &ldquo;Delivery Versus Payment&rdquo; (&ldquo;<U>DVP</U>&rdquo;) settlement with the Company or its designee. The
Company shall deliver to each Purchaser its respective Shares and a Warrant as determined pursuant to Section&nbsp;2.2(a), and the
Company and each Purchaser shall deliver the other items set forth in Section&nbsp;2.2 deliverable at the Closing. Upon satisfaction
of the covenants and conditions set forth in Sections 2.2 and 2.3, the Closing shall occur at the offices of Company Counsel or such
other location (including remotely by electronic transmission) as the parties shall mutually agree. Unless otherwise directed by the
Placement Agent, settlement of the Shares shall occur via DVP (i.e., on the Closing Date, the Company shall issue the Shares
registered in the Purchasers&rsquo; names and addresses and released by the Transfer Agent directly to the account(s)&nbsp;at the
Placement Agent identified by each Purchaser; upon receipt of such Shares, the Placement Agent shall promptly electronically deliver
such Shares to the applicable Purchaser, and payment therefor shall be made by the Placement Agent (or its clearing firm) by wire
transfer to the Company). Notwithstanding anything herein to the contrary, if at any time on or after the time of execution of this
Agreement by the Company and an applicable Purchaser, through, and including the time immediately prior to the Closing (the
 &ldquo;<U>Pre-Settlement Period</U>&rdquo;), if such Purchaser sells to any Person all, or any portion, of any Common Stock to be
issued hereunder to such Purchaser at the Closing (collectively, the &ldquo;<U>Pre-Settlement Shares</U>&rdquo;), such Purchaser
shall, automatically hereunder (without any additional required actions by such Purchaser or the Company), be deemed to be
unconditionally bound to purchase, and the Company shall be deemed unconditionally bound to sell, such Pre-Settlement Shares to such
Purchaser at the Closing; provided, that the Company shall not be required to deliver any Pre-Settlement Shares to such Purchaser
prior to the Company&rsquo;s receipt of the Subscription Amount for such Pre-Settlement Shares hereunder; provided, further, that
the Company hereby acknowledges and agrees that the forgoing shall not constitute a representation or covenant by such Purchaser as
to whether or not such Purchaser will elect to sell any Pre-Settlement Shares during the Pre-Settlement Period. The decision to sell
any shares of Common Stock will be made in the sole discretion of such Purchaser from time to time, including during the
Pre-Settlement Period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2 <U>Deliveries</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
or prior to the Closing Date, the Company shall deliver or cause to be delivered to each Purchaser the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;this
Agreement duly executed by the Company;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a
legal opinion of Company Counsel, directed to the Placement Agent and the Purchasers, in a form reasonably acceptable to the Placement
Agent and Purchasers;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
Company shall have provided each Purchaser with the Company&rsquo;s wire instructions, on Company letterhead and executed by the Chief
Executive Officer or Chief Financial Officer;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;subject
to the fifth sentence of Section&nbsp;2.1, a copy of the irrevocable instructions to the Transfer Agent instructing the Transfer Agent
to deliver on an expedited basis via The Depository Trust Company Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;)
Shares equal to such Purchaser&rsquo;s Subscription Amount divided by the Per Share Purchase Price, registered in the name of such Purchaser;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a
Warrant registered in the name of such Purchaser to purchase up to a number of shares of Common Stock equal to 100% of such Purchaser&rsquo;s
Shares, with an exercise price equal to $3.75, subject to adjustment therein; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
Prospectus and Prospectus Supplement (which may be delivered in accordance with Rule&nbsp;172 under the Securities Act).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
or prior to the Closing Date, each Purchaser shall deliver or cause to be delivered to the Company the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;this
Agreement duly executed by such Purchaser; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;such
Purchaser&rsquo;s Subscription Amount, which shall be made available for DVP settlement with the Company or its designee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3 <U>Closing
Conditions</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
obligations of the Company hereunder in connection with the Closing are subject to the following conditions being met:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse Effect,
in all respects) when made and on the Closing Date of the representations and warranties of the Purchasers contained herein (unless as
of a specific date therein in which case they shall be accurate as of such date);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;all
obligations, covenants and agreements of each Purchaser required to be performed at or prior to the Closing Date shall have been performed;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
delivery by each Purchaser of the items set forth in Section&nbsp;2.2(b)&nbsp;of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
respective obligations of the Purchasers hereunder in connection with the Closing are subject to the following conditions being met:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse Effect,
in all respects) when made and on the Closing Date of the representations and warranties of the Company contained herein (unless as of
a specific date therein in which case they shall be accurate as of such date);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;all
obligations, covenants and agreements of the Company required to be performed at or prior to the Closing Date shall have been performed;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
delivery by the Company of the items set forth in Section&nbsp;2.2(a)&nbsp;of this Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;there
shall have been no Material Adverse Effect with respect to the Company since the date hereof; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;from
the date hereof to the Closing Date, trading in the Common Stock shall not have been suspended by the Commission or the
Company&rsquo;s principal Trading Market, and, at any time prior to the Closing Date, trading in securities generally as reported by
Bloomberg L.P. shall not have been suspended or limited, or minimum prices shall not have been established on securities whose
trades are reported by such service, or on any Trading Market, nor shall a banking moratorium have been declared either by the
United States or New York State authorities nor shall there have occurred any material outbreak or escalation of hostilities or
other national or international calamity of such magnitude in its effect on, or any material adverse change in, any financial market
which, in each case, in the reasonable judgment of such Purchaser, makes it impracticable or inadvisable to purchase the Securities
at the Closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE&nbsp;III.</B><BR>
REPRESENTATIONS AND WARRANTIES</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1 <U>Representations
and Warranties of the Company</U>. Except as set forth in the Disclosure Schedules, which Disclosure Schedules shall be deemed a
part hereof and shall qualify any representation or otherwise made herein to the extent of the disclosure contained in the
corresponding section of the Disclosure Schedules, the Company hereby makes the following representations and warranties to each
Purchaser:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Subsidiaries</U>.
All of the direct and indirect subsidiaries of the Company are set forth in the SEC Reports. The Company owns, directly or indirectly,
all of the capital stock or other equity interests of each Subsidiary free and clear of any Liens, and all of the issued and outstanding
shares of capital stock of each Subsidiary are validly issued and are fully paid, non-assessable and free of preemptive and similar rights
to subscribe for or purchase securities. If the Company has no subsidiaries, all other references to the Subsidiaries or any of them
in the Transaction Documents shall be disregarded.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Organization
and Qualification</U>. The Company and each of the Subsidiaries is an entity duly incorporated or otherwise organized, validly existing
and in good standing under the laws of the jurisdiction of its incorporation or organization, with the requisite power and authority
to own and use its properties and assets and to carry on its business as currently conducted. Neither the Company nor any Subsidiary
is in violation nor default of any of the provisions of its respective certificate or articles of incorporation, bylaws or other organizational
or charter documents. Each of the Company and the Subsidiaries is duly qualified to conduct business and is in good standing as a foreign
corporation or other entity in each jurisdiction in which the nature of the business conducted or property owned by it makes such qualification
necessary, except where the failure to be so qualified or in good standing, as the case may be, could not have or reasonably be expected
to result in: (i)&nbsp;a material adverse effect on the legality, validity or enforceability of any Transaction Document, (ii)&nbsp;a
material adverse effect on the results of operations, assets, business, prospects or condition (financial or otherwise) of the Company
and the Subsidiaries, taken as a whole, or (iii)&nbsp;a material adverse effect on the Company&rsquo;s ability to perform in any material
respect on a timely basis its obligations under any Transaction Document (any of (i), (ii)&nbsp;or (iii), a &ldquo;<U>Material Adverse
Effect</U>&rdquo;) and no Proceeding has been instituted in any such jurisdiction revoking, limiting or curtailing or seeking to revoke,
limit or curtail such power and authority or qualification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Authorization;
Enforcement</U>. The Company has the requisite corporate power and authority to enter into and to consummate the transactions
contemplated by this Agreement and each of the other Transaction Documents and otherwise to carry out its obligations hereunder and
thereunder. The execution and delivery of this Agreement and each of the other Transaction Documents by the Company and the
consummation by it of the transactions contemplated hereby and thereby have been duly authorized by all necessary action on the part
of the Company and no further action is required by the Company, the Board of Directors or the Company&rsquo;s stockholders in
connection herewith or therewith other than in connection with the Required Approvals. This Agreement and each other Transaction
Document to which it is a party has been (or upon delivery will have been) duly executed by the Company and, when delivered in
accordance with the terms hereof and thereof, will constitute the valid and binding obligation of the Company enforceable against
the Company in accordance with its terms, except (i)&nbsp;as limited by general equitable principles and applicable bankruptcy,
insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors&rsquo; rights
generally, (ii)&nbsp;as limited by laws relating to the availability of specific performance, injunctive relief or other equitable
remedies and (iii)&nbsp;insofar as indemnification and contribution provisions may be limited by applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: lightgrey"></FONT></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; background-color: lightgrey"></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Conflicts</U>. The execution, delivery and performance by the Company of this Agreement and the other Transaction Documents to which
it is a party, the issuance and sale of the Securities and the consummation by it of the transactions contemplated hereby and thereby
do not and will not (i)&nbsp;conflict with or violate any provision of the Company&rsquo;s or any Subsidiary&rsquo;s certificate or articles
of incorporation, bylaws or other organizational or charter documents, or (ii)&nbsp;conflict with, or constitute a default (or an event
that with notice or lapse of time or both would become a default) under, result in the creation of any Lien upon any of the properties
or assets of the Company or any Subsidiary, or give to others any rights of termination, amendment, anti-dilution or similar adjustments,
acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument
(evidencing a Company or Subsidiary debt or otherwise) or other understanding to which the Company or any Subsidiary is a party or by
which any property or asset of the Company or any Subsidiary is bound or affected, or (iii)&nbsp;subject to the Required Approvals, conflict
with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or
governmental authority to which the Company or a Subsidiary is subject (including federal and state securities laws and regulations),
or by which any property or asset of the Company or a Subsidiary is bound or affected; except in the case of each of clauses (ii)&nbsp;and
(iii), such as could not have or reasonably be expected to result in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Filings,
Consents and Approvals</U>. The Company is not required to obtain any consent, waiver, authorization or order of, give any notice
to, or make any filing or registration with, any court or other federal, state, local or other governmental authority or other
Person in connection with the execution, delivery and performance by the Company of the Transaction Documents, other than:
(i)&nbsp;the filings required pursuant to Section&nbsp;4.4 of this Agreement, (ii)&nbsp;the filing with the Commission of the
Prospectus Supplement, (iii)&nbsp;application(s)&nbsp;to each applicable Trading Market for the listing of the Shares and Warrant
Shares for trading thereon in the time and manner required thereby, (iv)&nbsp;the filing of Form&nbsp;D with the Commission and
(v)&nbsp;such filings as are required to be made under applicable state securities laws (collectively, the &ldquo;<U>Required
Approvals</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Split-Segment; Name: SP2 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Issuance
of the Securities; Registration</U>. The Securities are duly authorized and, when issued and paid for in accordance with the applicable
Transaction Documents, will be duly and validly issued, fully paid and nonassessable, free and clear of all Liens imposed by the Company.
The Warrant Shares, when issued in accordance with the terms of the Warrants, will be validly issued, fully paid and nonassessable, free
and clear of all Liens imposed by the Company. The Company has reserved from its duly authorized capital stock the maximum number of
shares of Common Stock issuable pursuant to this Agreement and the Warrants. The Company has prepared and filed the Registration Statement
in conformity with the requirements of the Securities Act, which became effective on&nbsp;May&nbsp;26, 2021, including the Prospectus,
and such amendments and supplements thereto as may have been required to the date of this Agreement. The Company was at the time of the
filing of the Registration Statement eligible to use Form&nbsp;S-3. The Company is eligible to use Form&nbsp;S-3 under the Securities
Act and it meets the transaction requirements with respect to the aggregate market value of securities being sold pursuant to this offering
and during the twelve (12) calendar months prior to this offering, as set forth in General Instruction I.B.6 of Form&nbsp;S-3. The Registration
Statement is effective under the Securities Act and no stop order preventing or suspending the effectiveness of the Registration Statement
or suspending or preventing the use of the Prospectus has been issued by the Commission and no proceedings for that purpose have been
instituted or, to the knowledge of the Company, are threatened by the Commission. The Company, if required by the rules&nbsp;and regulations
of the Commission, shall file the Prospectus Supplement with the Commission pursuant to Rule&nbsp;424(b). At the time the Registration
Statement and any amendments thereto became effective, at the date of this Agreement and at the Closing Date, the Registration Statement
and any amendments thereto conformed and will conform in all material respects to the requirements of the Securities Act and did not
and will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary
to make the statements therein not misleading; and the Prospectus and any amendments or supplements thereto, at the time the Prospectus
or any amendment or supplement thereto was issued and at the Closing Date, conformed and will conform in all material respects to the
requirements of the Securities Act and did not and will not contain an untrue statement of a material fact or omit to state a material
fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Capitalization</U>.
The capitalization of the Company is as set forth in the SEC Reports. The Company has not issued any capital stock since its most recently
filed periodic report under the Exchange Act, other than pursuant to the exercise of employee stock options under the Company&rsquo;s
stock option plans, the issuance of shares of Common Stock to employees pursuant to the Company&rsquo;s employee stock purchase plans
and pursuant to the conversion and/or exercise of Common Stock Equivalents outstanding as of the date of the most recently filed periodic
report under the Exchange Act. No Person has any right of first refusal, preemptive right, right of participation, or any similar right
to participate in the transactions contemplated by the Transaction Documents. Except as set forth in the SEC Reports or as a result of
the purchase and sale of the Securities or as issued under the Company&rsquo;s existing stock plans (the &ldquo;<U>Stock Plans</U>&rdquo;),
there are no outstanding options, warrants, scrip rights to subscribe to, calls or commitments of any character whatsoever relating to,
or securities, rights or obligations convertible into or exercisable or exchangeable for, or giving any Person any right to subscribe
for or acquire, any shares of Common Stock or the capital stock of any Subsidiary, or contracts, commitments, understandings or arrangements
by which the Company or any Subsidiary is or may become bound to issue additional shares of Common Stock or Common Stock Equivalents
or capital stock of any Subsidiary. The issuance and sale of the Securities will not obligate the Company or any Subsidiary to issue
shares of Common Stock or other securities to any Person (other than the Purchasers). There are no outstanding securities or instruments
of the Company or any Subsidiary with any provision that adjusts the exercise, conversion, exchange or reset price of such security or
instrument upon an issuance of securities by the Company or any Subsidiary. There are no outstanding securities or instruments of the
Company or any Subsidiary that contain any redemption or similar provisions, and there are no contracts, commitments, understandings
or arrangements by which the Company or any Subsidiary is or may become bound to redeem a security of the Company or such Subsidiary.
The Company does not have any stock appreciation rights or &ldquo;phantom stock&rdquo; plans or agreements or any similar plan or agreement.
All of the outstanding shares of capital stock of the Company are duly authorized, validly issued, fully paid and nonassessable, have
been issued in compliance with all applicable federal and state securities laws, and none of such outstanding shares was issued in violation
of any preemptive rights or similar rights to subscribe for or purchase securities. No further approval or authorization of any stockholder,
the Board of Directors or others is required for the issuance and sale of the Securities. There are no stockholders agreements, voting
agreements or other similar agreements with respect to the Company&rsquo;s capital stock to which the Company is a party or, to the knowledge
of the Company, between or among any of the Company&rsquo;s stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SEC
Reports; Financial Statements</U>. The Company has filed all reports, schedules, forms, statements and other documents required to be
filed by the Company under the Securities Act and the Exchange Act, including pursuant to Section&nbsp;13(a)&nbsp;or 15(d)&nbsp;thereof,
for the two (2)&nbsp;years preceding the date hereof (or such shorter period as the Company was required by law or regulation to file
such material) (the foregoing materials, including the exhibits thereto and documents incorporated by reference therein, together with
the Prospectus and the Prospectus Supplement, being collectively referred to herein as the &ldquo;<U>SEC Reports</U>&rdquo;) on a timely
basis or has received a valid extension of such time of filing and has filed any such SEC Reports prior to the expiration of any such
extension. As of their respective dates, the SEC Reports complied in all material respects with the requirements of the Securities Act
and the Exchange Act, as applicable, and none of the SEC Reports, when filed, contained any untrue statement of a material fact or omitted
to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances
under which they were made, not misleading. The Company has never been an issuer subject to Rule&nbsp;144(i)&nbsp;under the Securities
Act. The financial statements of the Company included in the SEC Reports comply in all material respects with applicable accounting requirements
and the rules&nbsp;and regulations of the Commission with respect thereto as in effect at the time of filing. Such financial statements
have been prepared in accordance with United States generally accepted accounting principles applied on a consistent basis during the
periods involved (&ldquo;<U>GAAP</U>&rdquo;), except as may be otherwise specified in such financial statements or the notes thereto
and except that unaudited financial statements may not contain all footnotes required by GAAP, and fairly present in all material respects
the financial position of the Company and its consolidated Subsidiaries as of and for the dates thereof and the results of operations
and cash flows for the periods then ended, subject, in the case of unaudited statements, to normal, immaterial, year-end audit adjustments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Value: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Material
Changes; Undisclosed Events, Liabilities or Developments</U>. Since the date of the latest audited financial statements included within
the SEC Reports, except as set forth in subsequent SEC Reports filed prior to the date hereof, (i)&nbsp;there has been no event, occurrence
or development that has had or that could reasonably be expected to result in a Material Adverse Effect, (ii)&nbsp;the Company has not
incurred any liabilities (contingent or otherwise) other than (A)&nbsp;trade payables and accrued expenses incurred in the ordinary course
of business consistent with past practice and (B)&nbsp;liabilities not required to be reflected in the Company&rsquo;s financial statements
pursuant to GAAP or disclosed in filings made with the Commission, (iii)&nbsp;the Company has not altered its method of accounting, (iv)&nbsp;the
Company has not declared or made any dividend or distribution of cash or other property to its stockholders or purchased, redeemed or
made any agreements to purchase or redeem any shares of its capital stock and (v)&nbsp;the Company has not issued any equity securities
to any officer, director or Affiliate, except pursuant to the Stock Plans or as set forth in the SEC Reports. The Company does not have
pending before the Commission any request for confidential treatment of information. Except for the issuance of the Securities contemplated
by this Agreement or as set forth in the SEC Reports, no event, liability, fact, circumstance, occurrence or development has occurred
or exists or is reasonably expected to occur or exist with respect to the Company or its Subsidiaries or their respective businesses,
prospects, properties, operations, assets or financial condition that would be required to be disclosed by the Company under applicable
securities laws at the time this representation is made or deemed made that has not been publicly disclosed at least one (1)&nbsp;Trading
Day prior to the date that this representation is made.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Litigation</U>.
There is no action, suit, inquiry, notice of violation, proceeding or investigation pending or, to the knowledge of the Company, threatened
against or affecting the Company, any Subsidiary or any of their respective properties before or by any court, arbitrator, governmental
or administrative agency or regulatory authority (federal, state, county, local or foreign) (collectively, an &ldquo;<U>Action</U>&rdquo;)
which (i)&nbsp;adversely affects or challenges the legality, validity or enforceability of any of the Transaction Documents or the Securities
or (ii)&nbsp;could, if there were an unfavorable decision, have or reasonably be expected to result in a Material Adverse Effect. Neither
the Company nor any Subsidiary, nor any director or officer thereof, is or has been the subject of any Action involving a claim of violation
of or liability under federal or state securities laws or a claim of breach of fiduciary duty. There has not been, and to the knowledge
of the Company, there is not pending or contemplated, any investigation by the Commission involving the Company or any current or former
director or officer of the Company. The Commission has not issued any stop order or other order suspending the effectiveness of any registration
statement filed by the Company or any Subsidiary under the Exchange Act or the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Labor
Relations</U>. No labor dispute exists or, to the knowledge of the Company, is imminent with respect to any of the employees of the Company,
which could reasonably be expected to result in a Material Adverse Effect. None of the Company&rsquo;s or its Subsidiaries&rsquo; employees
is a member of a union that relates to such employee&rsquo;s relationship with the Company or such Subsidiary, and neither the Company
nor any of its Subsidiaries is a party to a collective bargaining agreement, and the Company and its Subsidiaries believe that their
relationships with their employees are good. To the knowledge of the Company, no executive officer of the Company or any Subsidiary,
is, or is now expected to be, in violation of any material term of any employment contract, confidentiality, disclosure or proprietary
information agreement or non-competition agreement, or any other contract or agreement or any restrictive covenant in favor of any third
party, and the continued employment of each such executive officer does not subject the Company or any of its Subsidiaries to any liability
with respect to any of the foregoing matters. The Company and its Subsidiaries are in compliance with all applicable U.S. federal, state,
local and foreign laws and regulations relating to employment and employment practices, terms and conditions of employment and wages
and hours, except where the failure to be in compliance could not, individually or in the aggregate, reasonably be expected to have a
Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Compliance</U>.
Neither the Company nor any Subsidiary: (i)&nbsp;is in default under or in violation of (and no event has occurred that has not been
waived that, with notice or lapse of time or both, would result in a default by the Company or any Subsidiary under), nor has the Company
or any Subsidiary received notice of a claim that it is in default under or that it is in violation of, any indenture, loan or credit
agreement or any other agreement or instrument to which it is a party or by which it or any of its properties is bound (whether or not
such default or violation has been waived), (ii)&nbsp;is in violation of any judgment, decree or order of any court, arbitrator or other
governmental authority or (iii)&nbsp;is or has been in violation of any statute, rule, ordinance or regulation of any governmental authority,
including without limitation all foreign, federal, state and local laws relating to taxes, environmental protection, occupational health
and safety, product quality and safety and employment and labor matters, except in each case as could not have or reasonably be expected
to result in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Environmental
Laws</U>. The Company and its Subsidiaries (i)&nbsp;are in compliance with all federal, state, local and foreign laws relating to pollution
or protection of human health or the environment (including ambient air, surface water, groundwater, land surface or subsurface strata),
including laws relating to emissions, discharges, releases or threatened releases of chemicals, pollutants, contaminants, or toxic or
hazardous substances or wastes (collectively, &ldquo;<U>Hazardous Materials</U>&rdquo;) into the environment, or otherwise relating to
the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials, as well as
all authorizations, codes, decrees, demands, or demand letters, injunctions, judgments, licenses, notices or notice letters, orders,
permits, plans or regulations, issued, entered, promulgated or approved thereunder (&ldquo;<U>Environmental Laws</U>&rdquo;); (ii)&nbsp;have
received all permits, licenses or other approvals required of them under applicable Environmental Laws to conduct their respective businesses;
and (iii)&nbsp;are in compliance with all terms and conditions of any such permit, license or approval where in each clause (i), (ii)&nbsp;and
(iii), the failure to so comply could be reasonably expected to have, individually or in the aggregate, a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Regulatory
Permits</U>. The Company and the Subsidiaries possess all certificates, authorizations and permits issued by the appropriate federal,
state, local or foreign regulatory authorities necessary to conduct their respective businesses as described in the SEC Reports, except
where the failure to possess such permits could not reasonably be expected to result in a Material Adverse Effect (&ldquo;<U>Material
Permits</U>&rdquo;), and neither the Company nor any Subsidiary has received any notice of proceedings relating to the revocation or
modification of any Material Permit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(o)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Title
to Assets</U>. The Company and the Subsidiaries have good and marketable title in fee simple to all real property owned by them and good
and marketable title in all personal property owned by them that is material to the business of the Company and the Subsidiaries, in
each case free and clear of all Liens, except for (i)&nbsp;Liens as do not materially affect the value of such property and do not materially
interfere with the use made and proposed to be made of such property by the Company and the Subsidiaries, and (ii)&nbsp;Liens for the
payment of federal, state or other taxes, for which appropriate reserves have been made therefor in accordance with GAAP and, the payment
of which is neither delinquent nor subject to penalties. Any real property and facilities held under lease by the Company and the Subsidiaries
are held by them under valid, subsisting and enforceable leases with which the Company and the Subsidiaries are in compliance, except
were the failure to be in compliance could not reasonably be expected to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(p)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Intellectual
Property</U>. The Company and the Subsidiaries have, or have rights to use, all patents, patent applications, trademarks, trademark applications,
service marks, trade names, trade secrets, inventions, copyrights, licenses and other intellectual property rights and similar rights
necessary or required for use in connection with their respective businesses as described in the SEC Reports and which the failure to
so have could have a Material Adverse Effect (collectively, the &ldquo;<U>Intellectual Property Rights</U>&rdquo;). None of, and neither
the Company nor any Subsidiary has received a notice (written or otherwise) that any of, the Intellectual Property Rights has expired,
terminated or been abandoned, or is expected to expire or terminate or be abandoned, within two (2)&nbsp;years from the date of this
Agreement. Neither the Company nor any Subsidiary has received, since the date of the latest audited financial statements included within
the SEC Reports, a written notice of a claim or otherwise has any knowledge that the Intellectual Property Rights violate or infringe
upon the rights of any Person, except as could not have or reasonably be expected to not have a Material Adverse Effect. To the knowledge
of the Company, all such Intellectual Property Rights are enforceable and there is no existing infringement by another Person of any
of the Intellectual Property Rights. The Company and its Subsidiaries have taken reasonable security measures to protect the secrecy,
confidentiality and value of all of their intellectual properties, except where failure to do so could not, individually or in the aggregate,
reasonably be expected to have a Material Adverse Effect. The Company has no knowledge of any facts that would preclude it from having
valid license rights or clear title to the Intellectual Property Rights. The Company has no knowledge that it lacks or will be unable
to obtain any rights or licenses to use all Intellectual Property Rights that are necessary to conduct its business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(q)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Insurance</U>.
The Company and the Subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks and in
such amounts as are prudent and customary in the businesses in which the Company and the Subsidiaries are engaged, including, but not
limited to, directors and officers insurance coverage at least equal to the aggregate Subscription Amount. Neither the Company nor any
Subsidiary has any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires
or to obtain similar coverage from similar insurers as may be necessary to continue its business without a significant increase in cost.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(r)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Transactions
With Affiliates and Employees</U>. Except as set forth in the SEC Reports, none of the officers or directors of the Company or any Subsidiary
and, to the knowledge of the Company, none of the employees of the Company or any Subsidiary is presently a party to any transaction
with the Company or any Subsidiary (other than for services as employees, officers and directors), including any contract, agreement
or other arrangement providing for the furnishing of services to or by, providing for rental of real or personal property to or from,
providing for the borrowing of money from or lending of money to or otherwise requiring payments to or from any officer, director or
such employee or, to the knowledge of the Company, any entity in which any officer, director, or any such employee has a substantial
interest or is an officer, director, trustee, stockholder, member or partner, in each case in excess of $120,000 other than for (i)&nbsp;payment
of salary or consulting fees for services rendered, (ii)&nbsp;reimbursement for expenses incurred on behalf of the Company and (iii)&nbsp;other
employee benefits, including stock option agreements under any stock option plan of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(s)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Sarbanes-Oxley;
Internal Accounting Controls</U>. The Company and the Subsidiaries are in compliance in all material respects with any and all applicable
requirements of the Sarbanes-Oxley Act of 2002 that are effective as of the date hereof, and any and all applicable rules&nbsp;and regulations
promulgated by the Commission thereunder that are effective as of the date hereof and as of the Closing Date. The Company and the Subsidiaries
maintain a system of internal accounting controls sufficient to provide reasonable assurance that: (i)&nbsp;transactions are executed
in accordance with management&rsquo;s general or specific authorizations, (ii)&nbsp;transactions are recorded as necessary to permit
preparation of financial statements in conformity with GAAP and to maintain asset accountability, (iii)&nbsp;access to assets is permitted
only in accordance with management&rsquo;s general or specific authorization, and (iv)&nbsp;the recorded accountability for assets is
compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences. The Company
and the Subsidiaries have established disclosure controls and procedures (as defined in Exchange Act Rules&nbsp;13a-15(e)&nbsp;and 15d-15(e))
for the Company and the Subsidiaries and designed such disclosure controls and procedures to ensure that information required to be disclosed
by the Company in the reports it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the
time periods specified in the Commission&rsquo;s rules&nbsp;and forms. The Company&rsquo;s certifying officers have evaluated the effectiveness
of the disclosure controls and procedures of the Company and the Subsidiaries as of the end of the period covered by the most recently
filed periodic report under the Exchange Act (such date, the &ldquo;<U>Evaluation Date</U>&rdquo;). The Company presented in its most
recently filed periodic report under the Exchange Act the conclusions of the certifying officers about the effectiveness of the disclosure
controls and procedures based on their evaluations as of the Evaluation Date. Since the Evaluation Date, there have been no changes in
the internal control over financial reporting (as such term is defined in the Exchange Act) of the Company and its Subsidiaries that
have materially affected, or is reasonably likely to materially affect, the internal control over financial reporting of the Company
and its Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(t)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Certain
Fees</U>. Except as set forth in the Prospectus Supplement, no brokerage or finder&rsquo;s fees or commissions are or will be payable
by the Company or any Subsidiary to any broker, financial advisor or consultant, finder, placement agent, investment banker, bank or
other Person with respect to the transactions contemplated by the Transaction Documents. The Purchasers shall have no obligation with
respect to any fees or with respect to any claims made by or on behalf of other Persons for fees of a type contemplated in this Section&nbsp;that
may be due in connection with the transactions contemplated by the Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(u)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Investment
Company</U>. The Company is not, and is not an Affiliate of, and immediately after receipt of payment for the Securities, will not be
or be an Affiliate of, an &ldquo;investment company&rdquo; within the meaning of the Investment Company Act of 1940, as amended. The
Company shall conduct its business in a manner so that it will not become an &ldquo;investment company&rdquo; subject to registration
under the Investment Company Act of 1940, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Registration
Rights</U>. No Person has any right to cause the Company or any Subsidiary to effect the registration under the Securities Act of any
securities of the Company or any Subsidiary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(w)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Listing
and Maintenance Requirements</U>. The Common Stock is registered pursuant to Section&nbsp;12(b)&nbsp;or 12(g)&nbsp;of the Exchange Act,
and the Company has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the registration
of the Common Stock under the Exchange Act nor has the Company received any notification that the Commission is contemplating terminating
such registration. The Company has not, in the 12 months preceding the date hereof, received notice from any Trading Market on which
the Common Stock is or has been listed or quoted to the effect that the Company is not in compliance with the listing or maintenance
requirements of such Trading Market. The Company is, and has no reason to believe that it will not in the foreseeable future continue
to be, in compliance with all such listing and maintenance requirements. The Common Stock is currently eligible for electronic transfer
through the Depository Trust Company or another established clearing corporation and the Company is current in payment of the fees to
the Depository Trust Company (or such other established clearing corporation) in connection with such electronic transfer, except where
such nonpayment would not reasonably be expected to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(x)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Application
of Takeover Protections</U>. The Company and the Board of Directors or a duly authorized committee thereof have taken all necessary action,
if any, in order to render inapplicable any control share acquisition, business combination, poison pill (including any distribution
under a rights agreement) or other similar anti&#45;takeover provision under the Company&rsquo;s certificate of incorporation (or similar
charter documents) or the laws of its state of incorporation that is or could become applicable to the Purchasers as a result of the
Purchasers and the Company fulfilling their obligations or exercising their rights under the Transaction Documents, including without
limitation as a result of the Company&rsquo;s issuance of the Securities and the Purchasers&rsquo; ownership of the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(y)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Disclosure</U>.
Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents, the Company confirms
that neither it nor any other Person acting on its behalf has provided any of the Purchasers or their agents or counsel with any information
that it believes constitutes material, non-public information which is not otherwise disclosed in the Prospectus Supplement. The Company
understands and confirms that the Purchasers will rely on the foregoing representation in effecting transactions in securities of the
Company. All of the disclosure furnished by or on behalf of the Company to the Purchasers regarding the Company and its Subsidiaries,
their respective businesses and the transactions contemplated hereby, including the Disclosure Schedules to this Agreement, is true and
correct in all material respects and does not contain any untrue statement of a material fact or omit to state any material fact necessary
in order to make the statements made therein, in the light of the circumstances under which they were made, not misleading. The press
releases disseminated by the Company during the twelve months preceding the date of this Agreement taken as a whole do not contain any
untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the
statements therein, in the light of the circumstances under which they were made and when made, not misleading. The Company acknowledges
and agrees that no Purchaser makes or has made any representations or warranties with respect to the transactions contemplated hereby
other than those specifically set forth in Section&nbsp;3.2 hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(z)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Integrated Offering</U>. Assuming the accuracy of the Purchasers&rsquo; representations and warranties set forth in Section&nbsp;3.2,
neither the Company, nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly, made any offers
or sales of any security or solicited any offers to buy any security, under circumstances that would cause this offering of the Securities
to be integrated with prior offerings by the Company for purposes of (i)&nbsp;the Securities Act which would require the registration
of the Warrants or Warrant Shares under the Securities Act, or (ii)&nbsp;any applicable shareholder approval provisions of any Trading
Market on which any of the securities of the Company are listed or designated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(aa)&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Solvency</U>.
Based on the consolidated financial condition of the Company as of the Closing Date, after giving effect to the receipt by the Company
of the proceeds from the sale of the Securities hereunder, (i)&nbsp;the fair saleable value of the Company&rsquo;s assets exceeds the
amount that will be required to be paid on or in respect of the Company&rsquo;s existing debts and other liabilities (including known
contingent liabilities) as they mature, (ii)&nbsp;the Company&rsquo;s assets do not constitute unreasonably small capital to carry on
its business as now conducted and as proposed to be conducted including its capital needs taking into account the particular capital
requirements of the business conducted by the Company, consolidated and projected capital requirements and capital availability thereof,
and (iii)&nbsp;the current cash flow of the Company, together with the proceeds the Company would receive, were it to liquidate all of
its assets, after taking into account all anticipated uses of the cash, would be sufficient to pay all amounts on or in respect of its
liabilities when such amounts are required to be paid. The Company does not intend to incur debts beyond its ability to pay such debts
as they mature (taking into account the timing and amounts of cash to be payable on or in respect of its debt). The Company has no knowledge
of any facts or circumstances which lead it to believe that it will file for reorganization or liquidation under the bankruptcy or reorganization
laws of any jurisdiction within one year from the Closing Date. The SEC Reports set forth as of the date hereof all outstanding secured
and unsecured Indebtedness of the Company or any Subsidiary, or for which the Company or any Subsidiary has commitments. For the purposes
of this Agreement, &ldquo;<U>Indebtedness</U>&rdquo; means (x)&nbsp;any liabilities for borrowed money or amounts owed in excess of $50,000
(other than trade accounts payable incurred in the ordinary course of business), (y)&nbsp;all guaranties, endorsements and other contingent
obligations in respect of indebtedness of others, whether or not the same are or should be reflected in the Company&rsquo;s consolidated
balance sheet (or the notes thereto), except guaranties by endorsement of negotiable instruments for deposit or collection or similar
transactions in the ordinary course of business; and (z)&nbsp;the present value of any lease payments in excess of $50,000 due under
leases required to be capitalized in accordance with GAAP. Neither the Company nor any Subsidiary is in default with respect to any Indebtedness.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(bb)&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Tax
Status</U>. Except for matters that would not, individually or in the aggregate, have or reasonably be expected to result in a Material
Adverse Effect, the Company and its Subsidiaries each (i)&nbsp;has made or filed all United States federal, state and local income and
all foreign income and franchise tax returns, reports and declarations required by any jurisdiction to which it is subject, (ii)&nbsp;has
paid all taxes and other governmental assessments and charges that are material in amount, shown or determined to be due on such returns,
reports and declarations and (iii)&nbsp;has set aside on its books provision reasonably adequate for the payment of all material taxes
for periods subsequent to the periods to which such returns, reports or declarations apply. There are no unpaid taxes in any material
amount claimed to be due by the taxing authority of any jurisdiction, and the officers of the Company or of any Subsidiary know of no
basis for any such claim.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(cc)&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Foreign
Corrupt Practices</U>. Neither the Company nor any Subsidiary, nor to the knowledge of the Company or any Subsidiary, any agent or other
person acting on behalf of the Company or any Subsidiary, has (i)&nbsp;directly or indirectly, used any funds for unlawful contributions,
gifts, entertainment or other unlawful expenses related to foreign or domestic political activity, (ii)&nbsp;made any unlawful payment
to foreign or domestic government officials or employees or to any foreign or domestic political parties or campaigns from corporate
funds, (iii)&nbsp;failed to disclose fully any contribution made by the Company or any Subsidiary (or made by any person acting on its
behalf of which the Company is aware) which is in violation of law, or (iv)&nbsp;violated in any material respect any provision of FCPA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(dd)&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Accountants</U>.
The Company&rsquo;s independent registered public accounting firm is set forth in the SEC Reports. To the knowledge and belief of the
Company, such accounting firm (i)&nbsp;is a registered public accounting firm as required by the Exchange Act and (ii)&nbsp;shall express
its opinion with respect to the financial statements to be included in the Company&rsquo;s Annual Report for the fiscal year ending December&nbsp;31,
2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ee)&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Acknowledgment
Regarding Purchasers&rsquo; Purchase of Securities</U>. The Company acknowledges and agrees that each of the Purchasers is acting solely
in the capacity of an arm&rsquo;s length purchaser with respect to the Transaction Documents and the transactions contemplated thereby.
The Company further acknowledges that no Purchaser is acting as a financial advisor or fiduciary of the Company (or in any similar capacity)
with respect to the Transaction Documents and the transactions contemplated thereby and any advice given by any Purchaser or any of their
respective representatives or agents in connection with the Transaction Documents and the transactions contemplated thereby is merely
incidental to the Purchasers&rsquo; purchase of the Securities. The Company further represents to each Purchaser that the Company&rsquo;s
decision to enter into this Agreement and the other Transaction Documents has been based solely on the independent evaluation of the
transactions contemplated hereby by the Company and its representatives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ff)&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Acknowledgment
Regarding Purchaser&rsquo;s Trading Activity</U>. Anything in this Agreement or elsewhere herein to the contrary notwithstanding (except
for Sections 3.2(e)&nbsp;and 4.14 hereof), it is understood and acknowledged by the Company that: (i)&nbsp;none of the Purchasers has
been asked by the Company to agree, nor has any Purchaser agreed, to desist from purchasing or selling, long and/or short, securities
of the Company, or &ldquo;derivative&rdquo; securities based on securities issued by the Company or to hold the Securities for any specified
term; (ii)&nbsp;past or future open market or other transactions by any Purchaser, specifically including, without limitation, Short
Sales or &ldquo;derivative&rdquo; transactions, before or after the closing of this or future private placement transactions, may negatively
impact the market price of the Company&rsquo;s publicly-traded securities; (iii)&nbsp;any Purchaser, and counter-parties in &ldquo;derivative&rdquo;
transactions to which any such Purchaser is a party, directly or indirectly, presently may have a &ldquo;short&rdquo; position in the
Common Stock, and (iv)&nbsp;each Purchaser shall not be deemed to have any affiliation with or control over any arm&rsquo;s length counter-party
in any &ldquo;derivative&rdquo; transaction. The Company further understands and acknowledges that (y)&nbsp;one or more Purchasers may
engage in hedging activities at various times during the period that the Securities are outstanding, including, without limitation, during
the periods that the value of the Warrant Shares deliverable with respect to Securities are being determined, and (z)&nbsp;such hedging
activities (if any) could reduce the value of the existing stockholders' equity interests in the Company at and after the time that the
hedging activities are being conducted. The Company acknowledges that such aforementioned hedging activities do not constitute a breach
of any of the Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Split-Segment; Name: SP3 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman; font-size: 10pt">(gg)</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Regulation
M Compliance</U>.&nbsp; The Company has not, and to its knowledge no one acting on its behalf has, (i)&nbsp;taken, directly or indirectly,
any action designed to cause or to result in the stabilization or manipulation of the price of any security of the Company to facilitate
the sale or resale of any of the Securities, (ii)&nbsp;sold, bid for, purchased, or, paid any compensation for soliciting purchases of,
any of the Securities, or (iii)&nbsp;paid or agreed to pay to any Person any compensation for soliciting another to purchase any other
securities of the Company, other than, in the case of clauses (ii)&nbsp;and (iii), compensation paid to the Company&rsquo;s placement
agent in connection with the placement of the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman; font-size: 10pt">(hh)</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>FDA</U>.
As to each product subject to the jurisdiction of the U.S. Food and Drug Administration (&ldquo;<U>FDA</U>&rdquo;) under the Federal
Food, Drug and Cosmetic Act, as amended, and the regulations thereunder (&ldquo;<U>FDCA</U>&rdquo;) that is manufactured, packaged,
labeled, tested, distributed, sold, and/or marketed by the Company or any of its Subsidiaries (each such product, a
 &ldquo;<U>Pharmaceutical Product</U>&rdquo;), such Pharmaceutical Product is being manufactured, packaged, labeled, tested,
distributed, sold and/or marketed by the Company in compliance with all applicable requirements under FDCA and similar laws,
rules&nbsp;and regulations relating to registration, investigational use, premarket clearance, licensure, or application approval,
good manufacturing practices, good laboratory practices, good clinical practices, product listing, quotas, labeling, advertising,
record keeping and filing of reports, except where the failure to be in compliance would not have a Material Adverse Effect. There
is no pending, completed or, to the Company's knowledge, threatened, action (including any lawsuit, arbitration, or legal or
administrative or regulatory proceeding, charge, complaint, or investigation) against the Company or any of its Subsidiaries, and
none of the Company or any of its Subsidiaries has received any notice, warning letter or other communication from the FDA or any
other governmental entity, which (i)&nbsp;contests the premarket clearance, licensure, registration, or approval of, the uses of,
the distribution of, the manufacturing or packaging of, the testing of, the sale of, or the labeling and promotion of any
Pharmaceutical Product, (ii)&nbsp;withdraws its approval of, requests the recall, suspension, or seizure of, or withdraws or orders
the withdrawal of advertising or sales promotional materials relating to, any Pharmaceutical Product, (iii)&nbsp;imposes a clinical
hold on any clinical investigation by the Company or any of its Subsidiaries, (iv)&nbsp;enjoins production at any facility of the
Company or any of its Subsidiaries, (v)&nbsp;enters or proposes to enter into a consent decree of permanent injunction with the
Company or any of its Subsidiaries, or (vi)&nbsp;otherwise alleges any violation of any laws, rules&nbsp;or regulations by the
Company or any of its Subsidiaries, and which, either individually or in the aggregate, would have a Material Adverse Effect. The
properties, business and operations of the Company have been and are being conducted in all material respects in accordance with all
applicable laws, rules&nbsp;and regulations of the FDA.&nbsp; The Company has not been informed by the FDA that the FDA will
prohibit the marketing, sale, license or use in the United States of any product proposed to be developed, produced or marketed by
the Company nor has the FDA expressed any concern as to approving or clearing for marketing any product being developed or proposed
to be developed by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Value: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Value: 21; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman; font-size: 10pt">(ii)</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Stock
Option Plans</U>. Each stock option granted by the Company under the Company&rsquo;s stock option plan was granted (i)&nbsp;in accordance
with the terms of the Company&rsquo;s stock option plan and (ii)&nbsp;with an exercise price at least equal to the fair market value
of the Common Stock on the date such stock option would be considered granted under GAAP and applicable law. No stock option granted
under the Company&rsquo;s stock option plan has been backdated. The Company has not knowingly granted, and there is no and has been no
Company policy or practice to knowingly grant, stock options prior to, or otherwise knowingly coordinate the grant of stock options with,
the release or other public announcement of material information regarding the Company or its Subsidiaries or their financial results
or prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman; font-size: 10pt">(jj)</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Cybersecurity</U>.
(i)(x)&nbsp;There has been no security breach or other compromise of or relating to any of the Company&rsquo;s or any Subsidiary&rsquo;s
information technology and computer systems, networks, hardware, software, data (including the data of its respective customers, employees,
suppliers, vendors and any third party data maintained by or on behalf of it), equipment or technology (collectively, <I>&ldquo;</I><U>IT
Systems and Data</U>&rdquo;) and (y)&nbsp;the Company and the Subsidiaries have not been notified of, and has no knowledge of any event
or condition that would reasonably be expected to result in, any security breach or other compromise to its IT Systems and Data; (ii)&nbsp;the
Company and the Subsidiaries are presently in compliance with all applicable laws or statutes and all judgments, orders, rules&nbsp;and
regulations of any court or arbitrator or governmental or regulatory authority, internal policies and contractual obligations relating
to the privacy and security of IT Systems and Data and to the protection of such IT Systems and Data from unauthorized use, access, misappropriation
or modification, except as would not, individually or in the aggregate, have a Material Adverse Effect; (iii)&nbsp;the Company and the
Subsidiaries have implemented and maintained commercially reasonable safeguards to maintain and protect its material confidential information
and the integrity, continuous operation, redundancy and security of all IT Systems and Data; and (iv)&nbsp;the Company and the Subsidiaries
have implemented backup and disaster recovery technology consistent with industry standards and practices.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman; font-size: 10pt">(kk)</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Office
of Foreign Assets Control</U>. Neither the Company nor any Subsidiary nor, to the Company's knowledge, any director, officer, agent,
employee or affiliate of the Company or any Subsidiary is currently subject to any U.S. sanctions administered by the Office of Foreign
Assets Control of the U.S. Treasury Department (&ldquo;<U>OFAC</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman; font-size: 10pt">(ll)</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>U.S.
Real Property Holding Corporation</U>. The Company is not and has never been a U.S. real property holding corporation within the meaning
of Section&nbsp;897 of the Internal Revenue Code of 1986, as amended, and the Company shall so certify upon Purchaser&rsquo;s request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman; font-size: 10pt">(mm)</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Bank
Holding Company Act</U>. Neither the Company nor any of its Subsidiaries or Affiliates is subject to the Bank Holding Company Act of
1956, as amended (the &ldquo;<U>BHCA</U>&rdquo;) and to regulation by the Board of Governors of the Federal Reserve System (the &ldquo;<U>Federal
Reserve</U>&rdquo;). Neither the Company nor any of its Subsidiaries or Affiliates owns or controls, directly or indirectly, five percent
(5%) or more of the outstanding shares of any class of voting securities or twenty-five percent (25%) or more of the total equity of
a bank or any entity that is subject to the BHCA and to regulation by the Federal Reserve. Neither the Company nor any of its Subsidiaries
or Affiliates exercises a controlling influence over the management or policies of a bank or any entity that is subject to the BHCA and
to regulation by the Federal Reserve.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman; font-size: 10pt">(nn)</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Money
Laundering</U>. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance in all material
respects with applicable financial record-keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of
1970, as amended, applicable money laundering statutes and applicable rules&nbsp;and regulations thereunder (collectively, the &ldquo;<U>Money
Laundering Laws</U>&rdquo;), and no Action or Proceeding by or before any court or governmental agency, authority or body or any arbitrator
involving the Company or any Subsidiary with respect to the Money Laundering Laws is pending or, to the knowledge of the Company or any
Subsidiary, threatened.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 2; Value: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman; font-size: 10pt">(oo)</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Private
Placement</U>. Assuming the accuracy of the Purchasers&rsquo; representations and warranties set forth in Section&nbsp;3.2, no registration
under the Securities Act is required for the offer and sale of the Warrants or the Warrant Shares by the Company to the Purchasers as
contemplated hereby. The issuance and sale of the Securities hereunder does not contravene the rules&nbsp;and regulations of the Trading
Market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman; font-size: 10pt">(pp)</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
General Solicitation</U>. Neither the Company nor any Person acting on behalf of the Company has offered or sold any of the Warrant or
Warrant Shares by any form of general solicitation or general advertising. The Company has offered the Warrants and Warrant Shares for
sale only to the Purchasers and certain other &ldquo;accredited investors&rdquo; within the meaning of Rule&nbsp;501 under the Securities
Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman; font-size: 10pt">(qq)</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Disqualification Events</U>. With respect to the Warrant and Warrant Shares to be offered and sold hereunder in reliance on
Rule&nbsp;506 under the Securities Act, none of the Company, any of its predecessors, any affiliated issuer, any director, executive
officer, other officer of the Company participating in the offering hereunder, any beneficial owner of 20% or more of the
Company&rsquo;s outstanding voting equity securities, calculated on the basis of voting power, nor any promoter (as that term is
defined in Rule&nbsp;405 under the Securities Act) connected with the Company in any capacity at the time of sale (each, an
 &ldquo;<U>Issuer Covered Person</U>&rdquo;) is subject to any of the &ldquo;Bad Actor&rdquo; disqualifications described in
Rule&nbsp;506(d)(1)(i)&nbsp;to (viii)&nbsp;under the Securities Act (a &ldquo;<U>Disqualification Event</U>&rdquo;), except for a
Disqualification Event covered by Rule&nbsp;506(d)(2)&nbsp;or (d)(3). The Company has exercised reasonable care to determine whether
any Issuer Covered Person is subject to a Disqualification Event. The Company has complied, to the extent applicable, with its
disclosure obligations under Rule&nbsp;506(e), and has furnished to the Purchasers a copy of any disclosures provided
thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman; font-size: 10pt">(rr)</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Other
Covered Persons</U>. Other than the Placement Agent, the Company is not aware of any person (other than any Issuer Covered Person) that
has been or will be paid (directly or indirectly) remuneration for solicitation of purchasers in connection with the sale of any Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman; font-size: 10pt">(ss)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notice
of Disqualification Events</U>. The Company will notify the Purchasers and the Placement Agent in writing, prior to the Closing Date
of (i)&nbsp;any Disqualification Event relating to any Issuer Covered Person and (ii)&nbsp;any event that would, with the passage of
time, reasonably be expected to become a Disqualification Event relating to any Issuer Covered Person, each case to which it is aware.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 3; Value: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman; font-size: 10pt">3.2</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Representations
and Warranties of the Purchasers</U>. Each Purchaser, for itself and for no other Purchaser, hereby represents and warrants as of the
date hereof and as of the Closing Date to the Company as follows (unless as of a specific date therein, in which case they shall be accurate
as of such date):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman; font-size: 10pt">(a)</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Organization;
Authority</U>. Such Purchaser is either an individual or an entity duly incorporated or formed, validly existing and in good standing
under the laws of the jurisdiction of its incorporation or formation with full right, corporate, partnership, limited liability company
or similar power and authority to enter into and to consummate the transactions contemplated by the Transaction Documents and otherwise
to carry out its obligations hereunder and thereunder. The execution and delivery of the Transaction Documents and performance by such
Purchaser of the transactions contemplated by the Transaction Documents have been duly authorized by all necessary corporate, partnership,
limited liability company or similar action, as applicable, on the part of such Purchaser. Each Transaction Document to which it is a
party has been duly executed by such Purchaser, and when delivered by such Purchaser in accordance with the terms hereof, will constitute
the valid and legally binding obligation of such Purchaser, enforceable against it in accordance with its terms, except: (i)&nbsp;as
limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application
affecting enforcement of creditors&rsquo; rights generally, (ii)&nbsp;as limited by laws relating to the availability of specific performance,
injunctive relief or other equitable remedies and (iii)&nbsp;insofar as indemnification and contribution provisions may be limited by
applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman; font-size: 10pt">(b)</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Understandings
or Arrangements</U>. Such Purchaser is acquiring the Securities as principal for its own account and has no direct or indirect arrangement
or understandings with any other persons to distribute or regarding the distribution of such Securities (this representation and warranty
not limiting such Purchaser&rsquo;s right to sell the Securities pursuant to the Registration Statement or otherwise in compliance with
applicable federal and state securities laws). Such Purchaser is acquiring the Securities hereunder in the ordinary course of its business.
Such Purchaser understands that the Warrants and the Warrant Shares are &ldquo;restricted securities&rdquo; and have not been registered
under the Securities Act or any applicable state securities law and is acquiring such Securities as principal for his, her or its own
account and not with a view to or for distributing or reselling such Securities or any part thereof in violation of the Securities Act
or any applicable state securities law, has no present intention of distributing any of such Securities in violation of the Securities
Act or any applicable state securities law and has no direct or indirect arrangement or understandings with any other persons to distribute
or regarding the distribution of such Securities in violation of the Securities Act or any applicable state securities law (this representation
and warranty not limiting such Purchaser&rsquo;s right to sell such Securities pursuant to a registration statement or otherwise in compliance
with applicable federal and state securities laws).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt; background-color: lightgrey"></FONT></P>

<!-- Field: Page; Sequence: 4; Value: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt; background-color: lightgrey"></FONT><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman; font-size: 10pt">(c)</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Purchaser
Status</U>. At the time such Purchaser was offered the Securities, it was, and as of the date hereof it is, and on each date on which
it exercises any Warrants, it will be either: (i)&nbsp;an &ldquo;accredited investor&rdquo; as defined in Rule&nbsp;501(a)(1), (a)(2),
(a)(3), (a)(7)&nbsp;or (a)(8)&nbsp;under the Securities Act or (ii)&nbsp;a &ldquo;qualified institutional buyer&rdquo; as defined in
Rule&nbsp;144A(a)&nbsp;under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman; font-size: 10pt">(d)</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Experience
of Such Purchaser</U>. Such Purchaser, either alone or together with its representatives, has such knowledge, sophistication and experience
in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment in the Securities,
and has so evaluated the merits and risks of such investment. Such Purchaser is able to bear the economic risk of an investment in the
Securities and, at the present time, is able to afford a complete loss of such investment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman; font-size: 10pt">(e)</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Access
to Information</U>. Such Purchaser acknowledges that it has had the opportunity to review the Transaction Documents (including all
exhibits and schedules thereto) and the SEC Reports and has been afforded, (i)&nbsp;the opportunity to ask such questions as it has
deemed necessary of, and to receive answers from, representatives of the Company concerning the terms and conditions of the offering
of the Securities and the merits and risks of investing in the Securities; (ii)&nbsp;access to information about the Company and its
financial condition, results of operations, business, properties, management and prospects sufficient to enable it to evaluate its
investment; and (iii)&nbsp;the opportunity to obtain such additional information that the Company possesses or can acquire without
unreasonable effort or expense that is necessary to make an informed investment decision with respect to the investment. Such
Purchaser acknowledges and agrees that neither the Placement Agent nor any Affiliate of the Placement Agent has provided such
Purchaser with any information or advice with respect to the Securities nor is such information or advice necessary or desired.
Neither the Placement Agent nor any Affiliate has made or makes any representation as to the Company or the quality of the
Securities and the Placement Agent and any Affiliate may have acquired non-public information with respect to the Company which such
Purchaser agrees need not be provided to it. In connection with the issuance of the Securities to such Purchaser, neither the
Placement Agent nor any of its Affiliates has acted as a financial advisor or fiduciary to such Purchaser.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman; font-size: 10pt">(f)</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Certain
Transactions and Confidentiality</U>. Other than consummating the transactions contemplated hereunder, such Purchaser has not, nor has
any Person acting on behalf of or pursuant to any understanding with such Purchaser, directly or indirectly executed any purchases or
sales, including Short Sales,&nbsp;of the securities of the Company during the period commencing as of the time that such Purchaser first
received a term sheet (written or oral) from the Company or any other Person representing the Company setting forth the material terms
of the transactions contemplated hereunder and ending immediately prior to the execution hereof. Notwithstanding the foregoing, in the
case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of such Purchaser&rsquo;s
assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers managing other
portions of such Purchaser&rsquo;s assets, the representation set forth above shall only apply with respect to the portion of assets
managed by the portfolio manager that made the investment decision to purchase the Securities covered by this Agreement. Other than to
other Persons party to this Agreement or to such Purchaser&rsquo;s representatives, including, without limitation, its officers, directors,
partners, legal and other advisors, employees, agents and Affiliates, such Purchaser has maintained the confidentiality of all disclosures
made to it in connection with this transaction (including the existence and terms of this transaction). Notwithstanding the foregoing,
for the avoidance of doubt, nothing contained herein shall constitute a representation or warranty, or preclude any actions, with respect
to locating or borrowing shares in order to effect Short Sales or similar transactions in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman; font-size: 10pt">(g)</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>General
Solicitation</U>. Such Purchaser is not purchasing the Securities as a result of any advertisement, article, notice or other communication
regarding the Securities published in any newspaper, magazine or similar media or broadcast over television or radio or presented at
any seminar or, to the knowledge of such Purchaser, any other general solicitation or general advertisement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">The Company
acknowledges and agrees that the representations contained in this Section&nbsp;3.2 shall not modify, amend or affect such Purchaser&rsquo;s
right to rely on the Company&rsquo;s representations and warranties contained in this Agreement or any representations and warranties
contained in any other Transaction Document or any other document or instrument executed and/or delivered in connection with this Agreement
or the consummation of the transactions contemplated hereby. Notwithstanding the foregoing, for the avoidance of doubt, nothing contained
herein shall constitute a representation or warranty, or preclude any actions, with respect to locating or borrowing shares in order
to effect Short Sales or similar transactions in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman; font-size: 10pt"><B>ARTICLE&nbsp;IV.</B></FONT><FONT STYLE="font-size: 10pt"><BR>
OTHER AGREEMENTS OF THE PARTIES</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman; font-size: 10pt">4.1</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Removal
of Legends.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman; font-size: 10pt">(a)</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Warrants and Warrant Shares may only be disposed of in compliance with state and federal securities laws. In connection with any transfer
of Warrants or Warrant Shares other than pursuant to an effective registration statement or Rule&nbsp;144, to the Company or to an Affiliate
of a Purchaser or in connection with a pledge as contemplated in Section&nbsp;4.1(b), the Company may require the transferor thereof
to provide to the Company an opinion of counsel selected by the transferor and reasonably acceptable to the Company, the form and substance
of which opinion shall be reasonably satisfactory to the Company, to the effect that such transfer does not require registration of such
transferred Warrant under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman; font-size: 10pt">(b)</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Purchasers agree to the imprinting, so long as is required by this Section&nbsp;4.1, of a legend on any of the Warrants or Warrant Shares
in the following form:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt"><U>NEITHER THIS SECURITY
NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAS BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES
COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;SECURITIES
ACT&rdquo;), AND, ACCORDINGLY, MAY&nbsp;NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES
ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT
AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY&nbsp;BE
PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT WITH A REGISTERED BROKER-DEALER OR OTHER LOAN WITH A FINANCIAL INSTITUTION THAT
IS AN &ldquo;ACCREDITED INVESTOR&rdquo; AS DEFINED IN RULE 501(a)&nbsp;UNDER THE SECURITIES ACT OR OTHER LOAN SECURED BY SUCH SECURITIES.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman; font-size: 10pt">(c)</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company acknowledges and agrees that a Purchaser may from time to time pledge pursuant to a bona fide margin agreement with a
registered broker-dealer or grant a security interest in some or all of the Warrants or Warrant Shares to a financial institution
that is an &ldquo;accredited investor&rdquo; as defined in Rule&nbsp;501(a)&nbsp;under the Securities Act and, if required under the
terms of such arrangement, such Purchaser may transfer pledged or secured Warrants or Warrant Shares to the pledgees or secured
parties. Such a pledge or transfer would not be subject to approval of the Company and no legal opinion of legal counsel of the
pledgee, secured party or pledgor shall be required in connection therewith. Further, no notice shall be required of such pledge. At
the appropriate Purchaser&rsquo;s expense, the Company will execute and deliver such reasonable documentation as a pledgee or
secured party of Warrants and Warrant Shares may reasonably request in connection with a pledge or transfer of the Warrants or
Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman; font-size: 10pt">(d)</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Certificates
evidencing the Warrant Shares shall not contain any legend (including the legend set forth in Section&nbsp;4.1(b)&nbsp;hereof): (i)&nbsp;while
a registration statement covering the resale of such security is effective under the Securities Act, or (ii)&nbsp;following any sale
of such Warrant Shares pursuant to Rule&nbsp;144 (assuming cashless exercise of the Warrants), or (iii)&nbsp;if such Warrant Shares are
eligible for sale under Rule&nbsp;144 (assuming cashless exercise of the Warrants), or (iv)&nbsp;if such legend is not required under
applicable requirements of the Securities Act (including judicial interpretations and pronouncements issued by the staff of the Commission).
The Company shall cause its counsel to issue a legal opinion to the Transfer Agent or the Purchaser promptly if required by the Transfer
Agent to effect the removal of the legend hereunder, or if requested by a Purchaser, respectively. If all or any portion of a Warrant
is exercised at a time when there is an effective registration statement to cover the resale of the Warrant Shares, or if such Warrant
Shares may be sold under Rule&nbsp;144 (assuming cashless exercise of the Warrants) or if such legend is not otherwise required under
applicable requirements of the Securities Act (including judicial interpretations and pronouncements issued by the staff of the Commission)
then such Warrant Shares shall be issued free of all legends. The Company agrees that following such time as such legend is no longer
required under this Section&nbsp;4.1(c), the Company will, no later than the earlier of (i)&nbsp;two (2)&nbsp;Trading Days and (ii)&nbsp;the
number of Trading Days comprising the Standard Settlement Period (as defined below) following the delivery by a Purchaser to the Company
or the Transfer Agent of a certificate representing Warrant Shares, as applicable, issued with a restrictive legend (such date, the &ldquo;<U>Legend
Removal Date</U>&rdquo;), deliver or cause to be delivered to such Purchaser a certificate representing such shares that is free from
all restrictive and other legends. The Company may not make any notation on its records or give instructions to the Transfer Agent that
enlarge the restrictions on transfer set forth in this Section&nbsp;4. Warrant Shares subject to legend removal hereunder shall be transmitted
by the Transfer Agent to the Purchaser by crediting the account of the Purchaser&rsquo;s prime broker with the Depository Trust Company
System as directed by such Purchaser. As used herein, &ldquo;Standard Settlement Period&rdquo; means the standard settlement period,
expressed in a number of Trading Days, on the Company&rsquo;s primary Trading Market with respect to the Common Stock as in effect on
the date of delivery of a certificate representing Warrant Shares issued with a restrictive legend.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt; background-color: lightgrey"></FONT></P>

<!-- Field: Page; Sequence: 7; Value: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt; background-color: lightgrey"></FONT><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman; font-size: 10pt">(e)</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition to such Purchaser&rsquo;s other available remedies, the Company shall pay to a Purchaser, in cash, (i)&nbsp;as partial
liquidated damages and not as a penalty, for each $1,000 of Warrant Shares (based on the VWAP of the Common Stock on the date such
Securities are submitted to the Transfer Agent) delivered for removal of the restrictive legend and subject to Section&nbsp;4.1(c),
$10 per Trading Day (increasing to $20 per Trading Day five (5)&nbsp;Trading Days after such damages have begun to accrue) for each
Trading Day after the Legend Removal Date until such certificate is delivered without a legend and (ii)&nbsp;if the Company fails to
(a)&nbsp;issue and deliver (or cause to be delivered) to a Purchaser by the Legend Removal Date a certificate representing the
Securities so delivered to the Company by such Purchaser that is free from all restrictive and other legends and (b)&nbsp;if after
the Legend Removal Date such Purchaser purchases (in an open market transaction or otherwise) shares of Common Stock to deliver in
satisfaction of a sale by such Purchaser of all or any portion of the number of shares of Common Stock, or a sale of a number of
shares of Common Stock equal to all or any portion of the number of shares of Common Stock, that such Purchaser anticipated
receiving from the Company without any restrictive legend, then an amount equal to the excess of such Purchaser&rsquo;s total
purchase price (including brokerage commissions and other out-of-pocket expenses, if any) for the shares of Common Stock so
purchased (including brokerage commissions and other out-of-pocket expenses, if any) (the &ldquo;<U>Buy-In Price</U>&rdquo;) over
the product of (A)&nbsp;such number of Warrant Shares that the Company was required to deliver to such Purchaser by the Legend
Removal Date multiplied by (B)&nbsp;the lowest closing sale price of the Common Stock on any Trading Day during the period
commencing on the date of the delivery by such Purchaser to the Company of the applicable Warrant Shares (as the case may be) and
ending on the date of such delivery and payment under this Section&nbsp;4.1(d).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman; font-size: 10pt">(f)</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Shares shall be issued free of legends.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman; font-size: 10pt">4.2</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Furnishing
of Information</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman; font-size: 10pt">(a)</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Until
the earlier of the time that (i)&nbsp;no Purchaser owns Securities and (ii)&nbsp;the Warrants have expired, the Company covenants to
timely file (or obtain extensions in respect thereof and file within the applicable grace period) all reports required to be filed by
the Company after the date hereof pursuant to the Exchange Act even if the Company is not then subject to the reporting requirements
of the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman; font-size: 10pt">(b)</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At
any time during the period commencing from the six (6)&nbsp;month anniversary of the date hereof and ending at such time that all of
the Warrant Shares (assuming cashless exercise) may be sold without the requirement for the Company to be in compliance with
Rule&nbsp;144(c)(1)&nbsp;and otherwise without restriction or limitation pursuant to Rule&nbsp;144, if the Company (i)&nbsp;shall
fail for any reason to satisfy the current public information requirement under Rule&nbsp;144(c)&nbsp;or (ii)&nbsp;has ever been an
issuer described in Rule&nbsp;144(i)(1)(i)&nbsp;or becomes an issuer in the future, and the Company shall fail to satisfy any
condition set forth in Rule&nbsp;144(i)(2)&nbsp;(a &ldquo;Public Information Failure&rdquo;) then, in addition to such
Purchaser&rsquo;s other available remedies, the Company shall pay to a Purchaser, in cash, as partial liquidated damages and not as
a penalty, by reason of any such delay in or reduction of its ability to sell the Warrant Shares, an amount in cash equal to two
percent (2.0%) of the aggregate Exercise Price of such Purchaser&rsquo;s Warrants on the day of a Public Information Failure and on
every thirtieth (30th) day (pro rated for periods totaling less than thirty days) thereafter until the earlier of (a)&nbsp;the date
such Public Information Failure is cured and (b)&nbsp;such time that such public information is no longer required for the
Purchasers to transfer the Warrant Shares pursuant to Rule&nbsp;144. The payments to which a Purchaser shall be entitled pursuant to
this Section&nbsp;4.2(b)&nbsp;are referred to herein as &ldquo;Public Information Failure Payments.&rdquo; Public Information
Failure Payments shall be paid on the earlier of (i)&nbsp;the last day of the calendar month during which such Public Information
Failure Payments are incurred and (ii)&nbsp;the third (3rd) Business Day after the event or failure giving rise to the Public
Information Failure Payments is cured. In the event the Company fails to make Public Information Failure Payments in a timely
manner, such Public Information Failure Payments shall bear interest at the rate of 1.5% per month (prorated for partial months)
until paid in full. Nothing herein shall limit such Purchaser&rsquo;s right to pursue actual damages for the Public Information
Failure, and such Purchaser shall have the right to pursue all remedies available to it at law or in equity including, without
limitation, a decree of specific performance and/or injunctive relief.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman; font-size: 10pt">4.3</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Integration</U>.
The Company shall not sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined in
Section&nbsp;2 of the Securities Act) that would be integrated with the offer or sale of the Securities in a manner that would require
the registration under the Securities Act of the sale of the Warrants or Warrant Shares or that would be integrated with the offer or
sale of the Securities for purposes of the rules&nbsp;and regulations of any Trading Market such that it would require shareholder approval
prior to the closing of such other transaction unless shareholder approval is obtained before the closing of such subsequent transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman; font-size: 10pt">4.4</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Securities
Laws Disclosure; Publicity</U>. The Company shall (a)&nbsp;by the Disclosure Time, issue a press release disclosing the material terms
of the transactions contemplated hereby, and (b)&nbsp;file a Current Report on Form&nbsp;8-K, including the Transaction Documents as
exhibits thereto, with the Commission within the time required by the Exchange Act. From and after the issuance of such press release,
the Company represents to the Purchasers that it shall have publicly disclosed all material, non-public information delivered to any
of the Purchasers by the Company or any of its Subsidiaries, or any of their respective officers, directors, employees or agents in connection
with the transactions contemplated by the Transaction Documents. In addition, effective upon the issuance of such press release, the
Company acknowledges and agrees that any and all confidentiality or similar obligations under any agreement, whether written or oral,
between the Company, any of its Subsidiaries or any of their respective officers, directors, agents, employees or Affiliates on the one
hand, and any of the Purchasers or any of their Affiliates on the other hand, shall terminate. The Company and each Purchaser shall consult
with each other in issuing any other press releases with respect to the transactions contemplated hereby, and neither the Company nor
any Purchaser shall issue any such press release nor otherwise make any such public statement without the prior consent of the Company,
with respect to any press release of any Purchaser, or without the prior consent of each Purchaser, with respect to any press release
of the Company, which consent shall not unreasonably be withheld or delayed, except if such disclosure is required by law, in which case
the disclosing party shall promptly provide the other party with prior notice of such public statement or communication. Notwithstanding
the foregoing, the Company shall not publicly disclose the name of any Purchaser, or include the name of any Purchaser in any filing
with the Commission or any regulatory agency or Trading Market, without the prior written consent of such Purchaser, except (a)&nbsp;as
required by federal securities law in connection with the filing of final Transaction Documents with the Commission and (b)&nbsp;to the
extent such disclosure is required by law or Trading Market regulations, in which case the Company shall provide the Purchasers with
prior notice of such disclosure permitted under this clause (b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman; font-size: 10pt">4.5</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Shareholder
Rights Plan</U>. No claim will be made or enforced by the Company or, with the consent of the Company, any other Person, that any Purchaser
is an &ldquo;<U>Acquiring Person</U>&rdquo; under any control share acquisition, business combination, poison pill (including any distribution
under a rights agreement) or similar anti-takeover plan or arrangement in effect or hereafter adopted by the Company, or that any Purchaser
could be deemed to trigger the provisions of any such plan or arrangement, by virtue of receiving Securities under the Transaction Documents
or under any other agreement between the Company and the Purchasers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman; font-size: 10pt">4.6</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Non-Public
Information</U>. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents,
which shall be disclosed pursuant to Section&nbsp;4.4, the Company covenants and agrees that neither it, nor any other Person acting
on its behalf will provide any Purchaser or its agents or counsel with any information that constitutes, or the Company reasonably believes
constitutes, material non-public information, unless prior thereto such Purchaser shall have consented to the receipt of such information
and agreed with the Company to keep such information confidential. The Company understands and confirms that each Purchaser shall be
relying on the foregoing covenant in effecting transactions in securities of the Company. To the extent that the Company , any of its
Subsidiaries, or any of their respective officers, directors, agents, employees or Affiliates, delivers any material, non-public information
to a Purchaser without such Purchaser&rsquo;s consent, the Company hereby covenants and agrees that such Purchaser shall not have any
duty of confidentiality to the Company, any of its Subsidiaries, or any of their respective officers, directors, agents, employees or
Affiliates, or a duty to the Company, any of its Subsidiaries or any of their respective officers, directors, agents, employees or Affiliates
not to trade on the basis of, such material, non-public information, provided that the Purchaser shall remain subject to applicable law.
To the extent that any notice provided pursuant to any Transaction Document constitutes, or contains, material, non-public information
regarding the Company or any Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current
Report on Form&nbsp;8-K. The Company understands and confirms that each Purchaser shall be relying on the foregoing covenant in effecting
transactions in securities of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Split-Segment; Name: SP4 -->
<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman; font-size: 10pt">4.7</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Use
of Proceeds</U>. Except as set forth in the Prospectus Supplement, the Company shall use the net proceeds from the sale of the Securities
hereunder for working capital purposes and shall not use such proceeds: (a)&nbsp;for the satisfaction of any portion of the Company&rsquo;s
debt (other than payment of trade payables in the ordinary course of the Company&rsquo;s business and prior practices), (b)&nbsp;for
the redemption of any Common Stock or Common Stock Equivalents, (c)&nbsp;for the settlement of any outstanding litigation or (d)&nbsp;in
violation of FCPA or OFAC regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman; font-size: 10pt">4.8</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Indemnification
of Purchasers</U>. Subject to the provisions of this Section&nbsp;4.8, the Company will indemnify and hold each Purchaser and its
directors, officers, shareholders, members, partners, employees and agents (and any other Persons with a functionally equivalent
role of a Person holding such titles notwithstanding a lack of such title or any other title), each Person who controls such
Purchaser (within the meaning of Section&nbsp;15 of the Securities Act and Section&nbsp;20 of the Exchange Act), and the directors,
officers, shareholders, agents, members, partners or employees (and any other Persons with a functionally equivalent role of a
Person </FONT>holding such titles notwithstanding a lack of such title or any other title) of such controlling persons (each, a
 &ldquo;Purchaser Party&rdquo;) harmless from any and all losses, liabilities, obligations, claims, contingencies, damages, costs and
expenses, including all judgments, amounts paid in settlements, court costs and reasonable attorneys&rsquo; fees and costs of
investigation that any such Purchaser Party may suffer or incur as a result of or relating to (a)&nbsp;any breach of any of the
representations, warranties, covenants or agreements made by the Company in this Agreement or in the other Transaction Documents or
(b)&nbsp;any action instituted against the Purchaser Parties in any capacity, or any of them or their respective Affiliates, by any
stockholder of the Company who is not an Affiliate of such Purchaser Party, with respect to any of the transactions contemplated by
the Transaction Documents (unless such action is solely based upon a material breach of such Purchaser Party&rsquo;s
representations, warranties or covenants under the Transaction Documents or any agreements or understandings such Purchaser Party
may have with any such stockholder or any violations by such Purchaser Party of state or federal securities laws or any conduct by
such Purchaser Party which is finally judicially determined to constitute fraud, gross negligence or willful misconduct), or
(c)&nbsp;in connection with any registration statement of the Company providing for the resale by the Purchasers of the Warrant
Shares issued and issuable upon exercise of the Warrants, the Company will indemnify each Purchaser Party, to the fullest extent
permitted by applicable law, from and against any and all losses, claims, damages, liabilities, costs (including, without
limitation, reasonable attorneys&rsquo; fees) and expenses, as incurred, arising out of or relating to (i)&nbsp;any untrue or
alleged untrue statement of a material fact contained in such registration statement, any prospectus or any form of prospectus or in
any amendment or supplement thereto or in any preliminary prospectus, or arising out of or relating to any omission or alleged
omission of a material fact required to be stated therein or necessary to make the statements therein (in the case of any prospectus
or supplement thereto, in the light of the circumstances under which they were made) not misleading, except to the extent, but only
to the extent, that such untrue statements or omissions are based solely upon information regarding such Purchaser Party furnished
in writing to the Company by such Purchaser Party expressly for use therein, or (ii)&nbsp;any violation or alleged violation by the
Company of the Securities Act, the Exchange Act or any state securities law, or any rule&nbsp;or regulation thereunder in connection
therewith. If any action shall be brought against any Purchaser Party in respect of which indemnity may be sought pursuant to this
Agreement, such Purchaser Party shall promptly notify the Company in writing, and the Company shall have the right to assume the
defense thereof with counsel of its own choosing reasonably acceptable to the Purchaser Party. Any Purchaser Party shall have the
right to employ separate counsel in any such action and participate in the defense thereof, but the fees and expenses of such
counsel shall be at the expense of such Purchaser Party except to the extent that (x)&nbsp;the employment thereof has been
specifically authorized by the Company in writing, (y)&nbsp;the Company has failed after a reasonable period of time to assume such
defense and to employ counsel or (z)&nbsp;in such action there is, in the reasonable opinion of counsel, a material conflict on any
material issue between the position of the Company and the position of such Purchaser Party, in which case the Company shall be
responsible for the reasonable fees and expenses of no more than one such separate counsel. The Company will not be liable to any
Purchaser Party under this Agreement (1)&nbsp;for any settlement by a Purchaser Party effected without the Company&rsquo;s prior
written consent, which shall not be unreasonably withheld or delayed; or (2)&nbsp;to the extent, but only to the extent that a loss,
claim, damage or liability is attributable to any Purchaser Party&rsquo;s breach of any of the representations, warranties,
covenants or agreements made by such Purchaser Party in this Agreement or in the other Transaction Documents. The indemnification
required by this Section&nbsp;4.8 shall be made by periodic payments of the amount thereof during the course of the investigation or
defense, as and when bills are received or are incurred. The indemnity agreements contained herein shall be in addition to any cause
of action or similar right of any Purchaser Party against the Company or others and any liabilities the Company may be subject to
pursuant to law.</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 31 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Reservation
of Common Stock</U>. As of the date hereof, the Company has reserved and the Company shall continue to reserve and keep available at
all times, free of preemptive rights, a sufficient number of shares of Common Stock for the purpose of enabling the Company to issue
Shares pursuant to this Agreement and Warrant Shares pursuant to any exercise of the Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Listing
of Common Stock</U>. The Company hereby agrees to use commercially reasonable efforts to maintain the listing or quotation of the Common
Stock on the Trading Market on which it is currently listed, and concurrently with the Closing, the Company shall apply to list or quote
all of the Shares and Warrant Shares on such Trading Market and promptly use commercially reasonable efforts to secure the listing of
all of the Shares and Warrant Shares on such Trading Market. The Company further agrees, if the Company applies to have the Common Stock
traded on any other Trading Market, it will then include in such application all of the Shares and Warrant Shares, and will take such
other action as is reasonably necessary to cause all of the Shares and Warrant Shares to be listed or quoted on such other Trading Market
as promptly as possible. The Company will then take all action reasonably necessary to continue the listing and trading of its Common
Stock on a Trading Market and will comply in all respects with the Company&rsquo;s reporting, filing and other obligations under the
bylaws or rules&nbsp;of the Trading Market. For so long as the Company maintains a listing or quotation of the Common Stock on a Trading
Market, the Company agrees to use commercially reasonable efforts to maintain the eligibility of the Common Stock for electronic transfer
through the Depository Trust Company or another established clearing corporation, including, without limitation, by timely payment of
fees to the Depository Trust Company or such other established clearing corporation in connection with such electronic transfer; provided,
however, that this Section&nbsp;4.10 shall not prevent a sale, merger or similar transaction involving the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Reserved</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Subsequent
Equity Sales</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;From
the date hereof until thirty (30) days after the Closing Date, neither the Company nor any Subsidiary shall (i)&nbsp;issue, enter into
any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents or (ii)&nbsp;file
any registration statement or amendment or supplement thereto, other than the Prospectus Supplement or filing a registration statement
on Form&nbsp;S-8 in connection with any employee benefit plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;From
the date hereof until the one (1)&nbsp;year anniversary of the Closing Date, the Company shall be prohibited from effecting or
entering into an agreement to </FONT>effect any issuance by the Company or any of its Subsidiaries of Common Stock or Common Stock
Equivalents (or a combination of units thereof) involving a Variable Rate Transaction. &ldquo;<U>Variable Rate
Transaction</U>&rdquo; means a transaction in which the Company (i)&nbsp;issues or sells any debt or equity securities that are
convertible into, exchangeable or exercisable for, or include the right to receive additional shares of Common Stock either
(A)&nbsp;at a conversion price, exercise price or exchange rate or other price that is based upon and/or varies with the trading
prices of or quotations for the shares of Common Stock at any time after the initial issuance of such debt or equity securities, or
(B)&nbsp;with a conversion, exercise or exchange price that is subject to being reset at some future date after the initial issuance
of such debt or equity security or upon the occurrence of specified or contingent events directly or indirectly related to the
business of the Company or the market for the Common Stock or (ii)&nbsp;enters into, or effects a transaction under, any agreement,
including, but not limited to, an equity line of credit, whereby the Company may issue securities at a future determined price;
provided, however, that after the six month anniversary of the Closing Date, the Company may enter into and effect sales pursuant to
an at&ndash;the-market offering facility with the Placement Agent as sales agent. Any Purchaser shall be entitled to obtain
injunctive relief against the Company to preclude any such issuance, which remedy shall be in addition to any right to collect
damages.</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Value: 31 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding
the foregoing, this Section&nbsp;4.12 shall not apply in respect of an Exempt Issuance, except that no Variable Rate Transaction shall
be an Exempt Issuance.</FONT></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Equal
Treatment of Purchasers</U>. No consideration (including any modification of this Agreement) shall be offered or paid to any Person to
amend or consent to a waiver or modification of any provision of this Agreement unless the same consideration is also offered to all
of the parties to this Agreement. For clarification purposes, this provision constitutes a separate right granted to each Purchaser by
the Company and negotiated separately by each Purchaser, and is intended for the Company to treat the Purchasers as a class and shall
not in any way be construed as the Purchasers acting in concert or as a group with respect to the purchase, disposition or voting of
Securities or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Certain
Transactions and Confidentiality</U>. Each Purchaser, severally and not jointly with the other Purchasers, covenants that neither it
nor any Affiliate acting on its behalf or pursuant to any understanding with it will execute any purchases or sales, including Short
Sales of any of the Company&rsquo;s securities during the period commencing with the execution of this Agreement and ending at such
time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release as
described in Section&nbsp;4.4.&nbsp; Each Purchaser, severally and not jointly with the other Purchasers, covenants that until such
time as the transactions contemplated by this Agreement are publicly disclosed by the Company pursuant to the initial press release
as described in Section&nbsp;4.4, such Purchaser will maintain the confidentiality of the existence and terms of this transaction
and the information included in the Disclosure Schedules.&nbsp; Notwithstanding the foregoing, and notwithstanding anything
contained in this Agreement to the contrary, the Company expressly acknowledges and agrees that (i)&nbsp;no Purchaser makes any
representation, warranty or covenant hereby that it will not engage in effecting transactions in any securities of the Company after
the time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release as
described in Section&nbsp;4.4, (ii)&nbsp;no Purchaser shall be restricted or prohibited from effecting any transactions in any
securities of the Company in accordance with applicable securities laws from and after the time that the transactions contemplated
by this Agreement are first publicly announced pursuant to the initial press release as described in Section&nbsp;4.4 and
(iii)&nbsp;no Purchaser shall have any duty of confidentiality or duty not to trade in the securities of the Company to the Company
or its Subsidiaries after the issuance of the initial press release as described in Section&nbsp;4.4.&nbsp; Notwithstanding the
foregoing, in the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage separate
portions of such Purchaser&rsquo;s assets and the portfolio managers have no direct knowledge of the investment decisions made by
the portfolio managers managing other portions of such Purchaser&rsquo;s assets, the covenant set forth above shall only apply with
respect to the portion of assets managed by the portfolio manager that made the investment decision to purchase the Securities
covered by this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Exercise
Procedures</U>. The form of Notice of Exercise included in the Warrants set forth the totality of the procedures required of the Purchasers
in order to exercise the Warrants. No additional legal opinion, other information or instructions shall be required of the Purchasers
to exercise their Warrants. Without limiting the preceding sentences, no ink-original Notice of Exercise shall be required, nor shall
any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise form be required in order to exercise
the Warrants. The Company shall honor exercises of the Warrants and shall deliver Warrant Shares in accordance with the terms, conditions
and time periods set forth in the Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: lightgrey"></FONT></P>

<!-- Field: Page; Sequence: 3; Value: 31 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; background-color: lightgrey"></FONT></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.17&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Form&nbsp;D;
Blue Sky Filings</U>. The Company agrees to timely file a Form&nbsp;D with respect to the Warrant and Warrant Shares as required under
Regulation D and to provide a copy thereof, promptly upon request of any Purchaser. The Company shall take such action as the Company
shall reasonably determine is necessary in order to obtain an exemption for, or to qualify the Warrant and Warrant Shares for, sale to
the Purchasers at the Closing under applicable securities or &ldquo;Blue Sky&rdquo; laws of the states of the United States, and shall
provide evidence of such actions promptly upon request of any Purchaser.</FONT></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman,serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE&nbsp;V.</B><BR>
MISCELLANEOUS</FONT></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination</U>.&nbsp;
This Agreement may be terminated by any Purchaser, as to such Purchaser&rsquo;s obligations hereunder only and without any effect whatsoever
on the obligations between the Company and the other Purchasers, by written notice to the other parties, if the Closing has not been
consummated on or before the fifth (5<SUP>th</SUP>) Trading Day following the date hereof; <U>provided</U>, <U>however</U>, that no such
termination will affect the right of any party to sue for any breach by any other party (or parties).</FONT></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Fees
and Expenses</U>. Except as expressly set forth in the Transaction Documents to the contrary, each party shall pay the fees and
expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident to
the negotiation, preparation, execution, delivery and performance of this Agreement. The Company shall pay all Transfer Agent fees
(including, without limitation, any fees required for same-day processing of any instruction letter delivered by the Company and any
exercise notice delivered by a Purchaser), stamp taxes and other taxes and duties levied in connection with the delivery of any
Securities to the Purchasers.</FONT></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Entire
Agreement</U>. The Transaction Documents, together with the exhibits and schedules thereto, the Prospectus and the Prospectus Supplement,
contain the entire understanding of the parties with respect to the subject matter hereof and thereof and supersede all prior agreements
and understandings, oral or written, with respect to such matters, which the parties acknowledge have been merged into such documents,
exhibits and schedules.</FONT></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notices</U>.
Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and shall
be deemed given and effective on the earliest of: (a)&nbsp;the time of transmission, if such notice or communication is delivered via
facsimile at the facsimile number or email attachment at the email address as set forth on the signature pages&nbsp;attached hereto at
or prior to 5:30 p.m.&nbsp;(New York City time) on a Trading Day, (b)&nbsp;the next Trading Day after the time of transmission, if such
notice or communication is delivered via facsimile at the facsimile number or email attachment at the email address as set forth on the
signature pages&nbsp;attached hereto on a day that is not a Trading Day or later than 5:30 p.m.&nbsp;(New York City time) on any Trading
Day, (c)&nbsp;the second (2<SUP>nd</SUP>)Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight courier
service or (d)&nbsp;upon actual receipt by the party to whom such notice is required to be given. The address for such notices and communications
shall be as set forth on the signature pages&nbsp;attached hereto. To the extent that any notice provided pursuant to any Transaction
Document constitutes, or contains, material, non-public information regarding the Company or any Subsidiaries, the Company shall simultaneously
file such notice with the Commission pursuant to a Current Report on Form&nbsp;8-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Amendments;
Waivers</U>. No provision of this Agreement may be waived, modified, supplemented or amended except in a written instrument signed,
in the case of an amendment, by the Company and Purchasers which purchased at least 50.1% in interest of the Shares based on the
initial Subscription Amounts hereunder (or, prior to the Closing Date, the Company and each Purchaser) or, in the case of a waiver,
by the party against whom enforcement of any such waived provision is sought, provided that if any amendment, modification or waiver
disproportionately and adversely impacts a Purchaser (or group of Purchasers), the consent of at least 50.1% in interest of such
disproportionately impacted Purchaser (or group of Purchasers) shall also be required. No waiver of any default with respect to any
provision, condition or requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any
subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission of any party
to exercise any right hereunder in any manner impair the exercise of any such right. Any proposed amendment or waiver that
disproportionately, materially and adversely affects the rights and obligations of any Purchaser relative to the comparable rights
and obligations of the other Purchasers shall require the prior written consent of such adversely affected Purchaser. Any amendment
effected in accordance with this Section&nbsp;5.5 shall be binding upon each Purchaser and holder of Securities and the
Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 4; Value: 31 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Headings</U>.
The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect any
of the provisions hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Successors
and Assigns</U>. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and permitted assigns.
The Company may not assign this Agreement or any rights or obligations hereunder without the prior written consent of each Purchaser
(other than by merger). Any Purchaser may assign any or all of its rights under this Agreement to any Person to whom such Purchaser assigns
or transfers any Securities, provided that such transferee agrees in writing to be bound, with respect to the transferred Securities,
by the provisions of the Transaction Documents that apply to the &ldquo;Purchasers.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Third-Party Beneficiaries</U>. The Placement Agent shall be the third party beneficiary of the representations and warranties of the
Company in Section&nbsp;3.1 and the representations and warranties of the Purchasers in Section&nbsp;3.2. This Agreement is intended
for the benefit of the parties hereto and their respective successors and permitted assigns and is not for the benefit of, nor may any
provision hereof be enforced by, any other Person, except as otherwise set forth in Section&nbsp;4.8 and this Section&nbsp;5.8.</FONT></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Governing
Law</U>. All questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents shall be
governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the
principles of conflicts of law thereof. Each party agrees that all legal Proceedings concerning the interpretations, enforcement and
defense of the transactions contemplated by this Agreement and any other Transaction Documents (whether brought against a party
hereto or its respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be commenced
exclusively in the state and federal courts sitting in the City of New York. Each party hereby irrevocably submits to the exclusive
jurisdiction of the state and federal courts sitting in the City of New York, Borough of Manhattan for the adjudication of any
dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect
to the enforcement of any of the Transaction Documents), and hereby irrevocably waives, and agrees not to assert in any Action or
Proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such Action or Proceeding is
improper or is an inconvenient venue for such Proceeding. Each party hereby irrevocably waives personal service of process and
consents to process being served in any such Action or Proceeding by mailing a copy thereof via registered or certified mail or
overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Agreement and
agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall
be deemed to limit in any way any right to serve process in any other manner permitted by law. If any party shall commence an Action
or Proceeding to enforce any provisions of the Transaction Documents, then, in addition to the obligations of the Company under
Section&nbsp;4.8, the prevailing party in such Action or Proceeding shall be reimbursed by the non-prevailing party for its
reasonable attorneys&rsquo; fees and other costs and expenses incurred with the investigation, preparation and prosecution of such
Action or Proceeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Survival</U>.
The representations and warranties contained herein shall survive the Closing and the delivery of the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Execution</U>.
This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement
and shall become effective when counterparts have been signed by each party and delivered to each other party, it being understood that
the parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission or by e-mail delivery
of a &ldquo;.pdf&rdquo; format data file, such signature shall create a valid and binding obligation of the party executing (or on whose
behalf such signature is executed) with the same force and effect as if such facsimile or &ldquo;.pdf&rdquo; signature page&nbsp;were
an original thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Severability</U>.
If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal,
void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force
and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially reasonable efforts
to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision,
covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would have executed the remaining
terms, provisions, covenants and restrictions without including any of such that may be hereafter declared invalid, illegal, void or
unenforceable.</FONT></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 31 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Rescission
and Withdrawal Right</U>. Notwithstanding anything to the contrary contained in (and without limiting any similar provisions of) any
of the other Transaction Documents, whenever any Purchaser exercises a right, election, demand or option under a Transaction Document
and the Company does not timely perform its related obligations within the periods therein provided, then such Purchaser may rescind
or withdraw, in its sole discretion from time to time upon written notice to the Company, any relevant notice, demand or election in
whole or in part without prejudice to its future actions and rights; provided, however, that in the case of a rescission of an exercise
of a Warrant, the applicable Purchaser shall be required to return any shares of Common Stock subject to any such rescinded exercise
notice concurrently with the return to such Purchaser of the aggregate exercise price paid to the Company for such shares and the restoration
of such Purchaser&rsquo;s right to acquire such shares pursuant to such Purchaser&rsquo;s Warrant (including, issuance of a replacement
warrant certificate evidencing such restored right).</FONT></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Replacement
of Securities</U>. If any certificate or instrument evidencing any Securities is mutilated, lost, stolen or destroyed, the Company shall
issue or cause to be issued in exchange and substitution for and upon cancellation thereof (in the case of mutilation), or in lieu of
and substitution therefor, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory to the Company
of such loss, theft or destruction. The applicant for a new certificate or instrument under such circumstances shall also pay any reasonable
third-party costs (including customary indemnity) associated with the issuance of such replacement Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Remedies</U>.
In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages, each of the Purchasers
and the Company will be entitled to specific performance under the Transaction Documents. The parties agree that monetary damages may
not be adequate compensation for any loss incurred by reason of any breach of obligations contained in the Transaction Documents and
hereby agree to waive and not to assert in any Action for specific performance of any such obligation the defense that a remedy at law
would be adequate.</FONT></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.16&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Payment
Set Aside</U>. To the extent that the Company makes a payment or payments to any Purchaser pursuant to any Transaction Document or a
Purchaser enforces or exercises its rights thereunder, and such payment or payments or the proceeds of such enforcement or exercise or
any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside, recovered from, disgorged by or
are required to be refunded, repaid or otherwise restored to the Company, a trustee, receiver or any other Person under any law (including,
without limitation, any bankruptcy law, state or federal law, common law or equitable cause of action), then to the extent of any such
restoration the obligation or part thereof originally intended to be satisfied shall be revived and continued in full force and effect
as if such payment had not been made or such enforcement or setoff had not occurred.</FONT></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.17&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Independent
Nature of Purchasers&rsquo; Obligations and Rights</U>. The obligations of each Purchaser under any Transaction Document are several
and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance or non-performance
of the obligations of any other Purchaser under any Transaction Document. Nothing contained herein or in any other Transaction Document,
and no action taken by any Purchaser pursuant hereto or thereto, shall be deemed to constitute the Purchasers as a partnership, an association,
a joint venture or any other kind of entity, or create a presumption that the Purchasers are in any way acting in concert or as a group
with respect to such obligations or the transactions contemplated by the Transaction Documents. Each Purchaser shall be entitled to independently
protect and enforce its rights including, without limitation, the rights arising out of this Agreement or out of the other Transaction
Documents, and it shall not be necessary for any other Purchaser to be joined as an additional party in any Proceeding for such purpose.
Each Purchaser has been represented by its own separate legal counsel in its review and negotiation of the Transaction Documents. For
reasons of administrative convenience only, each Purchaser and its respective counsel have chosen to communicate with the Company through
the legal counsel of the Placement Agent. The legal counsel of the Placement Agent does not represent any of the Purchasers and only
represents the Placement Agent. The Company has elected to provide all Purchasers with the same terms and Transaction Documents for the
convenience of the Company and not because it was required or requested to do so by any of the Purchasers. It is expressly understood
and agreed that each provision contained in this Agreement and in each other Transaction Document is between the Company and a Purchaser,
solely, and not between the Company and the Purchasers collectively and not between and among the Purchasers.</FONT></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: lightgrey"></FONT></P>

<!-- Field: Page; Sequence: 6; Value: 31 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; background-color: lightgrey"></FONT></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.18&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Liquidated
Damages</U>. The Company&rsquo;s obligations to pay any partial liquidated damages or other amounts owing under the Transaction
Documents is a continuing obligation of the Company and shall not terminate until all unpaid partial liquidated damages and other
amounts have been paid notwithstanding the fact that the instrument or security pursuant to which such partial liquidated damages or
other amounts are due and payable shall have been canceled.</FONT></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.19&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Saturdays,
Sundays, Holidays,&nbsp;etc.</U> If the last or appointed day for the taking of any action or the expiration
of any right required or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on
the next succeeding Business Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.20&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Construction</U>.
The parties agree that each of them and/or their respective counsel have reviewed and had an opportunity to revise the Transaction Documents
and, therefore, the normal rule&nbsp;of construction to the effect that any ambiguities are to be resolved against the drafting party
shall not be employed in the interpretation of the Transaction Documents or any amendments thereto. In addition, each and every reference
to share prices and shares of Common Stock in any Transaction Document shall be subject to adjustment for reverse and forward stock splits,
stock dividends, stock combinations and other similar transactions of the Common Stock that occur after the date of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.21&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>WAIVER
OF JURY TRIAL</U>. <U>IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY, THE PARTIES
EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY,&nbsp;IRREVOCABLY
AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Signature
Pages&nbsp;Follow)</I></FONT></P>

<P STYLE="font: 12pt Times New Roman; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 12pt Times New Roman; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I></I></FONT></P>

<!-- Field: Page; Sequence: 7; Value: 31 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized
signatories as of the date first indicated above.</FONT></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>NEUROBO PHARMACEUTICALS,&nbsp;INC.</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Address for Notice:</U></FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif">200 Berkeley Street, Office 19<SUP>th</SUP> Floor</TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; width: 45%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Richard Kang</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 49%">Boston, Massachusetts</TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Richard Kang</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif">E-mail: rkang@neurobopharma.com<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: President and Chief Executive Officer</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With a copy to (which shall not constitute notice):</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phillip D. Torrence</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Honigman LLP</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">650 Trade Centre Way, Suite&nbsp;200</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kalamazoo, Michigan 49002</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email: ptorrence@honigman.com</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[REMAINDER
OF PAGE INTENTIONALLY LEFT BLANK</FONT></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 12pt Times New Roman; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SIGNATURE
PAGE FOR PURCHASER FOLLOWS]</FONT></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 31 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[PURCHASER
SIGNATURE PAGES TO NRBO SECURITIES PURCHASE AGREEMENT]</FONT></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories
as of the date first indicated above.</FONT></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Purchaser: ______________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman,serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Signature
of Authorized Signatory of Purchaser</I>: _________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Authorized Signatory: _______________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
of Authorized Signatory: ________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email
Address of Authorized Signatory:_________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address
for Notice to Purchaser: __________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address
for Delivery of Warrants to Purchaser (if not same as address for notice):</FONT></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subscription
Amount: $_________________</FONT></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares:
_________________</FONT></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman,serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant
Shares: __________________ Beneficial Ownership Blocker <FONT STYLE="font-family: Wingdings">&#168;</FONT> 4.99% or <FONT STYLE="font-family: Wingdings">&#168;</FONT>
9.99%</FONT></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EIN Number:
____________________</FONT></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Wingdings">&#168;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
Notwithstanding anything contained in this Agreement to the contrary, by checking this box (i)&nbsp;the obligations of the above-signed
to purchase the securities set forth in this Agreement to be purchased from the Company by the above-signed, and the obligations of the
Company to sell such securities to the above-signed, shall be unconditional and all conditions to Closing shall be disregarded, (ii)&nbsp;the
Closing shall occur by the second (2nd) Trading Day following the date of this Agreement and (iii)&nbsp;any condition to Closing contemplated
by this Agreement (but prior to being disregarded by clause (i)&nbsp;above) that required delivery by the Company or the above-signed
of any agreement, instrument, certificate or the like or purchase price (as applicable) shall no longer be a condition and shall instead
be an unconditional obligation of the Company or the above-signed (as applicable) to deliver such agreement, instrument, certificate
or the like or purchase price (as applicable) to such other party on the Closing Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[SIGNATURE
PAGES CONTINUE]</FONT></P>

<P STYLE="font: 12pt Times New Roman; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 9; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>



<P STYLE="margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>5
<FILENAME>tm2129080d2_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

                           <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Exhibit
99.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white; color: #0076bc"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase; color: Black">NEUROBO
PHARMACEUTICALS ANNOUNCES $14 MILLION REGISTERED DIRECT OFFERING</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #09113a"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">BOSTON,&nbsp;October&nbsp;1,
2021&nbsp;/PRNewswire/ --<B>&nbsp;NeuroBo Pharmaceuticals,&nbsp;Inc.</B>&nbsp;(Nasdaq: NRBO), a clinical-stage biotechnology company
focused on developing and commercializing multimodal, disease-modifying therapies for viral, neuropathic and neurodegenerative diseases,
today announced that it has entered into a definitive agreement with several institutional investors for the purchase and sale in a registered
direct offering of 4,307,693 shares of the Company's common stock, at a purchase price of&nbsp;$3.25 per share. In a concurrent private
placement, the Company agreed to issue to the investors in the registered direct offering unregistered warrants to purchase up to 4,307,693
shares of the Company&#8217;s common stock. The closing of the offering is expected to occur on or about&nbsp;October&nbsp;5, 2021, subject
to the satisfaction of customary closing conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #09113a"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">H.C.
Wainwright&nbsp;&amp; Co.&nbsp;is acting as the exclusive placement agent for the offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #09113a"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
warrants have an exercise price of $3.75 per share, will be exercisable commencing six months following the date of issuance for a period
of three and one-half years from the date of issuance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #09113a"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
gross proceeds to NeuroBo from this offering are expected to be&nbsp;approximately $14 million, before deducting the placement agent's
fees and other offering expenses. The Company intends to use the net proceeds from this offering for working capital, capital expenditures
and general corporate purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #09113a"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
shares of common stock (but not the warrants or the shares of common stock underlying the warrants) are being offered by NeuroBo pursuant
to a &quot;shelf&quot; registration statement on Form&nbsp;S-3 (File No.&nbsp;333-256135) previously filed with the&nbsp;Securities and
Exchange Commission&nbsp;(the &quot;SEC&quot;) on&nbsp;May&nbsp;14, 2021&nbsp;and declared effective by the&nbsp;SEC&nbsp;on&nbsp;May&nbsp;26,
2021. The&nbsp;offering of the shares of common stock will be made only by means of a prospectus, including a prospectus supplement,
forming a part of the effective registration statement. A final prospectus supplement and accompanying prospectus relating to the shares
of common stock being offered will be filed with the SEC.&nbsp; Electronic copies of the final prospectus supplement and accompanying
prospectus may be obtained, when available, on the&nbsp;SEC's&nbsp;website at&nbsp;http://www.sec.gov&nbsp;or by contacting&nbsp;H.C.
Wainwright&nbsp;&amp; Co., LLC at&nbsp;430 Park Avenue, 3rd Floor,&nbsp;New York, NY&nbsp;10022, by phone at (212) 856-5711 or e-mail&nbsp;at&nbsp;placements@hcwco.com.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #09113a"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
warrants described above were offered in a private placement under Section&nbsp;4(a)(2)&nbsp;of the Securities Act of 1933, as amended
(the Act), and Regulation D promulgated thereunder and, along with the shares of common stock underlying the warrants, have not been
registered under the Act, or applicable state securities laws. Accordingly, the warrants and underlying shares of common stock may not
be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration
requirements of the Act and such applicable state securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #09113a"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">This
press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale
of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration
or qualification under the securities laws of any such state or other jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black"></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #09113a"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>About&nbsp;NeuroBo
Pharmaceuticals</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #09113a"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">NeuroBo
Pharmaceuticals,&nbsp;Inc., a clinical-stage biotechnology company focused on developing and commercializing multi-modal
disease-modifying therapies for viral, neuropathic, and neurodegenerative diseases, has a current portfolio of four drug candidates.
The company's recently acquired ANA001 candidate is a proprietary oral niclosamide formulation in development as a treatment for
patients with moderate to severe COVID-19 (patients not requiring ventilators). Niclosamide is a potential oral antiviral and
anti-inflammatory agent with a long history of use and a well-understood safety profile in humans. ANA001 is currently being studied
in a 60-subject Phase 2/3 clinical trial conducted at up to 20 clinical sites in the U.S. Niclosamide has demonstrated both
antiviral and immunomodulatory activity with possible downstream effects on coagulation abnormalities observed in COVID-19. The
company's NB-01 candidate has been shown in a Phase 2 study to significantly reduce pain symptoms associated with painful diabetic
neuropathy (PDN), with a superior safety profile when compared to currently available treatments. Due to the global COVID-19 crisis,
a planned Phase 3 study of NB-01 was postponed. In the interim, NeuroBo is exploring a potential orphan drug indication targeting
chronic pain for NB-01. NeuroBo's NB-02 drug candidate is focused on the treatment of Alzheimer's disease and neurodegenerative
diseases associated with the pathological dysfunction of tau proteins in the brain. The company's fourth program, Gemcabene, was
previously being developed for the treatment of dyslipidemia, a serious medical condition that increases the risk of
life-threatening cardiovascular disease. Gemcabene is currently being assessed as an acute treatment for COVID-19.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #09113a"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">For
more information, visit:&nbsp;<U>https://www.neurobopharma.com/</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #09113a"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Forward
Looking Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #09113a"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Any
statements in this press release that are not statements of historical fact constitute forward-looking statements within the meaning
of The Private Securities Litigation Reform Act of 1995, as amended, and Section&nbsp;21E of the Securities Exchange Act of 1934, as
amended. These statements include, but are not limited to, statements regarding the completion of the registered direct offering, the
satisfaction of customary closing conditions related to the registered direct offering and the intended use of net proceeds from the
registered direct offering as well as the development of NeuroBo's product candidates and the therapeutic potential, timing and nature
of clinical trials and potential regulatory approval of NeuroBo's clinical programs and pipeline. Forward-looking statements are usually
identified by the use of words, such as &quot;believes,&quot; &quot;anticipates,&quot; &quot;expects,&quot; &quot;intends,&quot; &quot;plans,&quot;
 &quot;may,&quot; &quot;potential,&quot; &quot;will,&quot; &quot;could&quot; and similar expressions. Actual results may differ materially
from those indicated by forward-looking statements as a result of various important factors and risks. These factors, risks and uncertainties
include, but are not limited to: the failure to obtain all of the benefits or recognize all of the synergies anticipated from the ANA
acquisition; the integration of ANA potentially diverting management resources from operational matters and other strategic opportunities;
the effect of future milestone payments and royalties specified in the ANA acquisition agreement on the results of operations and financial
position of NeuroBo; the occurrence of health epidemics or contagious diseases, such as COVID-19, and potential effects on NeuroBo's
business, clinical trial sites, supply chain and manufacturing facilities; NeuroBo's ability to continue as a going concern; the timing
of completion of NeuroBo's planned clinical trials, including with respect to ANA001 and Gemcabene; the timing of the availability of
data from NeuroBo's clinical trials, including with respect to ANA001 and Gemcabene; NeuroBo's plans to research, develop and commercialize
its current and future product candidates, including the potential alternative pathways for NB-01; NeuroBo's ability to successfully
collaborate with existing collaborators or enter into new collaborations and to fulfill its obligations under any such collaboration
agreements; the clinical utility, potential benefits and market acceptance of NeuroBo's product candidates, including ANA001 and Gemcabene;
the impact of government laws and regulations; NeuroBo's ability to protect its intellectual property position; and NeuroBo's need for
additional financing to fulfill its stated goals; and other factors discussed in the &quot;Risk Factors&quot; section of NeuroBo's Annual
Report on Form&nbsp;10-K filed with the Securities and Exchange Commission on or about the date hereof. In addition, the forward-looking
statements included in this press release represent NeuroBo's views as of the date hereof. NeuroBo anticipates that subsequent events
and developments will cause its views to change. However, while NeuroBo may elect to update these forward-looking statements at some
point in the future, NeuroBo specifically disclaims any obligation to do so, except as required by law. These forward-looking statements
should not be relied upon as representing NeuroBo's views as of any date subsequent to the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #09113a"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Contact:<BR>
Rx Communications Group<BR>
</B>Michael Miller<BR>
+1-917-633-6086<BR>
mmiller@rxir.com</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>nrbo-20211001.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.10a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +aA5w7xRiXgen8uLa3ZcWa+J2bOdzZR+GYkxtmB9bTn67yQqC11icykZXGPGUcQH -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:nrbo="http://neurobopharma.com/20211001" elementFormDefault="qualified" targetNamespace="http://neurobopharma.com/20211001">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://neurobopharma.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="nrbo-20211001_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="nrbo-20211001_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" />
    <import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd" />
    <import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>7
<FILENAME>nrbo-20211001_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.10a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>8
<FILENAME>nrbo-20211001_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.10a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://neurobopharma.com/role/Cover" xlink:href="nrbo-20211001.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://neurobopharma.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>tm2129080d2_ex5-1img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2129080d2_ex5-1img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  @ +4# 2(  A$! Q$!_\0
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MT*/7?$IA">)8H/B+X<9O"OF2-= 3>699%?S?[JO%/P2^(7B'Q'J.K:=^T_\
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M,6W_  D_B&Z\;?#2XFM/ -KX)E)F\;+X/D>9Q&;2'^@'_AGSXI?]'F_M'?\
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*E+DLS<!2@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>tm2129080d2_ex5-1img002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2129080d2_ex5-1img002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  C .0# 2(  A$! Q$!_\0
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M\2-&MIA;7.K^ O%WA_QAIEO<,&9;>>_\/:AJ-K%,0C$122K(0K$+@''^??\
M\':7[/?P7TO_ (*6_P#!-77-*^&OA31[OX[6MIX8^+SZ)HUGH4/Q#T_0OC/X
M2TVTE\3?V-!8/JNLC1_%^JZ/<ZY<RR:Q-H_]E:<UXMKI.G1P?W@_$?QU^SS^
MPS^SCXV^)WB2U\'?!3]GWX!^ +WQ%K5OX7\/Z;H'A_PUX3\+V.+;2O#_ (<T
M*UM+>6[G*VVC>&_#^EVOVG4]5O+#2--MY;N\@A< ^B:*_#C_ ()?_MK?M7_\
M%8?!>N_MD6":1^R9^QOJ'C'Q+X-_9[^&UKX9TCQY\=?BU8>$+^70_$OQ*^)_
MCKQ,FH^"?"V@CQ':7N@^'_!O@+PM=WT>IZ5XB75/&M_9Z?IEUK'GW[0?_!4_
MXI_\$POVZO@5^S=^WM>^%/'G[)/[8L^IZ?\ L]?M?>'_  ['X%\7?"_X@:9K
M&CZ5K7PV_:$\):=?7GA'6_#NFW/BGPG-:_%3P?I_@F'2M%\0V=SX@\+:A%I'
MB37=. /Z"**^!OV_=%_;[_X5-JOBW_@GY\5O@WX8^,.A0:='I'PV^/?P^/B/
MX=?$&ZN]6CLY=/E\8:5K6C:_X*UJYBO8(]'U"5-6\/&\M8K75[73[6_GUS3/
MRW_X(J_\%OM=_;-\6>/_ -A_]O3PGI?[.?\ P4P^"WB#Q1I?B?X7W.C7/@O1
M?B?H^AW-Q<W5WX%TG5]7U>>'Q;X3TT*_BGPM%J=\FJZ!%;?$+PA<ZKX:NM:B
M\, '](-%?D?XOT7_ (*CQ?MX^!_AAX7_ &E?A%#^Q[XK^$OQ&^*OB/Q7>_LR
MI??%?PCXE\'>+?!OAK2?A)8:_#X]3P1<#Q/!X\L_$.C>*-9\/1ZB=&\'>,M.
M.AW][%:ZS'\2_P#!P_\ MX?M[?\ !+C]G_P%^U?^S!\2_A!K/@K7_BQX<^#G
MBWX7_%KX0_\ "17NGZAXD\)>+/$.E>*O"_BS0/%?AFX>(S>"]0M=7T/6-/NP
M#J=M=:?J,$=G)93@'])5%?+/P!UKXG^ OV:]%^(_[6WQD\'>+?%5K\.[3XE_
M$_QOHO@VP^&/P[\'6$/A.W\1^*8]+TT:MKMU#X7\-QQZE<'6=<UN]OI]/MOM
M=S]E :!/R\_X)T_\%%/CI_P6&\2_'/XR_L_7MI^S7^PE\&?BC<_"'X:^+;[P
M3I_B_P"/7[2GBS2]#CU;Q+XGO!XR:Y\%_"7X?:/I^O\ A"]TO0+?P?XN\7:S
M?:K-;:EXH\.RZ-J>BS@'[TT5^/\ _P %#?VF_P!N3]@WX.0?$_X;^"/ ?[4O
M@?4O'?PN\!>(_&.OPW?@GQ[\![+Q]X]\/>$-1^)_B[PEX2L7\,_%OP+I=OJK
MI<)X=?X8ZMX4UB]TG4M8M?$GA./7K_1?LG]M0?M#:7\!?B%XU_9J^+GA'X5_
M$GP'X,\3^*M&;XA_#FU^(O@+Q%?:-IDNI6>D>*+*/6/#VO:7IUV]J]G+JVAZ
MPEQIZW1OGL=1%J+.< ^MZ*_G3_X(0_\ !63]H']N3Q'^V)^RC^W5X>\!> ?V
MW?V/?BIJ&B>*?"O@;0M1\+:5K7P_CU&;PE=ZC9Z/J>LZ[)=W7A'QYHVIZ9K.
MKV-\NFW>D>)_ MY;P9U)KFY]Q_X+X?\ !1_XQ?\ !-7]A;Q-\;/V<=)\$:]\
M9K?Q?\.].C3Q[IU]KOAWPGX,\1>++70]5\3ZEH>G:EI$VH7&H7TEKX8T.SGU
M2Q26?4M2UB W@\-7=HX!^W=%?GU_P3&^(7[0OQQ_8Q_9W_:._:.^)WA;QYXX
M_:'^"GPS^,DNB>!?AO:_#KPAX'C^(OAFS\86_AO2;>36_$FN:N^E:?K5AI5[
MJNK:PPO[[3[K4+2QT^WO([*V^??^"W__  4;\>_\$R/V)=8_:!^$O@-/B-\2
MX?'GPWL;31K[2;_5O#>@^ 6^(?A*S^)7B[QG_9UQ9SZ3X=;1=5M/AYINNFZC
M33/B%\1_ <DD-Y%)):3 '[#T5Y;\#_C)X#_:'^#?PM^._P +M777?AU\8? /
MA3XD>"M6"F-[SPWXPT6SUS2GN("2]K>QVM['#?V4N)[*]BGM)U2:%U'Y8?\
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$ '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>tm2129080d2_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="nrbo-20211001.xsd" xlink:type="simple"/>
    <context id="From2021-10-01to2021-10-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2021-10-01to2021-10-01">0001638287</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2021-10-01to2021-10-01">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2021-10-01to2021-10-01">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2021-10-01to2021-10-01">2021-10-01</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2021-10-01to2021-10-01">NeuroBo Pharmaceuticals,&#160;Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2021-10-01to2021-10-01">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2021-10-01to2021-10-01">001-37809</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2021-10-01to2021-10-01">47-2389984</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2021-10-01to2021-10-01">200 Berkeley Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2021-10-01to2021-10-01">19th Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2021-10-01to2021-10-01">Boston</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2021-10-01to2021-10-01">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2021-10-01to2021-10-01">02116</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2021-10-01to2021-10-01">857</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2021-10-01to2021-10-01">702-9600</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="From2021-10-01to2021-10-01">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2021-10-01to2021-10-01">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2021-10-01to2021-10-01">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2021-10-01to2021-10-01">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="From2021-10-01to2021-10-01">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2021-10-01to2021-10-01">NRBO</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2021-10-01to2021-10-01">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="From2021-10-01to2021-10-01">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="From2021-10-01to2021-10-01">true</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140531915346984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Oct. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Oct.  01,  2021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37809<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">NeuroBo Pharmaceuticals,&#160;Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001638287<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-2389984<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">200 Berkeley Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">19th Floor<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Boston<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02116<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">857<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">702-9600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NRBO<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Elected Not To Use the Extended Transition Period</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>13
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @
MO(5$4]6?8=OO    *P(  !$              ( !KP   &1O8U!R;W!S+V-O
M<F4N>&UL4$L! A0#%     @ O(5$4YE<G",0!@  G"<  !,
M ( !S0$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " "\A413MZQ1
MA(($  ")$0  &               @($."   >&PO=V]R:W-H965T<R]S:&5E
M=#$N>&UL4$L! A0#%     @ O(5$4Y^@&_"Q @  X@P   T
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;72YX;6Q02P4&      D "0 ^ @  &A0

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>96</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="tm2129080d2_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neurobopharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="tm2129080d2_8k.htm">tm2129080d2_8k.htm</File>
    <File>nrbo-20211001.xsd</File>
    <File>nrbo-20211001_lab.xml</File>
    <File>nrbo-20211001_pre.xml</File>
    <File>tm2129080d2_ex10-1.htm</File>
    <File>tm2129080d2_ex4-1.htm</File>
    <File>tm2129080d2_ex5-1.htm</File>
    <File>tm2129080d2_ex99-1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>18
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "tm2129080d2_8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "definitionLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "tm2129080d2_8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "nrbo-20211001_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "nrbo-20211001_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "nrbo-20211001.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 59,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2020-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 96,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "nrbo",
   "nsuri": "http://neurobopharma.com/20211001",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tm2129080d2_8k.htm",
      "contextRef": "From2021-10-01to2021-10-01",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://neurobopharma.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tm2129080d2_8k.htm",
      "contextRef": "From2021-10-01to2021-10-01",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://neurobopharma.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://neurobopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://neurobopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://neurobopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://neurobopharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://neurobopharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://neurobopharma.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://neurobopharma.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r9",
      "r11",
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://neurobopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://neurobopharma.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://neurobopharma.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://neurobopharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://neurobopharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://neurobopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://neurobopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://neurobopharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://neurobopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://neurobopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://neurobopharma.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://neurobopharma.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://neurobopharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://neurobopharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://neurobopharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://neurobopharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://neurobopharma.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://neurobopharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://neurobopharma.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://neurobopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://neurobopharma.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://neurobopharma.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://neurobopharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://neurobopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://neurobopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://neurobopharma.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://neurobopharma.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://neurobopharma.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://neurobopharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://neurobopharma.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://neurobopharma.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://neurobopharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://neurobopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://neurobopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://neurobopharma.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://neurobopharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://neurobopharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://neurobopharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://neurobopharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://neurobopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://neurobopharma.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://neurobopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://neurobopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://neurobopharma.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://neurobopharma.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://neurobopharma.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://neurobopharma.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://neurobopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://neurobopharma.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://neurobopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r10": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r11": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r12": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r13": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r14": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r15": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r16": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "Section",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>19
<FILENAME>0001104659-21-122546-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-21-122546-xbrl.zip
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MNAA?+&;S^0BE&68QIIR13R/&1S_]^.<_(?GS\2_C,;I*"(W/T1<>C>?L@?^
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MW20'$ <$4+=#@",9A)I1_G&:LXB+9UY[G6+&M[))W,]X#(]<>J+<HC6H"$W
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MNX(6 ,R%*%=ZI. S9D]B^YQ%^SO!(T+4&UUIU7[UW;4;&.V6G#<5J<G4H-"
M:'N+7X##0Q:HEL>'6A_F_Q:@>G%=K57'HZ?%(Y:G\7:;I:IGE?;@^^B=08X?
M4 PH@/&8HB,B(  'V(0>6>21* _]@(I@5(OV>@V7'E8Z)/'G_3UY($+-@%B2
M7?99'NZIXRID0*SK*[S!Q3$O^'H#@T#QK6ZAR\$4U3- *_4F6ID%^EUE@O)<
M;-^&K^^ZEEMRM]XE?ZUP2N2>_P)02P,$%     @ O(5$4Q@]<F5;!P  05D
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MVP>Z[NP!]R[@XAOWR[WOUA[Y'U!+ P04    " "\A413:ZF+[A,:  ".E@
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M _AC4[UIJ&S\B4UN)8"X6ZH6JWNKP*W%X!X-F:'"O^Z93ONW/:H[; 50N\?
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MYLC:GLYR5[3/_6W<EXPTU1T@,NE-)O&@:]K F9QK6OOD6*?*'2D"2L?4-?6
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MS'$)>X#!Q.:/F?IVGTQK<75*BZ]X#'PJ(N0YZOR]_[%U=Z(?F^J3U3F>C:F
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M[I#3H:6;$V9O;@&29H1<FOGD.JQL'YYJJU>SSXG"S4;\U>:EYB^G_A&<BFO
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MG_+?59Y^KB7YZ3F0'$TR]<: P21Q;Y):8-7!E&#!HFN.29?IYHAH8N/R#+R
M(*&:^T1ZFHXZHSE@75QFJ$S%G55'&WJZ2PUF>HX^V=YR(/-R>A/^OO^&V07T
M(B'S=T1C6Q(> +()-2;!LYZI PGX'OH;#1-V9_\/*O*/!IK+<HB:8;/KR*96
M5-BK6N/GY2@7'?+>= >:DK;9%L#\"I/$B3J9N97!K[;FPB)CT<0S_'3:23</
MX_%ES1V/):_;7<NF[+P6V522Q.I6#Q89CT<RM+6FA#Z1,/$XE<2*]2)@8Y@0
MR7*QXLO_5)L =@?LR'ND<=8FQ9*4AX%OTY.XM7KOOYKQB&8$ 7D'W(("RV3T
M+\!H@N74YV28'\]^%+^>R^Y79:-J,4O/:].)B$*0/T'B'(60RS0G%V,ZD>B7
M"36B+.7%R+]*\9N5XMA7BBN;H5W&@P*\00[# [O5Z\T+*=MGK8>C]Z>MEKZ6
M/>&YRC&?KM>F)$!I3HF1NIP'D<MJKKC3]?O8EM(;\<)?S?G-FB.G:T[3<3QF
M+]0?[X?ZXZC1*9Z=OZC^S%#WAVA1B>7*.\H*6N2_\!):M#H(\=]\13/\]$\S
M<%MLG^3\#WWUTEG/S?D*(4U_#AIGVGZ'(KCP,#;=WA+)&[,A_[/FMMA&1LE/
MZX"%818W?2)EQ6+1G-['%S4WC^\S96;%?%&9(=5:O73OUS4>- Z63?QD5!F(
MWQ2=.L["C;<UMLXL9%FLJ6G]M=9KFZ+0''9M?AZR,QEV37W'6;"O__+3Y\U
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M])>)G08#0"I!(6'I,#A/CD!JK?"<=Q(JMHNY+E4&B8!'D%>KY670[^7"FV1
M"N/]0^B(TK0T(U9_P"#887J6?# -K0\\AG3I*CN#O@(A%YH%U\Q.6V0=_M31
M7R5KUPH8;V2(7UU]-#3:A)U95_?$=*= \6^GP'H[!?YZACF>H?8J/<-9V) 6
M;@,%NS0B.7DA=_'ZI:6T[H1!<&!'?;N41.RM/5^)#^1RI#+%OVAU7T3O^ 6;
MF7HD"3,G']<K#"\M$O(:#[_Q,"3E*--J![E6N4BJ&RQ,<&0)MV4?/\FUB&:?
M,/RD >BZMI9UJ.'DDH>\:I4WSSHJ$4IJMWX2E6"6L#.O12;2S41".6?9MSQ[
MQ ?A=THFFWD7G]!;"G7"*LYB>,*-FLN1DM"+)S+DD!+QU8_NL"@7:U)54HNW
M;%S.R?F!.PQ7'\^^Y$!*;:H 8+_6EJF7\^"%Z0H'/A_7A.>2LZ+.1'E!K+ :
MW[*>WOX5]8PH(J<;7N#?*N:Q0V&/G\K<U"3FR$+%EX5ZY?G"MQC)BB+5BC+(
M>-+XJ,C\H6*Q^.#@YF5%EI8S'+AMLE"64K=UECIVN8+@+4OQ<TS=H_6&[,)^
MK6RP;4K!)/:7Z)<-"\3QUIW@*WBQ#T741H!_U/5LQE-TVQ&U5M=<47=>5.R6
M4*CU2LT<[7L=7F>1+2V67J'%;I@&-O5.6VRR(Z[(%7L3T_6^M__=,<#KF. <
M0:C5 DG NO#&Y"U"LZ+ 7?&Z=MNO:X/8+6% A4F>TSS[5Q!_\P1EJ;SFC'(Y
MO W<1N!%>-+$H@$5;6PGU*6$?]/,#M]HX/Z4?#MNGQ.7]D5[!;9&J:K?5^XW
MUC0-+%&)@:K_U98Q0S>WC+"N&M7C>PNEOWL+&SV%N,[OX&Z^OSRZOFD_^UN^
M-WUCQ=7489!$0\'CET+P+@>\%2*;=N1=]?0)4:CG\)8!S?&_YA;Q=$6D*^)>
MW&7L,MZ$[>\%\E*Q/T#T&L ['!SUW(%I:[^8NJ$6IWC1;[HH*-0L7@]<7'=-
M5 SC2B&E*(6_H[",39^MYU?P0#8VJ.\G?60Y^ 9>WRK/>7.V>,^O),"6NWWB
M61:S%7#57+0;'\Y(IW5^<]UL7782W^>:6G"-V\GX<H5+\N<NQ_Q+$)X4+LQB
MV7T.DN/)_B,8%CF5X&:U\M-)\'.]!VIK%%?.&5)=SRG4<C+U@E- @MH:?O6N
M2CY1/&,[(UM+K\X&EN+I(/%FI*>S_ADK_D=RDU\ ]UO8B5D,K^'PXDYCH+$>
MGA7ROV>FQ;]GQE[!(JZMF:6Z3"_+XUU0.AZ5Z-L,=_\?;[[9++)'HN'R 6F)
M9NM]<DX=]_4$Q\M&JB^Z3D^Z$R7587.&!%@*75.=<*$>N$.]GERR#@-^<G-'
MQNKX@#1/^"^W4O7XEM]]Q ]D"_;P]]C'\=G/&^G3Z.?1Y\%-X7-K-/ZA37Z<
M??O6MF[:[VW][/RTVVW\/+YT+X9*I_?!T;M#FS9'U:/1PQ6K?:RV3[OO]9]T
M^+ELE\V+SO 7_6IXIT?WA29M5+]_:.F>(37*Q^KN175WXGZHE7O#LX_]BY/&
M^?V/YFZC>273]OAKH].OW!7-KY\J)[_:C?+@JJR9LMR:?)%;@]I-]YOY7CIK
M?;DZ/[9+P^[=R*S]<)Q+5?ZLWGPL#H:3YK!JM0MW1\Z7S^,/S#._557Y6+^_
MT8;]T;76*5V;_Y;M#T[E^NC?#AW63O3V0Z<@M96K>^FN*MCQ_U!+ P04
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M'M'3:544)FWS2U,LHW ,[C>-'L;.Y@S<R1GX_=?#D\.#4]AQS6+R!RQ1!!L
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MS<:^WXU-Q"7+07S'TC.;+'OD([V"S:!D';Z(Q*J//3L)@3%J$W(X%8V7A41
M36PXNB I0CM6O1PC-7R!"U-_UL6A;JJZW/?>$N+B5;4DPP*1S!$"&R*?)X7C
M//XMJ=\;"NB[:GXM?[59V*]@87EYABMSR('U%-TS>KC11&E-N/X=%3TJ\D;@
MQ-"V95F4]=>TUG3[_+E K%@%\X$?O_GWZ2'<43"4%(=&'R5-EOP9O1""(>Y[
M\-4O1359^\TIU;.TNU* 2#B#R+GM:I9857#+>KH7:6J:!HF^A%#2S0WH!!4,
M9J/;W>]NMKD.(*ILU'_(B1":@-HI%)-9X4 "=/.Y2@LM%VBC3]4_?1TC#S7
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M2ZMJS:= 5.ASXF:@S0NKCYL$99:+4B=])Y#S$_'90OX'F#\YEA(B-B7,>6K
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M#C_FE5.6B"F%S6H7QH*5\)Y^3AP!RY#P<N<5",\2&T'U6WL"AN>X,R5VQ*I
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M(M]?LAW(@5Y_C;@?&S8,+F!'4-ZIP0B:C3 ZKB#_\31*+^"W*>':>="<'4M
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MAQ9J2@"D(  ?.#X?[^R+LVVC@=RY!O*?V]1 WE2,[#^O:6.\1:@N[%TVM0Y
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M)6?^"KD6!8[9T?/G24X3QC1-5L==\0Z7R)292:MY]6S%-ZX.XHQ-5,I+SEQ
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ML;S"AV2/ZJKFYQA_Z]M\JSET^S71KT#VV68\L%3?+0(.8XT1.217!+'[;8?
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MF5+BW:$!,61L.H[2I)"246UU3@ E[T+JE%9DM9:.L.(Q:*KY!;J*E8?#J,[
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MW_A<_X(\2G=HZ]\Q+\01LM=)]OR:S";)/6(N6\5$&VJ#?!7.$^9>T!8+.I%
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MCJH:0]J9H\@=BA&=DL0I*0B#KX.KVMENHC]E:;K=(K0J$5%)6B4V?MDR31!
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M%J!Z/GQ?2M)-Z*X&\&.K7CJ73KHOUBWMN7S" LL8?M0_XW.%3T<YAZ;,-#3
MN+=:)H*.*$DTAX*X CZFQ*BJ*]%1X=Z/ 1P-98<@CZZE!KV'_S_CBDT&B8YP
M)A+4FT'-*5:7%S8P-<(,\57Q:)C/*7+5-%RX3.D.C2=EXZ*%Z+N7;(_RC,SF
M ]/!41<^YH)OF-CY=@_,K:NILS[_+.RT^'\/9Y1,<686!6U26KPZH-3H *?1
M4:]_.%+6?Z2L%0TV:4NHIM!-X!VOM'"?F^(+UJOW* 1,^'$\3K+$Y"<!]KP-
MR[A403*IZ:&987HT-B\"8D1@K933)Y4%[N:&3<1U0?QF_;F9 9%[,23R 5+$
M\)Q==-*&=,_@3.5(#,BV19<<6S2^6CP1?>&+--=DK2E1!)8&56\/">%.Q0Q&
M*C$]P ];:_U;:YTP*(J+TQ7M-IBA=Z:#VJ/:0AWYA@D%X9 M@ZQ&;23!B9=#
M9=R\@6U+!H3OUGC27GCVPKU@8LHI4/2.MUU> ^<)V)1&U$;SZ=6(,NE,TXOW
MN55EJZ(>0<S"WTKORWQS8Y0/D*9 *4?]+X3!"00B\G(,I(?.)J&4/-.3TN^'
M0\P^!WI!W('&+9L<*U4@ LJ<&_0@'BR >+68]F8!S2I[_NK9DVSZ^(H]HBU8
M.']4];ML#W4-7<^W0S(19^$;V1RR2/YL P<@0B(L&CF$7-YHZ+*[';G-C1L-
M'0[#,!=D#(L)!#T'[LJ\E5+>FX[M9.[I2FAX!V9XFP)R-MG64W2Y)D-VN59X
M7&[0H=L$+1AA'@U,H[>/3Q]GY%$QW<F@NI@@!RTDGR?H5 %39 G^*/ J\ 2I
M.A$5ZKD;+!^KFJKDP\4+N[ZLKH+-49H=39L8-R+=N3(S(^$<D:."&)SL*2%!
MPO/BHW= 4@:5*M%O+!+IINGV*I'9&D4BW=GRT2J1V2*1R >BE,_KGEXG8&%'
M& F:GS8W?L?" U\&L:S4@"-D6*LP['&E OSD:0V8(_:*0/E<8 -!>HU-D<N'
MSX,MBTQ '49_SYK02[F!)D)/]J; :H9P[@,VJ\V>/WG\_;?P:B@1J#DXCJ@;
MBOM3Z;%< H+O@JTWJ$M*)NRP<I"W-;8@6:#WIPVC=<LXT= (D+WNQ*\38"^J
M_>@Q)$^.4JFDQ/.T@*-C$(C)X7ZGJ3"3AI(R0$ ?B^J63'OOQS4L-*FY&: O
MUB!A!@*@J/X"[;@AK!/X5^GZ1V6Z1HK+/8"*'X+JFFT!8U&I"S1]Z?PP27FW
M!?3.8GB#5PJ;'Y2]&$@&KFXILQEQU?TH!^6EA-P/9V#(9E'<!"EAX/.\>$NP
M1;R\.]F<=.'EPN2&8'9J R\#KB]& H.@=:!G(]0YVM+NQ[2L?G5K)8VGL!@>
MA#$9+X%ZA\150P"/K\(-E!:H:'DR@7^Y>2IKP>HK :@N6/PVU1@K*TO D,*=
M@S6;6@C^:NTLRYRKQS5 S"$?$U#OL$B3K,G[PH<%KR"F!JD]>@3YQ-$S4O%W
MU:G&\68D4^G]9KL'*)$7-=RN;1H@'1?G$,M'D@"?N!S271=&V**D( )I '4U
M!;UDE@EK<>! Y3ONB^N]'B#&!\%X?OC:8#P_W \8SQVNGGMAD?ZX1HOT%Y)5
MDM 1.(:7_"N1#\#B!/*QG/-8$B9B A?"L$)GW,BWY7AW+2@1"_0M_"V-:0R\
M7Y6VR%?)>DE7ND/ORW'X.:VG=4*M3F<#2#15-=_?.PVX&HJQ2EMLP46)Y<43
MI&$FRT"XTJ)8/%^4)48O^)V2>./ 94XOYW5M25XPAH1_C1>J"%V1&5/5"[ %
M5N5EH;41WOF;&U9I^WS.-*K;,>\+M(_;)I&)L8I$<;N2FC5QQ;L)"!G#@\8$
MPY'"#4M,6*>&<2GT8$BVEC]<%(*/"U7.8!X!']E-4V@YE/LVA*+,B[SG%6DW
M+TPB8]Q(Z,+A<[$:;O.8T5\/)\7:3XH7:\U9( ZH'CXB09E=W.8#BKWYU&#,
MF:2'!JXJ^#Y[[>?Z_4421(0%,@*MH\#2[I21/7O\O680;_0HZY1T'_:T<P :
M%@4L2EMVW$DB04\](\J[Z@ 4R@8X];JO(;<43YW ^Y94)C)081 $TOP]X_K2
M2:-L+GGCF1-"4$A'68FZT?6>7CR$/S^S+;].V9>?*=D!"9>#_)J%7MQN1@2M
M%,H.Z",:O1*42B][[_H^1*%J&Y0C>\%Y5FZ#AO3TZ1O$:]%=8',$;3BTQ"-(
M:,!K?D%E#[X3J[<,R/BTY2R0))T\6H?R#LKDYXR&R:"<,E.#"/7A/]P#!3O
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M\F+&Y'MUH<%\9X%BS)DKUC&K5N>C5JL$A169MPZ7FVL>\$,X"3APH;2#JFB
M]2\2K&!O'N,QF(#E[ 7$^ B47C.D2?5*4V"K4KFONWZ=QH4L(FL(*Q?_/$(O
M%=D3J2R]JJ^!U* A%-=T7**( /US6"*T8MCT^.^#R@WUQ(1AZ:X32&(0VO)7
MO6\X3AD&Y W7N=!N/T@WW_FQ<KL"N=U_N)/E]YW]?_9/-C>.WF3_Z^W)']G9
MR?[. 5F=$,\_S'8._\AV]L[VCPY=4][NG_6RHY/L^.1HK]]_O7_X<\8?<5_>
M/WV]CQ_,=D^.WO[\RUFV^P?^[7CGY,S]]//._N'I&?[FZ.R7_@G]WO7SES[^
MN-\_W=SH[^S]DOUZ>/2[>_8!?/VU>\-9_Q">NW-P !\_PF_\?-+?.>N[Y_7_
M&_Z<'?=/?ML_.^N_QK<>'Q_L[^WL'O2S@YW?W?W>/^G#KW=/CP[>GO7A,6\/
M]XX.7^_K<VE0]D].^O\\@F_^L;D!+^__]_%)__34-05'ZC1[<^0^X1J/ P7O
M@F%#:P$5\;XVLIS5_NN=2Q/N_V/K5,KG-C>./>/]&Y0#V/[[=_LKYV5MW;@A
M9^J^#N_GV+94JY;$GO[VM<6>_O:UQ)X^P=Z]^3[XK&_C_</-C=_WSP[=79']
M#M?-T9M>JE"1DCJ0</!\:X((EL!YR" )N=79>.[K]2BO&%KT^:R]K&K0+Q$1
MEPKU@W(UW- L&Y5U V@V)!L"6_J\>K\FK-F7=&E]5)L^C@W[#(T0T,<]/=[9
M<T;-?W[SY!O\]_'.Z]?R[P^.[5Z7P_82/OKD6STW(4633QLW%O+3-W@D_/WL
MY&/&]CU HP?Y6#:2.Z.^D2/F['6V=P0].OS/;YY^\^%/7V<&!?<UL9DZA_-5
M-IM.BQK0ZZA:?-A_>W*T>Y0=_[)S\MO.7O_MF;,+#T[%W#O<>QR8;6>O?1=U
M,=E?_I5]_08,]AVC$G2(U3>OR/CT/7#_.?E\9SXUJFL;ZJ=/GF2[1?VN&!=S
MYZ2Z8[1U#@M2U&7?OPS$>K,WXZJJ/\6 ?<03>7\_^W:=JV=W_BJYT.7A]MH<
M%Z.5%AF_XL.Z],/S;[L#1B]89U^_:[[+3DIWG=;#[-=\<K&TX]RTI]^F5^<M
M)O"'E^Z9NU730K#HM[QI\L&EN_M;P+I]A@MO7?U?YTR2];UR+M?6\CY2TKS*
MZG?N5?\U*69U=5Y-W<NO\L>#ZFJ-A_FG.[+OQ4(X UR<\\/<]4=2T!"QW+LL
MBU'&3$_.$*:SOOYB+O2':SMZ^.<]"NN;^=^1KY7)."L@YBVI()D3& 9%2T76
MV^G+^^N;@X>5N-Z5>'Q9CL?E-'L-E4PUIJ\>5MJ:Q_B7:E)>N ]FSN]_&-PU
M#^Z/SY^@<'"1[3FSH"ZRWP$I<3HK6TX\.Z_P8=#7/.B_YN/\*O]W53F_QMU<
MY85;W#^\?/+DZ<-(KWFD^^2/3%L^G/_KD@\3=$<>1ONOL0F^P\CN/[Z0B/=?
MG^KYWR?]WW;V#U\SV.!XY^=^F-G/#OIOSK+=@YW#7S\OK,CG/[:G^S\?[IR]
M/>EO;N"XO@&(QMN3O5]V3OLG[E\'!T>_G_Z?=8RJ3SG>*6WABZ\MH_SB?F24
M'XZ^Y-&G>W%S0[<JGH"G@&8Z/-D]RD[[>V]/]@$#I3LWV_GYI-__S9V0:]FZ
MG\EI>C>3]E=G^:G8C[C9[SS%GYD,/W(K?*(4_Y>Q!M:=>T#@OM8TOLK^[T?]
M[YY,P,T!-VN&"1F$GYN.';\73GDOS .B"< 3W6"J[LFL_&7;(C4/'[Q#'B;A
MX]-AZYN%AVFX171F<T-@.8NFXRN?AG6VB8>:!'H/E=+YHZ[HA]'^H-%^;02P
MF!&Y"<8^VRI')""$<D>-ROYYL3^3QWP8]$4!G=EY,ZC+*16.[F#M\:OL?SXL
MWP\?22RY>[6Y<5_'+FF1KQ6H0/M\<X.',G&Z>JGX<79TS>1>V>ZX&KQS1\+B
MIOQ>3BY0)]GU_W]\_^,+Z7_VP^.7+[^%(LP/_^[FQDOX\CV9W3ML4W__,#N<
M@31S:G=\H1OD5C4BRYJ[:+FMKX.;&X>+I$66\4-%LB,]B!T-+HO!.Z+& %ZH
MZD]W+6_3 "9X!U&* :)$CRB A;7+4PE4(>>6#V!YQ:]D4\X+_>:0U3@,/P@S
MXMF7>46O;JLV-Y3>#!1UQV.1_M76<.?#!VK)] Q4FI56#DFJQJ@53+_#KXO$
MI^<Q+!L2AH=';95FW%QS@@]3X3/WR37*/3?;>CH9;B,8 3[W&EDBH A1>$K2
MQ='8-O<N>1E*"D@S;2LMO^#F1E<"?NL<E4C*JO94XZ9#N#;&R':F"P+';IM*
MN9640H5.N7<R#Z)7'JP6(;Z05O0"GO^(81_I-,IW^+.N,5+]V )S435,MA4+
MEXVKR05(UA?$0\/#8C7DFK;(ARC0G$^B:5_,5I/H3*<-P/M&8\&D&RL[B4(U
M']!+I99L5:TS8[9>F?777RHA^&>0>HE2HZ?9GGOT_N';_LJ<RB<NNUUCY=KG
ML40^H(#XY4_9$?HZSKH\ *Z=KR'E^_+F*=^[S;_>8GV&C0A2R7=]UGRW>_3Z
M#X#??/?+V6\'[H?_#U!+ P04    " "\A413G::R&<=%  !0J@$ %0   '1M
M,C$R.3 X,&0R7V5X-"TQ+FAT;>U]>5/;6K;O_U3Q'?32??K!*X= AC,DZ509
M<$ZXEP 72*>[NKJZ9'L;=")+;DF&^'[ZMZ8]2C(F,20$3E6G$Y"TI[77^%MK
MO7YW^G[_S>K*ZW>][B[\?X3_O3[=.]WOO7G]A/\??OM$?OUZ^W#W']')Z3_V
M>W]]-,JSZF6TM3FIHM-DK,KH0%U&Q_DXSCK\@TYTHHID] A>E"\W__?Z2']R
M'!=G2?8R@F\^@O&/Z$W[:QGQ:7W$5Y'S:K3Y*JK4Y^IQG"9G\*,_IF65C&;P
MQ;>'!Z?NQQZ7R?\J7L.C-W_)^N7DU>LG^-#R!B^2L_/JJJ%?;\OHO<_G23^I
MHN<;6Z^?;+]9]F2^Z4XL./A!;^_T7>\X.GVW=Q*=]'8^'.^=_B,Z.,2?]%97
MY"=[O9/H+?SLX[N]G7?!L_#WWM][QSM[)]WM_5[TKONW7K3=ZQU$Q[W?]TY.
M>\>]W>@C#((?C)SO=0]VX<6==]V#WWO1SN'[]WLG)WN'!Q$/[3RYNN+^]BV\
MB)>B>]J+]G"0_;WNP4XO^G $O^T>X%S>'YWBHV^/#]_+)(Z[]),/![N]\.M1
M=^<4O[KUV[-GG:@+_W[?@\=VHS5\[B]_^O7IT\U7[F3@>?KIUJOU#BX"_MC9
M.3S>W3OX??\?G>A]]Q]\H >'I[ /\.FWM 6PK)/#?5IR[^@T.OIP?/*A"P=S
M>DBSAJ=V3O=@Z[P)TS)A/J>-4Z>YX(>#CW7_UMW;I\/P-Z.#S\*>=2/X_L$)
MO(R_P7F>?-C^+Q@?WN_0&-XDCGO_\V'OF*9Q@CM5WS^8"!PF?IEV@LZ#CKQ[
M=+2_MT-3X1-SWMOO?CS9"&@)/Q-\'L[] WV #E@HK<?S<%\U^[X-9'NTW]O]
MO4=3VCD\..CQ2GE*T?;A03=ZN[?;@W>.?Y=9?SB@G3RDR[!_"+M(7X9O; .U
M?0"JMW/:N.JN-C#IX*Y^&YXP4%FEB@78(UXX(K_#G?]&ZH);"GO^L7L,='.Z
M"*N\RSL@;U1%G)6CO!B_C*:3B2H&<:EH<PYZ'XX/MP^!RMYUC]]W=WH?3H'&
M]T\Z/.6]@YV-;[E%IW1;=GK[^T?=7>1*?WVT^8C^?7+4W='_EF_V\V*HBL>#
M/$WC20E?UG][%5TFP^H<A]K\Z1'I*J]/C_5K%ZJHDD&<ZFWMYU65CQ^)2O/Z
M='>1M<H SS=_\L\H5:,K1?C'N(#CJ:*3\[A0Y<OHW_R?V8O3W?I<9+RGN)YK
M;6S3Q^8M;!(/ATEV]A@7 L\D7[G6O;*<JF@WKM1+7F4'UO!TRYT>_'%\(V=T
MW;G.V;FOW_.OG\S]V*=KTN:UZ3%+JB1.H]YG8(I)*:0974&83X@O$8OZON1%
MIT2S:1%=6GZ89$.5\>8U36H4CY-T]K*^G-J448%AY;95UD9KU;G26NCK#YKO
MO7[RX8U60D&F 0&/$ABL.H^K#HQ31!=Q"CRC4 .57*AA1_-'_B^"!Y*JC.*R
MA.65JRO!(._R%(2"-T921K#FI$KQ8]-)GD7X"HC2,7PF&T;EM/^'&E11E=,O
MTF2<5'&5Y%D9P;-*4PH^BK\?Y-DPH5^OKIRK0B59/(*/1:6J</K5>2>**WAZ
M%E6PB_@)F#(_XJY#G_:B9Z"/NJ[RG'PX>K,%W\/_O^Y7&[Z'&PI4;[>T\<YX
M.XQ;P^N<% G\"3OYXN7F9C39&&\P;:_AB/_(BT_13E+QSJSC*][9_GNY>_+T
M!O?D%*@'#A[)H+X=_6D597F%U%(H.OD.;@G063DHDKXB*L<]FTR+P3FH9M&H
MR,<P@6F1;^?1$>@%XWB@IL3:2ZV:98,-H*S5E5V5QI>@.0 A%I.\X#D$MV G
M'T^  MU9(>GC+(3\2E(^HK6X=.D_'B*[&,-UB7#N4^ 6./=@\;X"XRT]']$=
MD?'QQUN_O"KQWV.8Y4F5#SZ!W01/F*4#Q0P4OI=GBF>%_W!?B&@:\-T$;IP>
M&YY,TPCV4OUG"K0I=]>0Z!%^%;:KC(9JE&1J&"7P-5@E;!;OY].U_OIW8PPU
M><:^E+5O;KSX6N8.9^SMU1:><>LU<M_<^,N??GO%+[7]"1_?Q3-A'HI?W@!!
M$D^ Z:;PI:%PYFD)?\5+@C<IQZMTB0>KCY,YKY#!>7RAZ/S'*LY 0R@M,\9S
M1]%"DB9F(I@6,#9LP9&FP>Y9H112?4V<U!_Q[]00[OXP.AQ4>5\5LEFL20#Q
M 06?N=?!B!!-_ 5,%$XRKO)BQMRBRK\93?Z?QX^CMXE*AR^CXVFJ'A_%9RIZ
M_/C-Z]V]O_E>U\=5/GD9/4-K4W[ >J?\3-LJ+]!6<5YVYX'/B?U&']M.8[CH
M\..HS--D:.<([[^1/YT)/O%F>$/;=/,'P:*;I52TEP%!D- @JF*J39!"/C\&
M2JK.2Z#H-,TO@<!75_"Q!(RK.!OP\^UTT\@REKN&IU>L@12N<[A!> 565X#5
M/X:+.XK6GFV\6(]F*D9YF(&Z5Y0Q7 61(M9X[("8R"^2(7('TA.3$8BMP3F/
M @,@DXBCTR)& P%>F<$C=B[)>*R&"3R:SMP]=![?^&(^?5ORX"N)U[D\>&U>
M 1_\SU0!\< +?(?($&NYZVA[U"[[S\XEUC^KW6-_:75/E>?;,D/0H)L-8_+:
MG,7H9;R*3F<3^'2WB/O)X%5T$(\5+_4@Q_5M>>Q#OT7\[<F1<)CZ'O1!?_OT
MN*] E,#7)K1Q[A1_;I@B[I6[;B]2I8\_&-*=VPUSM1]"(7FZ9(5$ZXVDC7S'
M3*#Q#/A/W.1;.HUX?:&MG[_KB__IG ^(CE'D^!$VK,8O,L/8%11-+:-"3<!&
M0>XRC/HS,B+T!V 79VA!C..A0G$179[GJ2('0P9WO:@"0[Z@_R]1?%F3GN14
MDX'L&,7,/^C1T&[$.0U5BI)OIHT8K2W"BN)H. 69I3Z#THHK&,6#,H%C@HT8
MY),9?OQH]VU$?P<S;IQ4LD[U>!PG:;0&#\A?XZJ*!^>HP1HK[2"OQ/8R,T_8
M.8*A Y3(,#"KVC"UF@U<?]W5C3>BCPGL-G\/!'R:P&[!LVO).A]K=0G??"K_
M<$0Q.V76$O,<O)]-QWUZW1/:)2Q\#/9CF8B>?5+!JW$Q!*E052FIZ]$1W)A\
M2(9NNRDX7#?38L-BW>H)5IO!X:T[".:)QUK&R9!,Y(A=3V*2R*'2+^(S,![.
M\ N^?4I^ 'S -ZBC<J(&Z!0;ZN.()Y,T&<1]//>&0X/SODR0P"CJ@_M41(.X
M/(<=-Q;XX%R!8!X6\66&5!E''X!H8038L@J&[,<9VMFI*EE9P]?I'V:]H( -
MU'!:P!2\^04[.9!M["O8/5)?VQ?30( ;\#-X\-/C'.XO7)2TX1F8@#;^"Y#C
ML'(X@"S7.X]7!]0]^"M>LK-IC%L+FB?>!;(CHPHT!?R@_1W\"C3(N$C^EZXF
MW1#\3M-FP_AZ6)QM=0ED7B+A(:W 2TCT9]H^E2L] -Y8@&;;0"BHN3HKP3<F
MY[,273\I7NJB4,;]80BERMD"T*QBFE5PQ9UO PLTK!#,:!A'[GQ :O$%\ 8Z
M"^/O,5:J?A2_U5?*ND+I*$?3-.VLKA#;3$ 3QQ!CP_):%^"QNA%1+"AD:<J\
M\5+S#K09UIXU<0E>T.H*7TT]#>)>+82#Y"CWDC?:F<(&Z(H%<7&]2AG!F31L
MV#2M< (H(&1W2V(+<33)"YJY[',%Y)1:OK7(O@>^##4:H5<.WH6;!$Q,.%$^
MK0RU.6PQ^+[,+A@!IAUGZ)< >O$=9\ZE;)VSH2?VX,DQ"[6LKNBSY&6 S,G(
MWU*H 9@(P ?.+3>]>@A#A,)XV=HS>\XS\$8$0A"62[*37)IX'NC5;+[)0F/H
M=US;JE,8/DM!B$EE)I#15S:BU]MO@BV ,8 **"BAX!X 2XX' S6IR#X/" GT
MBL&G++],U?",]808O4MBVL*K8'64EI3(]"TY'B$? NT$7HDGYQU?3JVN&/V'
MM(> *(/=]EV\BQ KWE,S@L,Q6$TZ@^W/@#&AMB2ZE0B46%@_4UY9D==, C&@
MT_"W\M$WQ1[<&?6[_PW5;]);6//&"^!H!WB[)LS%YKKPHYH''R[3GY]M_/("
M#[]S532BKH;Z.I6G@CZ0TA6D-+AU4MH1Q7)UQ;.YH[T1<A&2G&1LC2QM,6]@
M_SC[^D0V KL!5GF6E)5$P8BQ$+WPCTEJ=B+1LH&/HC):34O2QV*T!4B-(DU-
M.Q$]7N=Y69N9J A0%@7$2+.ZE1FG94[!*JU!A?8F,&YM<)*@H4WHSRB@43(O
M%XJO:>9"[5'BJD">#H8#2P <IRN1=?ADC>.OKLBJ/.7@/U,0>[BK>9]WC:S6
MY"(A4?G/M>[C[?5H[>_K_\*?KW77.S 1V-27=P)%=C483[R1=5]D@#.;@\N!
M+[0@G'&Z(<IKB[Y&$!3[N\9/PH%7ZG$YB=&/"QH%J 1F4L^^ *X%AQ?]5;93
M[^T"TVCD53*-7W^Y$K*&IK31/U\Z'@+D]'_[V#W2JH*KG;D^_0F2]#"PU:\V
M-DT4H=E4,$HA'/@Y6?[LA$&%S9H1H XA?R"!%=C"L>-2H  W^G/BF8F*U((6
MR N,2P1'C9H')37O.J.Z8QB(!ED3$X4!4URZ\!?@G-,T+M"90*^<YS"4YC&^
M%V5U!<-P/-K/FYMK?1D9/G9,7R&F?/#^!%GO>)J>D=JG50'@L K^!FRFM"'9
M-+XL"1A"Y^+%<ZQ'2 1%/A'=EFUAS8%50D;^VLSQ']TD$>&9_:]+L=O)4/P[
M%@UA-2&9!9Q"-D@FL'H]G_=Q\4E5Z%<J%.KMS&:WTSQ')GT6[6\<;>!OM8$I
M8M(NW?AZF&A@;\A=^K77P)#@<$I&Z")T$A(=F$9 OY[YK2U\UPM(WW!@,W#F
MV2"=TE?$Q5%_W/IA!VG.AL\"4R0OKC?']>M<99R:YZ%T*>PZ#(AIU[-RFX_!
MO\2,6VM]> [O6'R5<&A?M+5-US< ?1*TTH55?I%N8(-I7ZY>+! ??7H?XJ-/
M[T]\-"";>ZXMABJBHS]>J2UN?PMML8[SJ_G7T!,GW@.)7Y'2\0HYX4TPH@<C
MY5:-E+]_([*;FYI<^Z_5G4KJ_V4^38=HF9-[ =4#0J8K+YSM>!'0=3] 3SJZ
M(JXW$=2T',A[[<NB=IBA+]'/XOL>T.E@'RAB#J.=Q]GU9A+7XXH;W\M]_-)L
MBUOVV8%& 1K$69$#1\/4M[QXR1>,0#*BG8$%XKAJ%W#QS?FJ5NJ(&CH"79^1
MQMK1E@Q"$%5%T 8-L\ H7%%6Q@*Q88I!&D]+?0U(/<8D.*-[)@TV$R,(LRA-
MB*'#%- EQ2&$.#"@>%)]L,$FC@U&X2G[0>W;(R,*KA9H.R7CZ.47F<*K6CE&
M(2YX/;0AQ6;SHH]S9@Z[8:8^W\Y;ZU,4K&:\4Z+ ;R^?;4;Q_-P*4.Z?O]Q\
MVI2" 7MAGEL'NUJ;[<@)#D]W_F<;-QC_\O>ZD\+=XXL\G8Z172#2!E<$;!=U
MLTFK[8O;;F";JRL+;'8P'\]3!%,?S"<:2<)H(!PB %X368+A.&BMCG@EI:$6
M[_,Q(WHR>XKP*XR)'"79I^AP K\1ZL!EQA'A=F+$9IS%F> ,"$9T!HHV!OH'
M Z5X/G!VF.(TFF:#2H?]>!3<&Y[4.I_!."\K<N@"([<T[\5A:C,O<S-G\HVO
M#?4N9HP40.Z^NH(!_;(C(;JD0*Z'J^'L+)(*S:$><A&YS"#.(F1_$T4\$ ^P
MB('S8\94"O8GPPG.\ASA32BJA'^P4Z,D#A+#Z'_D!9(MNNK1%D*"D=4YD'XZ
M$3=$CB?)X50@&1.417GKQ_]EH4HQ_$A]AND*!H"NM@,ZF<2)87(:/?"]1)KN
MGM2R@3QTH3CAN_8,.7=;6"RMKEQ3+D7+%TLN<V^52\,8]NMK.6>[E&(TS->*
MJ>@KI12<QA+$5/3%4FIU98EB:A&5H":EP !=MIAJ&F>.E%I=N6$Q%<V54JLK
MMR.FHGE22D3'K8BIJ%5*&17X-L14U"2E##;+8Z6M'-D*LZ^7:;?DHGUV'URT
MS^Z/B_9VRNLL20E:2,W9JV,TXX*]/\Q92. T.$A$F4%P*K[3"AST/43L]/'"
M.\] EUG[S81H.?#D\*3N0 1FB$8GCE+%GY16*P;PBWB Z!K8IX&)2,I["!9&
MEN9@7328\QQX)9DPC,G7IGDP(+\N.R,XP@H6+I#!O/53UJFUX:*.7*@H[9=(
MW)P7A3^>Y&7" 5.-U.9QX(LU?/MWH^M_MZBRX:VCRMXKH,D,:)&$[=W/YMJZ
MQ=-*-F[[M'8EX<G-YM*7_P-ZP7UH8 WJ#4P23+4F7F7QXQ8P6A'RCG)C;'X4
M\9U3G2_3/5,V)T&@<_#0H%!8Z440(<A<$;W<C+F0LC1#Q0AP\_-^G!(_UF\3
M7S[%T7<5<1U,_3\MX'#-&JMS$"!GY_0]>0@_C^E4F+\38RY7M -OY,,$E-9R
M!D;#.%JSAO3NQ^Z.7P''J\IAK+V848<)XE XQ$!"2#Y(^J5@:;H6Z< 83!CW
M2@SF!)7KRNQ?"X[20 YA^V&5F%"5MF$M/96;;()M!X+1(%Z!T,X2#>:43_L?
MP?, 17QU1<S$'$V(+ -],!\]IN?=>D N=L)BG[:>/T=D5#D=DR.AECH5R,=U
M%HBVID4?;H+.^;'9@!QXX?I( _)J:%"KS:4*ZZRPJ:.?TT]E<0@5"LF5_/JL
M$;2'K?(ZOM0IK>3MC1]0TCDFPV&!^V(SPORCX-FV9;@9F(Q;4X#S"MF=LTAB
MH<&SS,FY;)F#"T!K31GA =PCI(6WY?\%@U-MA !79(_C"Q,?%UVS11)9:':T
M9MP@K!JVU "*-$>OU4+:8(8>[DC3]EI*<'RM0RRZPGX08OQ2\HCR?($S,EE2
MRE1?P9XHHQORGG'R40LW(58,?YE(NH&F;K?,4#WWK1,EA;R$O$\^K0%<X4+]
M(8,R%J#5S^BH0CIQ3H )92TW$5=]J0<FR:?&<*CDF:Z?IN_.G ,C]+U+$:,X
M24OK4Y5T)-@BD]7JB<HFH\')XFC,HKQR4AW/<R&"?Q+/H@!P#]N!&T"UGM+D
M/].$2_(,XS$8H:6I((21(Y!(69Q6,XYBJAA.^\];G<W-S09N9Q< U.AQ,^OT
MK SNKQWGN3 6$*3"G[<VR2?FN5(1 HD'("ZW/S^M/:.' LH%6J^SHRLV>MWN
M1OU=7'I@H/EO"RZ3MJA! %O8(8PAY *_&X#^6OI2PM?SQ$Z#!>M$0LRQ- G.
M,2ML(@GB*%!C<,5ONR>G>-W.BGB,OL04BS'%911D=.+GRYHK3B:%1[41=;D8
ME:[VUW&X8#O?=0,9#*3 297Z^=(^SQ9L!WUY*!Y9N,<MC+]#T<HFT0_B8!R3
M+NGY_$,F5X]CECB>3C;-YG*S!A&Q%/OJEKR$S^^#E_#Y@Y?PQS#+O[%=CG,S
M'KT&JWPO@)$YV>OU8@&<W.:J&/1X1^?\8?4#4>-C)ZMZ=85 <;:&0(A=\\RC
M('_P*E6L69<!QFL7'BE4UK*!J;@F165\6PHK-NB<:/SQ-+-NB$ D8E$'46>#
M8C0=43_=T7E+?52&L/*2H(-(;&0T"L3/<8 ^N+VNO%^W?\&.4?,I2W(T'Q,I
M.7<I4+^1K*R?J\%5)0ZMJW7Q.0D?3MT;=$(LHI)GOO?$K5A!MX,S3$G#"Q2\
M!Y*\BB0O;ITBD>145L8<_$"^M#V=/=ZC&D%O@0RG!7DI<.[I3%/# CY;^ (6
M:W<K<+ )*QS4IEG[YMSJ2G*C=Z$A2$;A-;?$QNI*^RV)^_F%\FY4[(*VPW)?
M<R^3P#>LH:7]6V#V6O^:*0P$ @-==OTB_Q0(G36NZX*YG!K_0#L2#S1ZP_@:
MUW4R?."^YJ^B0C9*BC$H ,8Y:6JN='3-Z!!)X?@%T(4,M%2.]-"$OZA[75L<
M,MJ]:-8?9VS6H47/#@U*!9SH##-KE,>.5<8D[!?J-9S+=R@8SS9Z%L25(%1D
M)D&F.U4NH;JCA,+ DELTV[7/CK,NV%2N 114NG92&NVF#V _63"4>HQUZY)M
MV?<R=^(=ZC/B<DH_[57JK;AI^V.L8#1)9SB^<6'.\_OB%$2STEMW&3MDV>H5
MPMW,LTS*\)BK9@NH51SCY:IZUF-;&>P>IDDP]I)V0:$6A$88%IK!^1?B7/9J
M \%J@4U+%:G8IJ_R?3,!@S"'V/,I2=@#K7T*9S YM!33(7\!;,8%D#G\L]5_
MCLQ5,#I^ND7,\>CS/,MQ0]>\DEK^PW7/J(A:-:2;W>Z?L]-JN\4V*\4J\1*$
M/X^'+@%PB1^0!^B%3A-)YB7NY'5+L!JX.1*GZ-!&]!;]3I]C^(;JZ!B53-E6
MU_(F"3,C%PUBI!ON%JSISUOLT4.)D5,U*"W10D\(5L*J*C6>5&KHQ6I:-HC>
MQY>LEY8X&P^]*$G2%#=QBAW)A&?@J>5$0E[-J>E4R1)%5X-S-*PB%WLLESV=
M7NDN\:FR2]J_X05&2C.I=X6X.+2Q3"24V$J)T<-9789'5/2+MUG6(B< -"$-
M.!Q[SQFVH^TMZS$=ZY K;6B:ER75W'-*[.DK06$Z8ST:'FQT4I+9RM5$\/XD
M*M!%$J_S 5R)-+Z4DJ"XMP3M$_[=L<%#&R/L8(T'-4!4#LZ:0UT#=/)A34T.
M!6?#)_3%/P@Z20%4N$6C-E^=Y^8;6:5,+J'<,MJ')KIMR"MSF)?#R5VMA@QI
M2A<SE;GNC)OOQ7UP\[UX<//]$#;?[9M\!_GJRMN"%700H:*= $,Z&13)A,TW
MH+&1?:0TCV#_FHFMJ8Q<N/Z<D4:B/9B62V%RJPDL48Q%S$3]/3?%J(8[8#W%
M05#X%:Z,X*U;"DU>R-45U$51>TE96S4:(,I0R7YUBM'Y HX^SR5'S=R;"VWR
MD_H9T<03!Y 4IK6#D$(HJ73N(34.R$_JAM'6/#A5KKQ@M^_FVX&3.5,8JSN-
M/TL,NB=(?7&/.%BH1KBME"77&@9!;L]"14O'Y]F,XE01]HQ4\6=C]F.-W@&Y
MBJFX+4VC04=SX5D-T=R.+B(L=]$LS*0@S,N/Z[ WORE*''*+^9@EN<W\VX+^
M'WO!:9CP$!29014BBUY%<"@:>8$' "<#/SG/+]4%]XKK1!I"37SJPD27&T+:
MC">TLXUE-A:AT3S_CA^ZN#S'6JDFM"%1 <,BS;:@NPKWT,%+=:G,++$B,*'&
MVJ#%^NZV7+M?.-YWOV@\MK'G</M$#^PP5,)TN<,'\8,:AVX0*\"<IV/XWPCT
MVT0<<:"0C_N@1BK4HS5Y>E3IT*)\V O\:VV>&&^:AKX^2GPQ"BOE:<$^/QY2
M6;-\H,I2BIFUE/PER#Q\=J1LY<8V'";G)\<9'RQ8*V B)"7N\"!5,97"<CNP
MB89/1IKD4)G4J/66.9.\*?(,#(3YT:H'-G\UF_\&?![L44X@'T7;>?ZIK..5
M*4""WATNH(5*1HE6F4#4^O@6PUZY2C8I#C.!H JO!64+&5)IHIM\L1OKA'3\
MTH W8L;=N09'/]\'@_#G!X/PATB>4;>>/.-[S!PK9-\BW]LR,9"U"78,?]C*
MEECRUCM?U&+';H<52LQR?.[N]]J#VEZ\JZ.Y()R24>HXXB8>6YF]F&>@+&L]
MF)]R^[W8II+Y JU,O&88:U5^IDB1,(&0P%'9!3TJ17\OV@W244"4RB-5E.@Z
M1\.108QQA$F&:!4V?S42U:LY5\4.)0!O&:#CU57O5E61]*F.*/?&\%N]8I5G
MJ6&5*50!J5])?DG&+T:C2H.3V39/1(>7(-?*\V3B$)=;579UA1K'K$L"'X4(
M#-3;U&PHU%GN>L/#_@4MGM!PIHUZ<8*.;6>'\&<-6V' .>@,5HN-OV"I+SQ+
M _2QP'2.$$O*.F]<HI,EN845]AWF:<'^+SXM_GRM()F KTSH.W0A,W:6_.!9
MGEFX5\N5O7KW+<V&9P"_:3H"OT^4G5^!U@OVDG2B=5-GAM3M)^-G*G_&YM*!
M(6)38_TPA1/"-2& R(L F)OK[7//! G!(/  \O9EY"QV\E12Q.&'<9J?Y5-C
MN3BOF8+VNO'0]78[:MWLU179;7TC>Y^Q-('/#A-=TS@,4W5TQQ#G M=S:A'[
M;N=+LV4>H8U@+$:4#K"@M)C<\_*<MYZ92A%R;C!E,,M!Z>@.*F/[%M-4E6(Z
M4_$%7;"Z]*I55S8:!+*ADOOFI&&'^UJ+EDN!#\]I&L9G==E_O4RYW!1"QQ"K
M66J 35EPK19- DHKF@_(7&"E)C6.!#IZ#W!3O"@B=BM/4BGW[>P[[0O."+2"
MNH1MI<XD:Z$ .0FNNR.U<CQ>A[B<RW,E7A:W?F'IPO4I?%XHV4/,*:0WW,O<
M<!E\.8J[X4L X$9U_B-][[5+K(WO!?.S_BZ^-'@BT3 I!X5J@B*8]DK4WJ_4
M+*TQJ2;$!DCF:UT!"'<V6G!C42HM>6>;&/O\C;7I*/X$*16(TE@$-V$8[ (Z
M2"?TB;EXYBQW(_BHHUZ@I3 328.(*58'![ 5\6!F7*C^/E/-;N^KL U]V(MJ
MYOG^PH(*HK06BOA(0D4*/*:PV (5,^Y0'S8G14'H4JNV5FMP<V.,!A'44V3P
M2%S:_+:@/IH+".00N;<S)OK#:BV";J;DUT7.H6"QQ(L9?&>%@E._YQL*A6L0
M3G03=&,MIJL()Q0FRZ0;DY=T!>$T@8[FT4W= &C6'_!:Z&VKMYF[>BH=:YVR
M,SR=+7@5O,]0Y>E"C6S%*#=WOH;F<.MB<1Y8,F#-+,.8(=>_$@%L3FS'@ 4[
MG- FR: < P&*M" W&(#RP7F *=#B +^=3X$$R(_O;S>EU.\TOAP@@NKO50XR
M%\0EN>LQRXUBQ*0E+F2,.%NL-<X/.GZLYX &?D';4\L::<P:;6HU$613\V7$
MKZ;<7 %!>$72J*PM!*;#X$[#6O;8OVN;95[KNC@"WG"^%F<&;8-K!A4^QJW-
MN.E8?%/@<:F9#W/M!BW+07%)1%]D>'/L%BNC6-YU=N#2*4C(_B@']MO R597
M+"MS4S+-3O[S^<9OO_WTY#?\\U]Z+YK.5]^\)DKUP'H-!T(E76M!UJ]Q$K@X
M/L'4R<T,Z\6-,8E8<H@58T3E[XNX9AIZ3S8P7S^KW?_NZDKCAY.,^KA1I%5C
ME^D0EGX&(!_=6['(&<SWSYRKM"V@6M^N6C*!-G6DDDV.!N&4C@V-'Y!XW8PP
MAGQ&8B1<=4PFS-173ET6TQ5X=>7GK=<G'X[>E-7K)_C_U(;*23S0.,]Y_7%/
M&]=G6Y':.P6+*JMBRIUG@/@0X#OF%NP4+Y?HEH7OZ+H&\%8"!X7L&$.IU:RM
M=GW+GA+HMRCHL+VYZ5BN=2AS/&Q=&)&&#RB]=80UP'5@(15=MH>H!QT;2.I7
M'8GX8:SI2VA^S&?_1!74LC.!5$TGLCUEE"ETFV(6-]W3,BDT+!4V'O2#E'NL
M!CYKQ]+F4W(KUM1,;ZKYXYT8T1T[HJB\9UG"Z+:&QEU)*[RY^.$O]R%^^,M#
M_/ FXH>W%#7$6A1>L<<%&S\\>K/QES_]M@#4015<A*-K8)#EW2VO=YOQW/C6
MX[EBB.XFE$PQ9#?;"1C^S>G&'=V^FQ+G01ZFJN8'=/0LIS_GA&IJ,:"%^\&J
M;.B%7Q%9]@D=?>CAM+8!2C?GW^1TLJH8VA6^EE<X(17)PLC-WYS<*\>JT:DI
MDB#2I.6MD>R7EB87>3+46N$PG_:KCA.EUE$^,2G;U/::^X(422>B'4C3=;>F
M6#GM\Q:6B]A!H(90X A1H45-5^YX9<0&^;@/&D#II1YB%I^TN$<34<DIED@F
MZ]>803G&D@8-4R!]9RVYT$6[<7]*;FX_2..RY+(-XM>=H^+[>SZ()PEB!WFV
MH>F*9K?O!:X:8-468>LAL&,/>FXAY[ R5<15[G137L@'L,9!6*X=@=K\M)B9
MS=$YGFT&C.00,W2=C"3/)<[AD2PG'^$",PO<M?/-)CNH]8K7OKE@+-LZ:U&#
M9=U;QM+MV;C?M38<6VOE-7^9@]!@Z;!&/63SR<'J$XI:@T7$#@\-B&>FRX.>
M+I62LX94?8\X $[%Y<BKH8OOUR(K#MH/5.^F-MSL\76XI\<JK?-WP5G9W]/$
MPFIQ%$C"T=A_R+S!5/DOU%_^]/S%*_^"/LCXJV1\__9E_+1?DHI>Z4HBT2$<
M/**2R]8*#/9:S"D*8B\#A5N853D*@BO>SJ@Z4(>%7TEH!<S2+NGI-NP#T1E/
MV4W5*=D+?RDEASJ>BU)4"C&#*T)[8QNZ6'LIY"Z:BR90#B+D>3RZ\CR(1WHR
MMCA+0P4!M_9)D'@4#P1#SX+?.BX<I)BVVH/!.@'["WY=SX$:V%QM&788)%%C
MVC8ZJ\+"KBV;P5^Q3)VB1<#/VKG[FD:_X)R+H:8SU__@" <NH)>/7!=S$WQF
M 8?7>I.P-"[F7"?0QYHNL%PL***9K:EPQDYMZPPL(EUXN/ET\H*N0B:G%WRX
M8T=W'=QUTK3[3T3J'X#)+G'\^UJR.!.^<K;16ICP$C7FN^@X00C=:,VAUF46
M6;"0:E8?7J!DL$30K[0 $I)D5Z\.T%WEL:]?.JN3ARE__M2:IF7K$M-JUZA4
M2P/J2#:UU6X@_*6LKOD @J'6;;ON^5,R:ARYF'&'^VK&#3\U&<@^.%4WD2L3
M:>+A4D00#2@Y,TD&XA-A&-(7G8I[][YG?>#FG("_W@<GX*\/3L ?0"%M:D/S
MD=O0#!;15.>\OT05]JC(07=%'6[7]06Q]KH[I00[P^!JE7M]IU0G;'' G'2(
MKH9"BOI+JY>:GVIUQ?=-L0,*]$:%@M135D7/<AZ@#G8UT5X'E[C^EFI:9*XO
M U42&PM;!%P<3I@+8)?:618"\SI6;\;?3E@SLU.*<0MX5^ KDP2_.>K4'#4=
MI_PZW'@\AS,*7'4(.\KYKLZ/G:E(0J13E6P]6HN]= .7"'S%V[4^K)WKMY-P
M@0JH,U@PH.!J@WP,ZY>X2HEPYZ6M#4S@K.%=O=($I)8[GQ/,&+:%"U5T5(O3
M%B_++:GHCHORME3T45U%!\5<Z^CUK;\!!;R^NX4B#U&S FY/4_ +=?*XEMK=
M0D#_%_;A2H7;&_6KU.VH2=LVI>^NI6Z'-R54MF5J;3JWY^@-')9-*O><X=8M
M(,-BA^LOM:K;^LPQ&PDG&S3]J6O?"[E_ODA%-T?Q#71TJX;=)>WG6_0?>PN:
M4CRFL@;25HJEG(ZW73/&UG&:V;CQ#2YOD<X8GJ+_1;(.6]*@FI,C#R.4/EY4
M.Y-2',/LFQLKBALQ#IEL$..P=K4H0KW06"0VW&Q$-W3EOK(F)1;(NX%4CI[*
M!,1 P7D=Q.'I.E,5F_7V1;GS16=')TH5B?$T&6#%$;Q'N@Y&QQ29Z'#ZE%C-
M1@,!C4GW^"->0Z4D,4< M[SB+"DI<.)H?W9?XP@I6TF3V_KNTG:8(K'VK$BY
MTZOJ.!4!1S372I<U'_%I* U*YY^LZ;R,.MS6/PWJ^**5 ;^2FU30=*1?S><D
MC;J8LZ,#UT[,F1(,EQ2:0X\:U4PJE)0[;EHD!MU"A]*'U,2I1N+,Z<7F3YI\
M-1&Z02I?F;91Q>O=CM45031?<3OJBB_H1$$_9'B&U7?SLR9X(@>N\6"F:9D7
M,_$IV4VMG53](TEI8SI4<U.G+=*M=$YHN."I=.A>K'W9'D;M6XBL9#H><V:/
MM49XQ8;RJ;/+F (79K;]:8D!ZM(+1UUI" 6GTJF="1LSC\F8L1S/V"I D-98
M6=<)2NZUPL<Y(P5.5V=A7Z+ [HLBUORTV(DE;Q:A&XG :X3=CDVPL /N2=,*
M/'#1J.%L_/1Q,(&I.DY!VALB_CA(#Z2>#Y)8.H_'&M'M9!Q<_1UN''C5D4>U
M$Z=<)GWD8!.2R>;6<G8D:Q0(5C\T(RAH5I%U<&Q.00*KSNF:0TUU["E$Z_2+
M\@MZM];,M1::7^O7+^J:Y(5QP>>8 U0HMP!7R])-HXNFVL57VWN$B&G!S[;4
MZ7/P*@M9J3(C"R9%LJ(K023O5DW*BT#G(!LO,0W^RFEQP4AZYRVI)D$138YP
MQH2D!CU#R7>#P%XW!7,NHYJ].^YS7I=,/FTZNB9[H^4X&#KBPF6OWB%VY]M^
M<VTIEXWD,G<R-WK\]6PL8Y#ZY15K*(CJ/,1S.)6LXPE*IB()<"$:$6_6; XQ
M\LXP\OJQV8K!;8^;^\GYK*8('LHW9EQUJ--5%[(Q!1!F+]9G??DX3S;E5E=:
M)YH1$6+O/9JOP.8ENTQ;@IR1"\SG(DZG2A_*,$$%$CD@*A^PM,RVK6F[# 0,
MG*<G(O9<\I?.<UJ$*44P5PMDEXII2)A0Y]G6S6P.^?7U\,;_5IM#ZSY6>NS2
MR(AV4![P^C3-+XWWN66>[6V)Y4X(ZR.GR8S/LLU*C$S%=Y>(I&Z Y8*HM/EL
M[<0,TZ-A/':&]P=[TBHWETUL'!8Y3E7VP/"3SLGNMF@:9_GMSGXW'TP95+)(
M=XVH(2O&)N=Z^K"D^QGU@0; S!")IY+Q-E#VCLQL]XG<]CEU<G2(U7!33(8!
MA%)SFCD7;@A7:[:^(.<U0*VY\CEL.V4[?636*&#OD[OW^GZ9BC[AR9O*Z0)E
MU'N74"8.Z5Z^L:M=\@FW?0FW5./D;+5*),] /!%PEC-NL)P$::I-HJ\&VJ2-
M-$M879$UK$E2(:B5I+O13]==@*_F-E=ZQSE[V\CSN2#%U97%<"QS9>-B5,*B
M0G<2L, 8[B$@'G&N@>$/QP]X3<U9Y6[9Y#6L!52QHL[>&^D_WBPRB!);=K76
MUWG>#<#/FZ_.FV$G3/YT0#'^4@QV(M@,KL1BO/.LE>"7X(I7CH!4H!GFXV3@
MKM95N1IT+.8-QIYU'<@MBY>>WN::M+&D9@;F,2INF<Q3\*T"HVW-DYUUUL#"
MB402J54\U;[B"205%8C%?5PK<S9I1D4^YMP]IWNTA&VNGD!#DN!UA CH-ZHH
M;.*UC1(ZV?,VAY<>)SZG8I.T&.Z!' ^F^1DJ4E1NE6T]_.4DOU2A-6*Y.IG)
M*$RM!(V6+T"-R.0(HQ36*]$F8DA2[7 1XT=F)Q8<'NIZ 'H:''.\2\T;?KL/
M,)O?'F V\V V[HYB/LKC$W6&]T-OY,G14Y[30B$I_D$'#N>V0U/AT VU/I<8
M@]JQM<,81(.69>J6%"M=MN0KX$'9>=-M &5R11="U_C0/]MZLK6YB>$ATZ:A
MJ1H)N0RH)O&<"B[/%O0K>66M).&*TF+<[MWLEQ!CD826Q7JP+35>U$WCI/!$
MK1D\S?/X$I8[EU*7279?#F[[CN_2:)EWB8NK$1B$E;(OS77]$<[TQLJX7[FH
M9&.)9VHSE^E<?7\<!^H_GJM,78C"&SCL@&D9UZ3?_W-F-=ZY_,UW%F$]L4F5
MSK!L55/3OC[V/AV0F4YQ-TQT2['9!)?JJ)=6"AV,-I?/28?3CG/V;1/#]+?%
MYXMA^PO4AKV!XZA?8.LR:I.H.T/@-]#@T94DC2_-CO5PEV[]+BWU,CD,LHON
M4DM]0+<.RT27<E,%M "@&UM8KB[48G ;%J]%;E*@,[PL:$6OBU?&!XMU;)//
M>0-2:[X8P6U9@<XU;NB!KFN+$,X8^E&H(;:);(GR=VS)M*I>>RR>5N=Y >=
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M)(R]TQM;"KI%.!_,H.^,*)-E$N6^"6I0#&$_<6NBH;BW@D)[>\0M1;F[-BZ
MC:TI@_#"1(-]KMDN/W,;JS1)TRY@%C'E&=P'":CHTK4CSXV/@C2Y2%*%PBGW
MFT(RY9]1QF;"!;6Y :$LUG^^5O!'-Q"4E=9ZT,_/*$"!RH5:2/S901,JU<1%
MS$,@,UW> 5S1!$18:2()\ON'.W?;=^Z/Y5J)+-EK%B+=+=UTF[D\J@F-97^=
M\GX:4]J?<:*=57"PH@ 5=49MG14W,??"JN)<DFT I.Z'_*QN<B5$A!K)BF$+
M%T1QN7Q1%]G3K8&N0Q!KJ&VA5@IJ'=_KD=@1B(E'R61U+];I.!,&'2APC>"G
M%L5_14M$:2.@YY>S.6&2)QF@HCCKD0ID9QP%8X#)P$Q.;Y(7%F7,!VMK,RJ%
M'U_*:IV5/MS8V[ZQGY8*)-=](4LVBKM45$YL8J?457N-T(8"G8[THO9F3N3.
MMAL6VF4)EF1B5I,PZ*M,C1*!KQ"U];G_A'4=F4;9/(35(+DJ7JW?B)[6(N])
M.U7F7_-N8*'(-9\-C>:J!:RW@ID1OV'%D[E%KG08@$LIA/7)(BN2?3_;PX6\
M[0N9+A4JC/@;-#^,#*V7XAOG0ZXRBG)ES/2G-3M+KI+9*= A8P'I:GH2UZPW
MK^$+!F(N.J>T?^KGZ])>Z%;1;Y JB.\\D.!MD^!XJ3)!7805I#\B,:'O:@(J
M3$)%<4E9:7?Q&2YF@I=.D4,NX2(5^OIN<P9D@!0(K563(0V085C):+ZGSPX.
MCYPG_41T2&YXU/YU*3AL/NNLP<Y0"RD!YVG/K1Y)@'$R#H5S-<Q.?A;;/&AJ
M?C%T_+^NM"F<9_"-=DGT<-]N^[YER[QO[Q2AM5VKZ5Q^%$W+>J<84CRTID'M
MPK)$.RRHJSG_(TN=-N1H#W2,(2)URACBS,UQ8Q.M\"I)W4/2:@JW+W/6_Z_A
MOX==7O8NO]Y[LW9")?:GB%-#I  OY&V.%;O*]=?;QWJ@0:KBXF74!PT&W?U[
MM9S(6UKL@@F;>XUSG(=;>7XO<"O/[R=NY:9OTFW<_UO) -P[ +&V=WK0.SF)
M/K[K'?<.W_K17>PQ0(TI@PX#HJ3:]AEN1AMC-Z>9[K+AY@#ZG0)&25%6C&Y'
M+^"0TBKNHK%TVMW>[T4[O?W]H^[N[M[![W]]M/F(_GURU-W1_VYC"L)/,- <
M3TKXL?[;*]"4A]4Y/K?YTR.Z-Z]/CUN_@UU2L0*XIB&^G(_T?3O=;7G3KNIT
MUWEXYQ!G?_#71T\?7?\ B&PYX24O@$%,)Q-58($2.(SM-P>]#\>'VX?1T;ON
M\?ON3N_#Z=Y.=_]$ZC3L'>QL\#3XWY&>WO8;FB+\<?RC;(8SV(TNRY#2"Z2D
MQB5>>UGRQ:?PP>W9R^:OS9>5?,&N-=KS7W^ZO5U;SDXMZRLDW^_;HD\Q</4R
M:CSQ)\1WB07?G C^_C6'!;':+^Z%SOOB?NJ\WS^^Z\;M6U K#D&/Z*VN'+Z-
M>G_O'>_LG?18:;AK^N1WSLCF:C2G^<NO<O\9[7!UI5T]?#C66S(1U[:NX=BE
MBC(42) >4A+25@B@+3WTU[_EOUIQTZ!$JU.6-,A%5[:GH_[&&KEXDY&MC4:P
M1T1+2W%#BDT7I:EI84IAZ/;7&G/#,##322_HP(5)[S92XG=][$@TY@Z:L7>1
M/I]>@SZ/^+!75S@"0%GNE 2 *=5  6M 35B/R!YM/_^\_O+^'21G4K<&DY:Y
M@'^NKOR+"G7&EW#5"$UF0)H?,@I4GF :4ODJRHN'D[CQDQBYX'.JV=%0^[4U
M3SW&NE@V"[P3M:#.\<9-T]BOPH'=>Y741WBZ-ECOM .)Z4.ZJ(_(AG'\.1E/
MQ^V3$^$3]+>3%D1AKARGAPPI5M(RRP@G^<#F;X7-/[L.FT\50;FYM AUUJP7
MN*+<!Z<CEZNV<!H/43IC>.A!IFW;T;BOTOSR'@J'A8Y_V?B"?\__[^$4EBX.
M2)D/[DT]KTCSSU&NVS[M?NSN1%WI6G- O/CADCQ<DH=3>#B%AU/XWD]AR5K;
M\VMH;0CU'G >'/IM]K(+55:YT\[-U= PH2[337!B\QHB2NDMZ8*#.MM0C70!
MH&-3+S;:1?T>3)"S>%[_,4J4W/KMV3-N=,C(\@>-_U;]R?\\V?O]H'OZX9@=
M^^\.]W=[Q_^Z>V=P;8S(=58AD;1Z'"V D#CQXC \#%]H.6:<O(G<7I[#17M<
M3F*,*6;Y91%/[!@O?O(_D:I1M<R=Q6B?WM<OPPK2C6;>@LIJ#Q,C82+FL#"^
MO#AZH9&CRF;\^@+WFZ/?%+)VP]4/]/H]T.O3S1NFU]=[;QS(+5">[7L0\2]R
MSM@-*1+QK"]=HO36=!59SEOSK\UK]L :#^3Z79+K76&O343^P&(?:/9&:);P
M8>UD=S,\M'E1#SST.Z%'_MSFQM-:V&S9U(<EWUXNC[/=:6YV)QJV_7PO0) _
M/X @[R<(LGN"WI+WO8/3U96WA\?O[YZ;Y#;<G"P9EIU<>9JOKG#1% UQX%8@
MMBZ$)$PQE(% 1Y2./)U,TIFM_Y=D5'$(W90;T6Y.A8NFI?N6#XM03>75"..$
MQ4_6;R)]\XZ2P3*G#;=K=>5OW?T/O>BXM]/;^UMOM]-\[G3(&#>5"D"VXD^E
MRU45RE2N*L7#7>5W[]"L_NCJBZ$^>>U5..KAG&2YQORXQ09HT#/=-)FOS_VZ
M.3*4G"#7R+FQ#*P;7LKK#V\PV.-ITRUY3C_\L0;WZ^OR]&YXKFL:;X43/"J2
MK%I_.$/4Q89#$,#E_-OYW<SV#MV^T-!:HGI DHRF>(,CS.739&E],9.^P:U9
M/K\(>,71]TYU2T^+_7Z7^H6>F*/S/(.##5%_-ZF6W)$-?:"=JU[KC>,DY2EH
MR1D]4- ]I* ;%T#HM!^^Y+G6@('TDT[MYW=#B:N;#7?LD)=3F.2J3]_HILP+
MBG[5$AQ'R$_+))J@@Y(!K'Q#MX*M]K*\:C7SAGFQW!V]Y6MXEZ[>';_5WPVG
M#R[M0KZ&&_8$WN IW\[5-.'V.^!JOQ/!]E]>18?<0/IEM!^7U>W$WG^8$'3S
MR3_9/MS]!T%$WIV^WX>__']02P,$%     @ O(5$4^QKB^>("0  TRH  !4
M  !T;3(Q,CDP.#!D,E]E>#4M,2YH=&WM6FUO&KD6_H[$?_!R[U:IQ,L >=D
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MOC'!OW"ZIFSKY1*"RIPXN/  $N1A3#:BV#5$+L2VXMXMAV4*J+<*=D90X4;
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MPYL+/2RGOC@$SRE)>G!?AC 9AW21MF\MLRJ5'@--ZZ+L5E=NNJI;U;U7)2W
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MY3'=3?1ZH>&]?W+^K^ID3U6O,',L&<[K1FUO;(K"9+MBAYZ-@>?*UL_X=#$
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M"O\O6_P'4$L! A0#%     @ O(5$4[B9^:%( P  H0P  !$
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3!@     (  @ $P(  !]  0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
